Oligonucleotide compositions and methods thereof

EP4153604A4Pending Publication Date: 2024-11-27WAVE LIFE SCI LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
EP2021807794
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-05-22
Filing Date
2021-05-24
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Natural oligonucleotides face challenges such as low stability and activity, which limit their effectiveness in therapeutic applications, and existing technologies have not adequately addressed these issues.

Method used

Development of chirally controlled oligonucleotide compositions with modified sugars and internucleotidic linkages, including those connected through nitrogen atoms and acyclic sugars, to enhance stability, activity, delivery, selectivity, clearance, and toxicity profiles.

Benefits of technology

The described oligonucleotide compositions demonstrate improved stability, activity, and therapeutic efficacy, particularly in therapeutic uses, by incorporating modified sugars and internucleotidic linkages that provide chirally controlled configurations, enhancing their performance compared to natural oligonucleotides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and / or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.
Need to check novelty before this filing date? Find Prior Art

Description

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to United States Provisional Application No. 63 / 029,387, filed May 22, 2020, the entirety of which is incorporated herein by reference. BACKGROUND

[0002] Oligonucleotides are useful in various applications, e.g., therapeutic, diagnostic, and / or research applications. For example, oligonucleotides targeting various genes can be useful for treatment of conditions, disorders or diseases related to such target genes. SUMMARY

[0003] Oligonucleotides are useful for many purposes. However, natural oligonucleotides have been found to suffer disadvantages, such as low stability, low activity, etc., that can reduce or negate their usefulness, e.g., as therapeutics. Certain technologies have been developed that can improve oligonucleotide properties and usefulness. For example, certain modifications, e.g., to nucleobases, sugars, and / or internucleotidic linkages, etc., have been described that can improve oligonucleotide properties and / or activities. In some embodiments, technologies that permit chiral control of chiral internucleotidic linkages can be particularly useful and effective.

[0004] Among other things, the present Applicant appreciated that technologies that can effectively incorporate various type of modifications and / or patterns thereof (e.g., those described in various embodiments of present disclosure), particularly into chirally controlled oligonucleotide compositions, can provide significant benefits and advantages. In various embodiments, the present disclosure describes developments of oligonucleotides and compositions thereof, particularly chirally controlled oligonucleotide compositions, that can provide various benefits and advantages (e.g., with respect to stability, activity, delivery, selectivity, clearance, toxicity, etc.), and may be particularly useful, for example, for therapeutic uses.

[0005] For example, in some embodiments, the present disclosure provides oligonucleotides comprising one or more modified sugars which are connected to internucleotidic linkages through nitrogen atoms (e.g., morpholine as in various oligonucleotides described herein). In some embodiments, provided oligonucleotides comprise one or more acyclic sugars. In some embodiments, provided oligonucleotides comprises one or more one or more modified sugars which are connected to internucleotidic linkages through nitrogen atoms or one or more acyclic sugars, and one or more ribose sugars each of which is independently and optionally modified. In some embodiments, provided oligonucleotides comprises oneor more one or more modified sugars which are connected to internucleotidic linkages through nitrogen atoms or one or more acyclic sugars, and one or more ribose sugars each of which is independently and optionally modified. In some embodiments, provided oligonucleotides comprises one or more one or more modified sugars which are connected to internucleotidic linkages through nitrogen atoms or one or more acyclic sugars, and one or more modified ribose sugars (different from sugars typically found in natural DNA and RNA molecules, e.g., those with R2sthat are not −H or −OH). In some embodiments, provided oligonucleotides comprises one or more one or more modified sugars which are connected to internucleotidic linkages through nitrogen atoms or one or more acyclic sugars, one or more modified ribose sugars, and one or more natural DNA sugars (which, as appreciated by those skilled in the art, have no substitution at 2’-carbon as typically found in natural DNA molecules).

[0006] As demonstrated in many embodiments herein, the present disclosure provides oligonucleotides comprising sugars, including modified sugars described above, connected by various types of internucleotidic linkages, e.g., natural phosphate linkages (as typically found in natural DNA and RNA molecules), modified internucleotidic linkages comprising linkage phosphorus, modified internucleotidic linkages that comprise no linkage phosphorus (e.g., −C(O)−O− or −C(O)−N(R’)− as described in various embodiments, in which, in some embodiments, −C(O)− may be bonded to a nitrogen atom of a sugar, and −O− or −N(R’)− may be bonded to a carbon atom of a sugar). In some embodiments, modified internucleotidic linkages comprising linkage phosphorus are non-negatively charged internucleotidic linkages; in some embodiments, they are neutral internucleotidic linkages. In some embodiments, modified internucleotidic linkages comprise nitrogen atoms bonded to linkage phosphorus atoms, wherein the nitrogen atoms are not bonded to sugar atoms (e.g., sugar carbon atoms). In some embodiments, provided technologies provide chiral control of chiral internucleotidic linkages, e.g., control of stereochemical configurations of chiral linkage phosphorus atoms.

[0007] In some embodiments, provided technologies comprise one or more modified sugars (e.g., those described above) and / or one or more modified internucleotidic linkages (e.g., those described above), wherein one or more chiral internucleotidic linkages are independently chirally controlled. Among other things, the present disclosure provides technologies that are particularly useful for chirally controlled compositions of such oligonucleotides. For example, in some embodiments, the present disclosure provides technologies that are particularly effective for incorporating certain types of sugars (e.g., those bonded to linkage phosphorus through nitrogen atoms) which are compatible with chirally controlled incorporation of various types of internucleotidic linkages, e.g., various internucleotidic linkages having the structure of −Y−PL(−X−RL)−Z− such as natural phosphate linkages, n006, etc. In some embodiments, each linkage having the structure of −Y−PL(−X−RL)−Z− is independently chirally controlled. In some embodiments, each phosphorothioate internucleotidic linkage is independently chirally controlled.

[0008] In some embodiments, an oligonucleotides of the present disclosure, e.g., in an oligonucleotide composition such as a chirally controlled oligonucleotide composition (e.g., an oligonucleotide of a plurality in chirally controlled oligonucleotide compositions) comprises: a sugar that is bonded to an internucleotidic linkage through a nitrogen atom and / or an acyclic sugar, and / or an internucleotidic linkage having the structure of: −Y−PL(−X−RL)−Z−, −C(O)−O−, −C(O)−N(R’)−, or −LL1−CyIL−LL2−; wherein: PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; each of X, Y and Z is independently –O–, –S–, –N(–LL–RL)–, or LL; each RLis independently –LL–R’ or −N=C(–LL–R’)2; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; Q−is an anion; each of Ls, LL1, LL2and LLis independently L; −CyIL− is −Cy−; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0009] In some embodiments, PLis P, P(=W), or PN. In some embodiments, PLis P. In some embodiments, PLis P(=O). In some embodiments, PLis P(=S). In some embodiments, PLis PN. In some embodiments, a linkage has the structure of −Y−PL(−X−RL)−Z−, or a salt form thereof.

[0010] In some embodiments, an oligonucleotide comprises a sugar that is bonded to an internucleotidic linkage through a nitrogen atom. In some embodiments, an oligonucleotide comprises a sugar that is bonded to an internucleotidic linkage through a nitrogen atom, and an internucleotidic linkage having the structure of −PL(−X−RL)−Z−, −C(O)−O−, or −C(O)−N(R’)−, wherein the PLor −C(O)− is bonded to the nitrogen of the sugar. In some embodiments, a sugar has the structure ofwherein Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms, and Lsis L as described herein. In some embodiments, an oligonucleotide comprises a sugar having the structure ofand an internucleotidic linkage having the structure of −PL(−X−RL)−Z−, −C(O)−O−, −C(O)−N(R’)−, or−LL1−CyIL−LL2−, wherein each variable is independently as described herein. In some embodiments, an oligonucleotide comprises asugar having the structure of, and an internucleotidic linkage having the structure of −PL(−X−RL)−Z−, −C(O)−O−, or −C(O)−N(R’)−, wherein each variable is independently as described herein. In some embodiments, an oligonucleotide comprises a sugar having the structure of anL Ld an internucleotidic linkage having the structure of −P (−X−R )−Z−, −C(O)−O−, or −C(O)−N(R’)−, wherein the PLor −C(O)− is bonded to the nitrogen of the sugar, each variable is independently as described herein.

[0011] In some embodiments, an oligonucleotide comprises an acyclic sugar. In some embodiments, an acyclic sugar has the structure of −CH2−CH(−LSA−)−CH2−, wherein each of the CH2and CH is independently optionally substituted, and LSAis L as described herein. In some embodiments, LSAis −O−CH2−, wherein the −CH2− is optionally substituted. In some embodiments, LSAis bonded to a nucleobase. In some embodiments, each of the optionally substituted −CH2− is independently bonded to an internucleotidic linkage. In some embodiments, an acyclic sugar is −CH2−CH(−O−CH2−)−CH2−, −CH2−CH(−O−CH2−)−CH(CH3)−, −CH2−CH(−O−CH(CH3)−)−CH2−, or −CH2−CH(−O−CH(CH2OH)−)−CH2−. In some embodiments,

[0012] In some embodiments, an oligonucleotide comprises an internucleotidic linkage having the structure of −Y−PL(−X−RL)−Z−. In some embodiments, Y is a covalent bond. In some embodiments, an oligonucleotide comprises an internucleotidic linkage having the structure of −PL(−X−RL)−Z−. In some embodiments, PLis bonded to a sugar through a nitrogen atom. In some embodiments, PLis P. In some embodiments, PLis P(=W). In some embodiments, PLis P(=O). In some embodiments, PLis PN. In some embodiments, Z is −O−. In some embodiments, Y is −O− and Z is −O−. In some embodiments, an comprises an internucleotidic linkage having the structure of −C(O)−O− or −C(O)−N(R’)−. In some embodiments, an comprises an internucleotidic linkage having the structure of −C(O)−O− or −C(O)−N(R’)−, wherein −C(O)− is bonded to a sugar through a nitrogen atom. In some embodiments, −O− or −N(R’)− is bonded a carbon atom of a sugar. In some embodiments, an oligonucleotide comprises an internucleotidic linkage having the structure of −LL1−CyIL−LL2−. In some embodiments, each of LL1andLL2is independently optionally substituted bivalent C1-6aliphatic or heteroaliphatic having 1-4 heteroatoms. In some embodiments, each of LL1and LL2is independently optionally substituted bivalent C1-6aliphatic. In some embodiments, −CyIL− is independently an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms. In some embodiments, −CyIL− is independently an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms. In some embodiments, −CyIL− is .

[0013] In some embodiments, the present disclosure provides oligonucleotide compositions, particularly chirally controlled oligonucleotide compositions in which configurations of one or more or all linkage phosphorus are each independently chirally controlled. In some embodiments, the present disclosure provides an oligonucleotide composition comprising a plurality of oligonucleotides, wherein oligonucleotides of the plurality share: 1) a common base sequence, and 2) the same linkage phosphorus stereochemistry independently at one or more (e.g., about 1-50, 1-40, 1-30, 1-25, 1-20, 1-15, 1-10, 5-50, 5-40, 5-30, 5-25, 5-20, 5-15, 5-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more) chiral internucleotidic linkages (“chirally controlled internucleotidic linkages”); wherein the composition is enriched, relative to a substantially racemic preparation of oligonucleotides having the same common base sequence, for oligonucleotides of the plurality.

[0014] In some embodiments, the present disclosure provides an oligonucleotide composition comprising a plurality of oligonucleotides, wherein oligonucleotides of the plurality share: 1) a common constitution, and 2) the same linkage phosphorus stereochemistry at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) chiral internucleotidic linkages (chirally controlled internucleotidic linkages), wherein the composition is enriched, relative to a substantially racemic preparation of oligonucleotides sharing the common constitution, for oligonucleotides of the plurality.

[0015] As appreciated by those skilled in the art, oligonucleotides may be in various forms, e.g., acid forms, salt forms, etc. Unless indicated otherwise, references to oligonucleotides include various forms of such oligonucleotides. In some embodiments, the present disclosure provides pharmaceutical compositions comprising a provided oligonucleotide and a pharmaceutically acceptable carrier. In some embodiments, an oligonucleotide is in a salt form, e.g., pharmaceutically acceptable salt form.. In some embodiments, a salt is a sodium salt.

[0016] Among other things, the present disclosure provides technologies (e.g., compounds, methods, etc.) useful for preparing oligonucleotides and compositions, particularly chirally controlledoligonucleotide compositions, of the present disclosure. In some embodiments, a provided method utilizes a compound of LG-I, LG-II, M-I, or M-II, or a salt thereof.

[0017] Technologies of the present disclosure are useful for various purposes. In some embodiments, provided technologies are useful for modulating levels of nucleic acids (e.g., transcripts, mRNA, etc.) and / or products thereof (e.g., proteins) in various systems (e.g., in vitro assays, cells, tissues, organs, organisms, subjects, etc.). In some embodiments, provided technologies can be utilized to reduce expression, levels, activities, etc. of target nucleic acids (e.g., transcripts, mRNA, etc.) and / or products thereof (e.g., through cleavage by RNase H, RNAi, etc., steric hindrance, etc.). In some embodiments, provided technologies can increase expression, levels, activities, etc. of target nucleic acids (e.g., transcripts, mRNA, etc.) and / or products thereof through modulation of splicing. Those skilled in the art appreciates that in many embodiments, base sequences of provided oligonucleotides may be complementary or identical to those of their target nucleic acids, and provided oligonucleotides may hybridize with target nucleic acids under suitable conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1. Provided technologies provide high activities. Figure 1 demonstrates that provided technologies can provide effective splicing modulation provide desired exon-skipping products. H2K cells were grown in 96 well plates for 4 days, dosed, and left to further differentiate for an additional 4 days. RNA isolation was performed using the bead-based assay. cDNA was synthesized, pre-amplified, and multiplex Taqman was performed. Gblocks were used for quantification.

[0019] Figure 2. Provided technologies provide high activities. Figure 2 demonstrates that provided technologies can provide effective splicing modulation provide desired exon-skipping products. H2K cells were seeded into a 24WP (40K / W, pre-diff) and dosed (3-1-0.3uM) for 3h, washed, and further differentiated for 4 days prior to RNA extraction using Trizol and the Promega 96WP RNA kit. qPCR was performed on cDNA and % skipping values were extrapolated from an absolute curve generated with gBlocks.

[0020] Figure 3. Provided technologies provide high activities. As demonstrated in Figure 3, provided technologies can effectively reduce target nucleic acids. K562 cells were seeded into a 96WP (15K / W) and dosed (10 nM-3 uM) for 4 days prior to RNA extraction using the Promega 96WP kit. qPCR was performed on cDNA and %mRNA remaining values were normalized against mock values.

[0021] Figure 4. Provided technologies provide high activities. As demonstrated in Figure 4, provided technologies can effectively reduce target nucleic acids. GABA iNeurons with 4 day treatment.

[0022] Figure 5. Provided technologies provide high activities. Figure 5 demonstrates that provided technologies can provide effective splicing modulation provide desired exon-skipping products.H2K cells 4 days treatment.

[0023] Figure 6. Provided oligonucleotide compositions provide activities in vivo. (A): Dosing schedule. (B): Provided compositions reduced mRNA levels. (C): Oligonucleotides were delivered to tissue.

[0024] Figure 7. Technologies of the present disclosure can provide various advantages. (A): Schematic representation of dosing regimen with arrows indicating administration of intracerebroventricular dose (day 0, D0) and day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS, WV-8587 and WV-11533 at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n=8 * P<0.05, ** P<0.01, *** P<0.001 mixed-effects model with multiple comparisons. (B): Schematic representation of dosing regimen with arrow indicating administration of ICV dose (day 0, D0) and day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4-weeks post treatment with PBS, WV- 8587 and WV-11533. Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS, WV-8587 and WV-11533. Data are presented as in panel A, n=4 **** P<0.0001 one-way ANOVA with multiple comparisons. (C): Schematic representation of dosing regimen with arrow indicating administration of intracerebroventricular dose (day 0, D0) and day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in indicated tissue in CNS 10-weeks post treatment with PBS, WV-8587 and WV-11533. Data are presented as in panel A, n=3 one- way ANOVA with multiple comparisons. Bottom row asterisks show comparison of WV-11533 to PBS; top row asterisks WV-11533 to WV-8587. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0025] Technologies of the present disclosure may be understood more readily by reference to the following detailed description of certain embodiments. Definitions

[0026] As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001.

[0027] As used herein in the present disclosure, unless otherwise clear from context, (i) the term“a” or “an” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and / or”; (iii) the terms “comprising”, “comprise”, “including” (whether used with “not limited to” or not), and “include” (whether used with “not limited to” or not) may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; (iv) the term “another” may be understood to mean at least an additional / second one or more; (v) the terms “about” and “approximately” may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (vi) where ranges are provided, endpoints are included.

[0028] Unless otherwise specified, description of oligonucleotides and elements thereof (e.g., base sequence, sugar modifications, internucleotidic linkages, linkage phosphorus stereochemistry, etc.) is from 5’ to 3’. Unless otherwise specified, oligonucleotides described herein may be provided and / or utilized in salt forms, particularly pharmaceutically acceptable salt forms, e.g., sodium salts. As those skilled in the art will appreciate, in some embodiments, individual oligonucleotides within a composition may be considered to be of the same constitution and / or structure even though, within such composition (e.g., a liquid composition), particular such oligonucleotides might be in different form(s) (e.g., different salt form(s) and may be dissolved and the oligonucleotide chain may exist as an anion form when, e.g., in a liquid composition) at a particular moment in time. For example, those skilled in the art will appreciate that, at a given pH, individual internucleotidic linkages along an oligonucleotide chain may be in an acid (H) form, or in one of a plurality of possible salt forms (e.g., a sodium salt, or a salt of a different cation, depending on which ions might be present in the preparation or composition), and will understand that, so long as their acid forms (e.g., replacing all cations, if any, with H+) are of the same constitution and / or structure, such individual oligonucleotides may properly be considered to be of the same constitution and / or structure (and share the same pattern of backbone linkages and / or pattern of backbone chiral centers).

[0029] Aliphatic: As used herein, “aliphatic” means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is completely saturated or that contains one or more units of unsaturation (but not aromatic), or combinations thereof. In some embodiments, aliphatic groups contain 1-50 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-20 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-9 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-7 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstitutedalkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0030] Alkenyl: As used herein, the term “alkenyl” refers to an aliphatic group, as defined herein, having one or more double bonds.

[0031] Alkyl: As used herein, the term “alkyl” is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, alkyl has 1-100 carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C1-C20for straight chain, C2-C20for branched chain), and alternatively, about 1-10. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure where such rings are monocyclic, bicyclic, or polycyclic, and alternatively about 5, 6 or 7 carbons in the ring structure. In some embodiments, an alkyl group may be a lower alkyl group, wherein a lower alkyl group comprises 1-4 carbon atoms (e.g., C1-C4for straight chain lower alkyls).

[0032] Alkynyl: As used herein, the term “alkynyl” refers to an aliphatic group, as defined herein, having one or more triple bonds.

[0033] Analog: The term “analog” includes any chemical moiety which differs structurally from a reference chemical moiety or class of moieties, but which is capable of performing at least one function of such a reference chemical moiety or class of moieties. As non-limiting examples, a nucleotide analog differs structurally from a nucleotide but performs at least one function of a nucleotide; a nucleobase analog differs structurally from a nucleobase but performs at least one function of a nucleobase; etc.

[0034] Animal: As used herein, the term “animal” refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non- human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate and / or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish and / or worms. In some embodiments, an animal may be a transgenic animal, a genetically-engineered animal and / or a clone.

[0035] Antisense: The term “antisense", as used herein, refers to a characteristic of an oligonucleotide or other nucleic acid having a base sequence complementary or substantially complementary to a target nucleic acid to which it is capable of hybridizing. In some embodiments, a target nucleic acid is a target gene mRNA. In some embodiments, hybridization is required for or results in at one activity, e.g., an increase in the level of skipping of a deleterious exon in a target nucleic acid and / or an increase in production of a gene product produced from a target nucleic acid from which a deleterious exon has been skipped. The term “antisense oligonucleotide”, as used herein, refers to an oligonucleotidecomplementary to a target nucleic acid. In some embodiments, an antisense oligonucleotide is capable of directing an increase in the level of skipping of a deleterious exon in a target nucleic acid and / or increase in production of a gene product produced from a target nucleic acid from which a deleterious exon has been skipped.

[0036] Aryl: The term “aryl", as used herein, used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic, bicyclic or polycyclic ring systems having a total of five to thirty ring members, wherein at least one ring in the system is aromatic. In some embodiments, an aryl group is a monocyclic, bicyclic or polycyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 7 ring members. In some embodiments, an aryl group is a biaryl group. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but is not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.

[0037] Chiral control: As used herein, “chiral control” refers to control of the stereochemical designation of the chiral linkage phosphorus in a chiral internucleotidic linkage within an oligonucleotide. As used herein, a chiral internucleotidic linkage is an internucleotidic linkage whose linkage phosphorus is chiral. In some embodiments, a control is achieved through a chiral element that is absent from the sugar and base moieties of an oligonucleotide, for example, in some embodiments, a control is achieved through use of one or more chiral auxiliaries during oligonucleotide preparation as described in the present disclosure, which chiral auxiliaries often are part of chiral coupling partners (e.g., chiral phosphoramidites) used during oligonucleotide preparation. In contrast to chiral control, a person having ordinary skill in the art appreciates that conventional oligonucleotide synthesis which does not use chiral auxiliaries cannot control stereochemistry at a chiral internucleotidic linkage if such conventional oligonucleotide synthesis is used to form the chiral internucleotidic linkage. In some embodiments, the stereochemical designation of each chiral linkage phosphorus in each chiral internucleotidic linkage within an oligonucleotide is controlled.

[0038] Chirally controlled oligonucleotide composition: The terms “chirally controlled oligonucleotide composition”, “chirally controlled nucleic acid composition”, and the like, as used herein, refers to a composition that comprises a plurality of oligonucleotides (or nucleic acids) which share a common constitution; or which share 1) a common base sequence, and / or 2) a common pattern of backbone linkages, and 3) a common pattern of backbone phosphorus modifications, wherein the plurality ofoligonucleotides (or nucleic acids) share the same linkage phosphorus stereochemistry at one or more chiral internucleotidic linkages (chirally controlled or stereodefined internucleotidic linkages, whose chiral linkage phosphorus is Rp or Sp in the composition (“stereodefined”), not a random Rp and Sp mixture as non-chirally controlled internucleotidic linkages). Level of the plurality of oligonucleotides (or nucleic acids) in a chirally controlled oligonucleotide composition is pre-determined / controlled (e.g., through chirally controlled oligonucleotide preparation to stereoselectively form one or more chiral internucleotidic linkages). In some embodiments, about 1%-100%, (e.g., about 5%-100%, 10%-100%, 20%-100%, 30%- 100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80-100%, 90-100%, 95-100%, 50%-90%, or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of all oligonucleotides in a chirally controlled oligonucleotide composition are oligonucleotides of the plurality. In some embodiments, about 1%-100%, (e.g., about 5%- 100%, 10%-100%, 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80-100%, 90-100%, 95-100%, 50%-90%, or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of all oligonucleotides in a chirally controlled oligonucleotide composition that share the common base sequence, the common pattern of backbone linkages, and the common pattern of backbone phosphorus modifications are oligonucleotides of the plurality. In some embodiments, a level is about 1%-100%, (e.g., about 5%-100%, 10%-100%, 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80-100%, 90- 100%, 95-100%, 50%-90%, or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of all oligonucleotides in a composition, or of all oligonucleotides in a composition that share a common base sequence (e.g., of a plurality of oligonucleotide or an oligonucleotide type), or of all oligonucleotides in a composition that share a common base sequence, a common pattern of backbone linkages, and a common pattern of backbone phosphorus modifications, or of all oligonucleotides in a composition that share a common base sequence, a common patter of base modifications, a common pattern of sugar modifications, a common pattern of internucleotidic linkage types, and / or a common pattern of internucleotidic linkage modifications. In some embodiments, the plurality of oligonucleotides share the same stereochemistry at about 1-50 (e.g., about 1- 10, 1-20, 5-10, 5-20, 10-15, 10-20, 10-25, 10-30, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) chiral internucleotidic linkages. In some embodiments, the plurality of oligonucleotides share the same stereochemistry at about 1%-100% (e.g., about 5%-100%, 10%-100%, 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80-100%, 90-100%, 95-100%, 50%-90%, about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%) of chiral internucleotidic linkages. In some embodiments, oligonucleotides (or nucleic acids) of a plurality are of the same constitution. In some embodiments, level of the oligonucleotides (or nucleic acids) of the plurality is about 1%-100%, (e.g., about 5%-100%, 10%-100%, 20%-100%, 30%- 100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80-100%, 90-100%, 95-100%, 50%-90%, or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of all oligonucleotides (or nucleic acids) in a composition that share the same constitution as the oligonucleotides (or nucleic acids) of the plurality. In some embodiments, each chiral internucleotidic linkage is a chiral controlled internucleotidic linkage, and the composition is a completely chirally controlled oligonucleotide composition. In some embodiments, oligonucleotides (or nucleic acids) of a plurality are structurally identical. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, typically at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 95%. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 96%. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 97%. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 98%. In some embodiments, a chirally controlled internucleotidic linkage has a diastereopurity of at least 99%. In some embodiments, a percentage of a level is or is at least (DS)nc, wherein DS is a diastereopurity as described in the present disclosure (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% or more) and nc is the number of chirally controlled internucleotidic linkages as described in the present disclosure (e.g., 1-50, 1-40, 1-30, 1-25, 1-20, 5-50, 5-40, 5-30, 5-25, 5-20, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more). In some embodiments, a percentage of a level is or is at least (DS)nc, wherein DS is 95%-100%. For example, when DS is 99% and nc is 10, the percentage is or is at least 90% ((99%)10≈ 0.90 = 90%). In some embodiments, level of a plurality of oligonucleotides in a composition is represented as the product of the diastereopurity of each chirally controlled internucleotidic linkage in the oligonucleotides. In some embodiments, diastereopurity of an internucleotidic linkage connecting two nucleosides in an oligonucleotide (or nucleic acid) is represented by the diastereopurity of an internucleotidic linkage of a dimer connecting the same two nucleosides, wherein the dimer is prepared using comparable conditions, in some instances, identical synthetic cycle conditions (e.g., for the linkage between Nx and Ny in an oligonucleotide ….NxNy….., the dimer is NxNy).In some embodiments, not all chiral internucleotidic linkages are chiral controlled internucleotidic linkages, and the composition is a partially chirally controlled oligonucleotide composition. In some embodiments, a non-chirally controlled internucleotidic linkage has a diastereopurity of less than about 80%, 75%, 70%, 65%, 60%, 55%, or of about 50%, as typically observed in stereorandom oligonucleotide compositions (e.g., as appreciated by those skilled in the art, from traditional oligonucleotide synthesis, e.g., the phosphoramidite method). In some embodiments, oligonucleotides (or nucleic acids) of a plurality are of the same type. In some embodiments, a chirally controlled oligonucleotide composition comprises non- random or controlled levels of individual oligonucleotide or nucleic acids types. For instance, in some embodiments a chirally controlled oligonucleotide composition comprises one and no more than one oligonucleotide type. In some embodiments, a chirally controlled oligonucleotide composition comprises more than one oligonucleotide type. In some embodiments, a chirally controlled oligonucleotide composition comprises multiple oligonucleotide types. In some embodiments, a chirally controlled oligonucleotide composition is a composition of oligonucleotides of an oligonucleotide type, which composition comprises a non-random or controlled level of a plurality of oligonucleotides of the oligonucleotide type.

[0039] Comparable: The term “comparable” is used herein to describe two (or more) sets of conditions or circumstances that are sufficiently similar to one another to permit comparison of results obtained or phenomena observed. In some embodiments, comparable sets of conditions or circumstances are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will appreciate that sets of conditions are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under the different sets of conditions or circumstances are caused by or indicative of the variation in those features that are varied.

[0040] Cycloaliphatic: The term “cycloaliphatic,” “carbocycle,” “carbocyclyl,” “carbocyclic radical,” and “carbocyclic ring,” are used interchangeably, and as used herein, refer to saturated or partially unsaturated, but non-aromatic, cyclic aliphatic monocyclic, bicyclic, or polycyclic ring systems, as described herein, having, unless otherwise specified, from 3 to 30 ring members. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, a cycloaliphatic group has 3–6 carbons. In some embodiments, a cycloaliphatic group is saturated and is cycloalkyl. The term “cycloaliphatic” may also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl. In some embodiments, a cycloaliphatic group is bicyclic. In some embodiments, a cycloaliphatic group is tricyclic. In some embodiments, a cycloaliphatic group is polycyclic. In some embodiments, “cycloaliphatic” refersto C3-C6monocyclic hydrocarbon, or C8-C10bicyclic or polycyclic hydrocarbon, that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule, or a C9-C16polycyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.

[0041] Dosing regimen: As used herein, a “dosing regimen” or “therapeutic regimen” refers to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount.

[0042] Heteroaliphatic: The term “heteroaliphatic”, as used herein, is given its ordinary meaning in the art and refers to aliphatic groups as described herein in which one or more carbon atoms are independently replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like). In some embodiments, one or more units selected from C, CH, CH2, and CH3are independently replaced by one or more heteroatoms (including oxidized and / or substituted forms thereof). In some embodiments, a heteroaliphatic group is heteroalkyl. In some embodiments, a heteroaliphatic group is heteroalkenyl.

[0043] Heteroalkyl: The term “heteroalkyl”, as used herein, is given its ordinary meaning in the art and refers to alkyl groups as described herein in which one or more carbon atoms are independently replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like). Examples of heteroalkyl groups include, but are not limited to, alkoxy, poly(ethylene glycol)-, alkyl- substituted amino, tetrahydrofuranyl, piperidinyl, morpholinyl, etc.

[0044] Heteroaryl: The terms “heteroaryl” and “heteroar–”, as used herein, used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to monocyclic, bicyclic or polycyclic ring systems having a total of five to thirty ring members, wherein at least one ring in the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, a heteroaryl group is a group having 5 to 10 ring atoms (i.e., monocyclic, bicyclic or polycyclic), in some embodiments 5, 6, 9, or 10 ringatoms. In some embodiments, a heteroaryl group has 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, a heteroaryl is a heterobiaryl group, such as bipyridyl and the like. The terms “heteroaryl” and “heteroar–”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3– b]–1,4–oxazin–3(4H)–one. A heteroaryl group may be monocyclic, bicyclic or polycyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0045] Heteroatom: The term “heteroatom", as used herein, means an atom that is not carbon or hydrogen. In some embodiments, a heteroatom is boron, oxygen, sulfur, nitrogen, phosphorus, or silicon (including oxidized forms of nitrogen, sulfur, phosphorus, or silicon; charged forms of nitrogen (e.g., quaternized forms, forms as in iminium groups, etc.), phosphorus, sulfur, oxygen; etc.). In some embodiments, a heteroatom is oxygen, sulfur or nitrogen. In some embodiments, at least one heteroatom is nitrogen.

[0046] Heterocycle: As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring", as used herein, are used interchangeably and refer to a monocyclic, bicyclic or polycyclic ring moiety (e.g., 3-30 membered) that is saturated or partially unsaturated and has one or more heteroatom ring atoms. In some embodiments, a heterocyclyl group is a stable 5– to 7– membered monocyclic or 7– to 10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0–3 heteroatoms selected from oxygen, sulfur and nitrogen, the nitrogen may be N (as in 3,4–dihydro–2H– pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N–substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturatedheterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H–indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be monocyclic, bicyclic or polycyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0047] Identity: As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., oligonucleotides, DNA, RNA, etc.) and / or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. Calculation of the percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of a reference sequence. The nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0). In some exemplary embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using a NWSgapdna.CMP matrix.

[0048] Internucleotidic linkage: As used herein, the phrase “internucleotidic linkage” refers generally to a linkage linking nucleoside units of an oligonucleotide or a nucleic acid. In someembodiments, an internucleotidic linkage is a phosphodiester linkage, as extensively found in naturally occurring DNA and RNA molecules (natural phosphate linkage (−OP(=O)(OH)O−), which as appreciated by those skilled in the art may exist as a salt form). In some embodiments, an internucleotidic linkage is a modified internucleotidic linkage (not a natural phosphate linkage). In some embodiments, an internucleotidic linkage is a “modified internucleotidic linkage” wherein at least one oxygen atom or −OH of a phosphodiester linkage is replaced by a different organic or inorganic moiety. In some embodiments, such an organic or inorganic moiety is selected from =S, =Se, =NR’, –SR’, –SeR’, –N(R’)2, B(R’)3,–S–, – Se–, and –N(R’)–, wherein each R’ is independently as defined and described in the present disclosure. In some embodiments, an internucleotidic linkage is a phosphorothioate linkage (or phosphorothioate diester linkage, −OP(=O)(SH)O−, which as appreciated by those skilled in the art may exist as a salt form). In some embodiments, an internucleotidic linkage is one of, e.g., PNA (peptide nucleic acid) or PMO (phosphorodiamidate Morpholino oligomer) linkage. In some embodiments, a modified internucleotidic linkage is a non-negatively charged internucleotidic linkage. In some embodiments, a modified internucleotidic linkage is a neutral internucleotidic linkage (e.g., n001 in certain provided oligonucleotides). In some embodiments, a modified internucleotidic linkage comprise no linkage phosphorus (e.g., −C(O)−O− or −C(O)−N(R’)− as described herein). It is understood by a person of ordinary skill in the art that internucleotidic linkages may exist as anions or cations at a given pH due to the existence of acid or base moieties in the linkages.

[0049] In certain embodiments, a non-negatively charged internucleotidic linkage comprises a cyclic guanidine moiety. In certain embodiments, a modified internucleotidic linkage comprising a cyclic guanidine moiety has the structure of:. In certain embodiments, a neutral internucleotidic linkage comprising a cyclic guanidine moiety is chirally controlled. In certain embodiments, the present disclosure pertains to a composition comprising an oligonucleotide comprising at least one neutral internucleotidic linkage and at least one phosphorothioate internucleotidic linkage.

[0050] In certain embodiments, the present disclosure pertains to a composition comprising an oligonucleotide comprising at least one neutral internucleotidic linkage and at least one phosphorothioate internucleotidic linkage, wherein the phosphorothioate internucleotidic linkage is a chirally controlled internucleotidic linkage in the Sp configuration.

[0051] In certain embodiments, the present disclosure pertains to a composition comprising an oligonucleotide comprising at least one neutral internucleotidic linkage and at least one phosphorothioate internucleotidic linkage, wherein the phosphorothioate is a chirally controlled internucleotidic linkage inthe Rp configuration.

[0052] In certain embodiments, the present disclosure pertains to a composition comprising an oligonucleotide comprising at least one neutral internucleotidic linkage of a neutral internucleotidic linkage comprising a Tmg group (least one phosphorothioate.

[0053] In certain embodiments, each internucleotidic linkage in an oligonucleotide is independently selected from a natural phosphate linkage, a phosphorothioate linkage, and a non-negatively charged internucleotidic linkage (e.g., n001, n003, n004, n006, n008, n009, n013, n020, n021, n025, n026, n029, n031, n037, n046, n047, n048, n054, or n055). In some embodiments, each internucleotidic linkage in an oligonucleotide is independently selected from a natural phosphate linkage, a phosphorothioate linkage, and a neutral internucleotidic linkage (e.g., n001, n003, n004, n006, n008, n009, n013 n020, n021, n025, n026, n029, n031, n037, n046, n047, n048, n054, or n055). In some embodiments, an oligonucleotide comprises an internucleotidic linkage selected from n001, n002, n003, n004, n006, n008, n009, n012, n013 n020, n021, n024, n025, n026, n029, n030, n031, n033, n034, n035, n036, n037, n041, n043, n044, n046, n047, n048, n051, n052, n054, n055, and n057.

[0054] As used herein, the phrase “linkage phosphorus” is used to indicate that the particular phosphorus atom being referred to is the phosphorus atom present in an internucleotidic linkage, which phosphorus atom corresponds to the phosphorus atom of a phosphodiester internucleotidic linkage as occurs in naturally occurring DNA and RNA. In some embodiments, a linkage phosphorus atom is in a modified internucleotidic linkage, wherein each oxygen atom of a phosphodiester linkage is optionally and independently replaced by an organic or inorganic moiety. In some embodiments, a linkage phosphorus atom is the P of Formula I as described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858). In some embodiments, a linkage phosphorus atom is chiral. In some embodiments, a linkage phosphorus atom is achiral (e.g., as in natural phosphate linkages). In some embodiments, a linkage phosphorus is bonded to a sugar through an oxygen or a nitrogen atom.

[0055] Linker: The terms “linker”, “linking moiety” and the like refer to any chemical moiety which connects one chemical moiety to another. As appreciated by those skilled in the art, a linker can be bivalent or trivalent or more, depending on the number of chemical moieties the linker connects. In some embodiments, a linker is a moiety which connects one oligonucleotide to another oligonucleotide in amultimer. In some embodiments, a linker is a moiety optionally positioned between the terminal nucleoside and the solid support or between the terminal nucleoside and another nucleoside, nucleotide, or nucleic acid. In some embodiments, in an oligonucleotide a linker connects a chemical moiety (e.g., a targeting moiety, a lipid moiety, a carbohydrate moiety, etc.) with an oligonucleotide chain (e.g., through its 5’-end, 3’-end, nucleobase, sugar, internucleotidic linkage, etc.)

[0056] Modified nucleobase: The terms "modified nucleobase", "modified base" and the like refer to a chemical moiety which differs structurally from a natural nucleobase but is capable of performing at least one function of a natural nucleobase. In some embodiments, a modified nucleobase is capable of, e.g., forming a moiety in a polymer capable of base-pairing to a nucleic acid comprising a complementary sequence of bases. In some embodiments, a modified nucleobase is substituted A, T, C, G, or U, or a substituted tautomer of A, T, C, G, or U. In some embodiments, a modified nucleobase in the context of oligonucleotides refer to a nucleobase that is not A, T, C, G or U.

[0057] Modified nucleoside: The term "modified nucleoside" refers to a moiety derived from or chemically similar to a natural nucleoside, but which comprises a chemical modification which differentiates it from a natural nucleoside. Non-limiting examples of modified nucleosides include those which comprise a modification at the base and / or the sugar. In some embodiments, a modified nucleoside comprises a modified nucleobase. In some embodiments, a modified nucleoside comprises a modified sugar. In some embodiments, a modified nucleoside comprises a modified nucleobase and a modified sugar. Non-limiting examples of modified nucleosides include those with a 2’ modification at a sugar. Non-limiting examples of modified nucleosides also include abasic nucleosides (which lack a nucleobase). In some embodiments, a modified nucleoside is capable of at least one function of a nucleoside, e.g., forming a moiety in a polymer capable of base-pairing to a nucleic acid comprising a complementary sequence of bases.

[0058] Modified nucleotide: The term “modified nucleotide” refers to a chemical moiety which differs structurally from a natural nucleotide but is capable of performing at least one function of a natural nucleotide. In some embodiments, a modified nucleotide comprises a modification at a sugar, base and / or internucleotidic linkage. In some embodiments, a modified nucleotide comprises a modified sugar, a modified nucleobase and / or a modified internucleotidic linkage. In some embodiments, a modified nucleotide is capable of, e.g., forming a subunit in a polymer capable of base-pairing to a nucleic acid comprising an at least complementary sequence of bases.

[0059] Modified sugar: The term “modified sugar” refers to a moiety which differs structurally from the natural ribose and deoxyribose sugars typically found in natural DNA and RNA and can replace a sugar in an oligonucleotide or a nucleic acid. A modified sugar mimics the spatial arrangement, electronic properties, or some other physicochemical property of a sugar. In some embodiments, as described in thepresent disclosure, a modified sugar is substituted ribose or deoxyribose. In some embodiments, a modified sugar comprises a 2’-modification. Examples of useful 2’- modification are widely utilized in the art and described herein. In some embodiments, a 2’-modification is 2’-OR, wherein R is optionally substituted C1-10aliphatic. In some embodiments, a 2’-modification is 2’-OMe. In some embodiments, a 2’- modification is 2’-MOE. In some embodiments, a modified sugar is a bicyclic sugar (e.g., a sugar used in LNA, BNA, etc.). In some embodiments, a modified sugar comprises a ring that is not a 5-membered ring. In some embodiments, a modified sugar is acyclic sugar. In some embodiments, a modified sugar comprises a nitrogen atom. In some embodiments, a modified sugar comprises a nitrogen atom, and is bond to an internucleotidic linkage through the nitrogen atom.

[0060] Nucleic acid: The term “nucleic acid”, as used herein, includes any nucleotides and polymers thereof. The term “polynucleotide”, as used herein, refers to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) or a combination thereof. These terms refer to the primary structure of the molecules and, thus, include double- and single-stranded DNA, and double- and single-stranded RNA. These terms include, as equivalents, analogs of either RNA or DNA comprising modified nucleotides and / or modified polynucleotides, such as, though not limited to, methylated, protected and / or capped nucleotides or polynucleotides. The terms encompass poly- or oligo- ribonucleotides (RNA) and poly- or oligo-deoxyribonucleotides (DNA); RNA or DNA derived from N- glycosides or C-glycosides of nucleobases and / or modified nucleobases; nucleic acids derived from sugars and / or modified sugars; and nucleic acids derived from phosphate bridges and / or modified internucleotidic linkages. The term encompasses nucleic acids containing any combinations of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges or modified internucleotidic linkages. Examples include, and are not limited to, nucleic acids containing ribose moieties, nucleic acids containing deoxy- ribose moieties, nucleic acids containing both ribose and deoxyribose moieties, nucleic acids containing ribose and modified ribose moieties. Unless otherwise specified, the prefix poly- refers to a nucleic acid containing 2 to about 10,000 nucleotide monomer units and wherein the prefix oligo- refers to a nucleic acid containing 2 to about 200 nucleotide monomer units.

[0061] Nucleobase: The term “nucleobase” refers to moieties that forms parts of nucleic acids that are involved in the hydrogen-bonding that binds one nucleic acid strand to another complementary strand in a sequence specific manner. The most common naturally-occurring nucleobases are adenine (A), guanine (G), uracil (U), cytosine (C), and thymine (T). In some embodiments, a naturally-occurring nucleobases are modified adenine, guanine, uracil, cytosine, or thymine. In some embodiments, a naturally- occurring nucleobases are methylated adenine, guanine, uracil, cytosine, or thymine. In some embodiments, a nucleobase comprises a heteroaryl ring wherein a ring atom is nitrogen, and when in a nucleoside, the nitrogen is bonded to a sugar moiety. In some embodiments, a nucleobase comprises aheterocyclic ring wherein a ring atom is nitrogen, and when in a nucleoside, the nitrogen is bonded to a sugar moiety. In some embodiments, a nucleobase is a “modified nucleobase,” and is a nucleobase other than adenine (A), guanine (G), uracil (U), cytosine (C), and thymine (T). In some embodiments, a modified nucleobase is substituted A, T, C, G or U. In some embodiments, a modified nucleobase is a substituted tautomer of A, T, C, G, or U. In some embodiments, a modified nucleobases is methylated adenine, guanine, uracil, cytosine, or thymine. In some embodiments, a modified nucleobase mimics the spatial arrangement, electronic properties, or some other physicochemical property of the nucleobase and retains the property of hydrogen-bonding that binds one nucleic acid strand to another in a sequence specific manner. In some embodiments, a modified nucleobase can pair with all of the five naturally occurring bases (uracil, thymine, adenine, cytosine, or guanine) without substantially affecting the melting behavior, recognition by intracellular enzymes or activity of the oligonucleotide duplex. As used herein, the term “nucleobase” also encompasses structural analogs used in lieu of natural or naturally-occurring nucleotides, such as modified nucleobases. In some embodiments, a nucleobase is optionally substituted A, T, C, G, or U, or an optionally substituted tautomer of A, T, C, G, or U. In some embodiments, a “nucleobase” refers to a nucleobase unit in an oligonucleotide or a nucleic acid (e.g., A, T, C, G or U as in an oligonucleotide or a nucleic acid).

[0062] Nucleoside: The term “nucleoside” refers to a moiety wherein a nucleobase or a modified nucleobase is covalently bound to a sugar or a modified sugar. In some embodiments, a nucleoside is a natural nucleoside, e.g., adenosine, deoxyadenosine, guanosine, deoxyguanosine, thymidine, uridine, cytidine, or deoxycytidine. In some embodiments, a nucleoside is a modified nucleoside, e.g., a substituted natural nucleoside selected from adenosine, deoxyadenosine, guanosine, deoxyguanosine, thymidine, uridine, cytidine, and deoxycytidine. In some embodiments, a nucleoside is a modified nucleoside, e.g., a substituted tautomer of a natural nucleoside selected from adenosine, deoxyadenosine, guanosine, deoxyguanosine, thymidine, uridine, cytidine, and deoxycytidine. In some embodiments, a “nucleoside” refers to a nucleoside unit in an oligonucleotide or a nucleic acid.

[0063] Nucleotide: The term “nucleotide” as used herein refers to a monomeric unit of a polynucleotide that consists of a nucleobase, a sugar, and one or more internucleotidic linkages (e.g., phosphate linkages in natural DNA and RNA). The naturally occurring bases [guanine, (G), adenine, (A), cytosine, (C), thymine, (T), and uracil (U)] are derivatives of purine or pyrimidine, though it should be understood that naturally and non-naturally occurring base analogs are also included. The naturally occurring sugar is the pentose (five-carbon sugar) deoxyribose (which forms DNA) or ribose (which forms RNA), though it should be understood that naturally and non-naturally occurring sugar analogs are also included. Nucleotides are linked via internucleotidic linkages to form nucleic acids, or polynucleotides. Many internucleotidic linkages are known in the art (such as, though not limited to, phosphate,phosphorothioates, boranophosphates and the like). Artificial nucleic acids include PNAs (peptide nucleic acids), phosphotriesters, phosphorothionates, H-phosphonates, phosphoramidates, boranophosphates, methylphosphonates, phosphonoacetates, thiophosphonoacetates and other variants of the phosphate backbone of native nucleic acids, such as those described herein. In some embodiments, a natural nucleotide comprises a naturally occurring base, sugar and internucleotidic linkage. As used herein, the term “nucleotide” also encompasses structural analogs used in lieu of natural or naturally-occurring nucleotides, such as modified nucleotides. In some embodiments, a “nucleotide” refers to a nucleotide unit in an oligonucleotide or a nucleic acid.

[0064] Oligonucleotide: The term "oligonucleotide" refers to a polymer or oligomer of nucleotides, and may contain any combination of natural and non-natural nucleobases, sugars, and internucleotidic linkages.

[0065] Oligonucleotides can be single-stranded or double-stranded. A single-stranded oligonucleotide can have double-stranded regions (formed by two portions of the single-stranded oligonucleotide) and a double-stranded oligonucleotide, which comprises two oligonucleotide chains, can have single-stranded regions for example, at regions where the two oligonucleotide chains are not complementary to each other. Example oligonucleotides include, but are not limited to structural genes, genes including control and termination regions, self-replicating systems such as viral or plasmid DNA, single-stranded and double-stranded RNAi agents and other RNA interference reagents (RNAi agents or iRNA agents), shRNA, antisense oligonucleotides, ribozymes, microRNAs, microRNA mimics, supermirs, aptamers, antimirs, antagomirs, Ul adaptors, triplex-forming oligonucleotides, G-quadruplex oligonucleotides, RNA activators, immuno-stimulatory oligonucleotides, and decoy oligonucleotides.

[0066] Oligonucleotides of the present disclosure can be of various lengths. In particular embodiments, oligonucleotides can range from about 2 to about 200 nucleosides in length. In various related embodiments, oligonucleotides, single-stranded, double-stranded, or triple-stranded, can range in length from about 4 to about 10 nucleosides, from about 10 to about 50 nucleosides, from about 20 to about 50 nucleosides, from about 15 to about 30 nucleosides, from about 20 to about 30 nucleosides in length. In some embodiments, the oligonucleotide is from about 9 to about 39 nucleosides in length. In some embodiments, the oligonucleotide is at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleosides in length. In some embodiments, the oligonucleotide is at least 4 nucleosides in length. In some embodiments, the oligonucleotide is at least 5 nucleosides in length. In some embodiments, the oligonucleotide is at least 6 nucleosides in length. In some embodiments, the oligonucleotide is at least 7 nucleosides in length. In some embodiments, the oligonucleotide is at least 8 nucleosides in length. In some embodiments, the oligonucleotide is at least 9 nucleosides in length. In some embodiments, the oligonucleotide is at least 10 nucleosides in length. In some embodiments, the oligonucleotide is at least11 nucleosides in length. In some embodiments, the oligonucleotide is at least 12 nucleosides in length. In some embodiments, the oligonucleotide is at least 15 nucleosides in length. In some embodiments, the oligonucleotide is at least 15 nucleosides in length. In some embodiments, the oligonucleotide is at least 16 nucleosides in length. In some embodiments, the oligonucleotide is at least 17 nucleosides in length. In some embodiments, the oligonucleotide is at least 18 nucleosides in length. In some embodiments, the oligonucleotide is at least 19 nucleosides in length. In some embodiments, the oligonucleotide is at least 20 nucleosides in length. In some embodiments, the oligonucleotide is at least 25 nucleosides in length. In some embodiments, the oligonucleotide is at least 30 nucleosides in length. In some embodiments, the oligonucleotide is a duplex of complementary strands of at least 18 nucleosides in length. In some embodiments, the oligonucleotide is a duplex of complementary strands of at least 21 nucleosides in length. In some embodiments, each nucleoside counted in an oligonucleotide length independently comprises A, T, C, G, or U, or optionally substituted A, T, C, G, or U, or an optionally substituted tautomer of A, T, C, G or U.

[0067] Oligonucleotide type: As used herein, the phrase “oligonucleotide type” is used to define an oligonucleotide that has a particular base sequence, pattern of backbone linkages (i.e., pattern of internucleotidic linkage types, for example, phosphate, phosphorothioate, phosphorothioate triester, etc.), pattern of backbone chiral centers [i.e., pattern of linkage phosphorus stereochemistry (Rp / Sp)], and pattern of backbone phosphorus modifications (e.g., pattern of “−XLR1” groups in Formula I as described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858). In some embodiments, oligonucleotides of a common designated “type” are structurally identical to one another.

[0068] One of skill in the art will appreciate that synthetic methods of the present disclosure provide for a degree of control during the synthesis of an oligonucleotide strand such that each nucleotide unit of the oligonucleotide strand can be designed and / or selected in advance to have a particular stereochemistry at the linkage phosphorus and / or a particular modification at the linkage phosphorus, and / or a particular base, and / or a particular sugar. In some embodiments, an oligonucleotide strand is designed and / or selected in advance to have a particular combination of stereocenters at the linkage phosphorus. In some embodiments, an oligonucleotide strand is designed and / or determined to have a particular combination of modifications at the linkage phosphorus. In some embodiments, an oligonucleotide strand is designed and / or selected to have a particular combination of bases. In some embodiments, an oligonucleotide strand is designed and / or selected to have a particular combination of one or more of theabove structural characteristics. In some embodiments, the present disclosure provides compositions comprising or consisting of a plurality of oligonucleotide molecules (e.g., chirally controlled oligonucleotide compositions). In some embodiments, all such molecules are of the same type (i.e., are structurally identical to one another). In some embodiments, however, provided compositions comprise a plurality of oligonucleotides of different types, typically in pre-determined relative amounts.

[0069] Optionally Substituted: As described herein, compounds, e.g., oligonucleotides, of the disclosure may contain optionally substituted and / or substituted moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. In some embodiments, an optionally substituted group is unsubstituted. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein. Certain substituents are described below.

[0070] Suitable monovalent substituents on a substitutable atom, e.g., a suitable carbon atom, are independently halogen; –(CH2)0–4R°; –(CH2)0–4OR°; −O(CH2)0-4Ro, –O–(CH2)0–4C(O)OR°; –(CH2)0–4CH(OR°)2; –(CH2)0–4Ph, which may be substituted with R°; −(CH2)0–4O(CH2)0–1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0–1-pyridyl which may be substituted with R°; –NO2; –CN; –N3; -(CH2)0–4N(R°)2; –(CH2)0–4N(R°)C(O)R°; –N(R°)C(S)R°; −(CH2)0–4N(R°)C(O)NR°2; −N(R°)C(S)NR°2; –(CH2)0–4N(R°)C(O)OR°; –N(R°)N(R°)C(O)R°; −N(R°)N(R°)C(O)NR°2; −N(R°)N(R°)C(O)OR°; –(CH2)0–4C(O)R°; –C(S)R°; –(CH2)0–4C(O)OR°; −(CH2)0–4C(O)SR°; -(CH2)0–4C(O)OSiR°3; –(CH2)0–4OC(O)R°; –OC(O)(CH2)0–4SR°, −SC(S)SR°; −(CH2)0–4SC(O)R°; –(CH2)0–4C(O)NR°2; –C(S)NR°2; –C(S)SR°; -(CH2)0–4OC(O)NR°2; -C(O)N(OR°)R°; –C(O)C(O)R°; –C(O)CH2C(O)R°; −C(NOR°)R°; -(CH2)0–4SSR°; –(CH2)0–4S(O)2R°; –(CH2)0–4S(O)2OR°; –(CH2)0–4OS(O)2R°; −S(O)2NR°2; -(CH2)0–4S(O)R°; –N(R°)S(O)2NR°2; –N(R°)S(O)2R°; –N(OR°)R°; −C(NH)NR°2; –Si(R°)3; –OSi(R°)3; −B(R°)2; −OB(R°)2; −OB(OR°)2; −P(R°)2; −P(OR°)2; −P(R°)(OR°); −OP(R°)2; −OP(OR°)2; −OP(R°)(OR°); −P(O)(R°)2; −P(O)(OR°)2; −OP(O)(R°)2; −OP(O)(OR°)2; −OP(O)(OR°)(SR°); −SP(O)(R°)2; −SP(O)(OR°)2; −N(R°)P(O)(R°)2; −N(R°)P(O)(OR°)2; −P(R°)2[B(R°)3]; −P(OR°)2[B(R°)3]; −OP(R°)2[B(R°)3]; −OP(OR°)2[B(R°)3]; –(C1–4straight or branchedalkylene)0-N(R°)2; or -(C1-4 straight or branched alkylene)C(0)0-N(R°)2, wherein each R° may be substituted as defined herein and is independently hydrogen, Ci-20 aliphatic, Ci-20 heteroaliphatic having 1- 5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, -CH2-(C6-i4 aryl), -0(CH2)o-i(C6-i4aryl), -CH2-(5-14 membered heteroaryl ring), a 5-20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 5-20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, which may be substituted as defined below.

[0071] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o-2R*, - (haloR*), -(CH2)O-2OH, -(CH2)O-2OR·, -(CH2)O-2CH(OR●)2; -0(haloR●), -CN, -N3, -(CH2)o-2C(0)R●, - (CH2)O-2C(0)OH, -(CH2)O-2C(0)OR·, -(CH2)O-2SR●, -(CH2)O-2SH, -(CH2)O-2NH2, -(CH2)O-2NHR·, - (CH2)O-2NR●2, -NO2, -SiR*3, -OSiR*3, -C(0)SR* -(C1-4 straight or branched alkylene)C(0)OR*, or - SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1-4 aliphatic, -CH2PI1, -0(CH2)o-iPh, and a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0072] Suitable divalent substituents, e.g., on a suitable carbon atom, are independently the following: =0, =S, =NNR*2 =NNHC(0)R*=NNHC(0)OR*=NNHS(0)2R*, =NR*, =NOR*-0(C(R*2))2- 3O-, or -S(C(R*2))2-3S-, wherein each independent occurrence of R*is selected from hydrogen, C1-6aliphatic which may be substituted as defined below, and an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -0(CR*2)2-30-, wherein each independent occurrence of R*is selected from hydrogen, C1-6aliphatic which may be substituted as defined below, and an unsubstituted 5-6-membered saturated, partially unsaturated, and aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0073] Suitable substituents on the aliphatic group of R●are independently halogen,-R·, -(haloR*), -OH, -OR●, -0(haloR●), -CN, -C(0)OH, -C(0)OR●, -NH2, NHR\ -NRV or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4aliphatic, -CH2Ph , -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0074] In some embodiments, suitable substituents on a substitutable nitrogen are independently-R†, -NR†2, -C(0)R†, -C(0)0R†, -C(0)C(0)R†, -C(0)CH2C(0)R†, -S(0)2R†, -S(0)2NR†2, -C(S)NR†2, - C(NH)NR†2, or -N(R†)S(0)2R†; wherein each R†is independently hydrogen, Ci_6aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0075] Suitable substituents on the aliphatic group of R†are independently halogen,-R·, -(haloR*), -OH, -OR●, -0(haloR●), -CN, -C(0)OH, -C(0)OR●, -NH2, NHR\ -NRV or -N02, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci^taliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0076] P-modification: as used herein, the term “P-modification” refers to any modification at the linkage phosphorus other than a stereochemical modification. In some embodiments, a P-modification comprises addition, substitution, or removal of a pendant moiety covalently attached to a linkage phosphorus.

[0077] Partially unsaturated: As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0078] Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, an active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonary, and to other mucosalsurfaces.

[0079] Pharmaceutically acceptable: As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0080] Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically- acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

[0081] Pharmaceutically acceptable salt: The term “pharmaceutically acceptable salt”, as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, i.e., salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In some embodiments, pharmaceutically acceptable salt include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate,digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, a provided compound comprises one or more acidic groups, e.g., an oligonucleotide, and a pharmaceutically acceptable salt is an alkali, alkaline earth metal, or ammonium (e.g., an ammonium salt of N(R)3, wherein each R is independently defined and described in the present disclosure) salt. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a pharmaceutically acceptable salt is a sodium salt. In some embodiments, a pharmaceutically acceptable salt is a potassium salt. In some embodiments, a pharmaceutically acceptable salt is a calcium salt. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate. In some embodiments, a provided compound comprises more than one acid groups, for example, an oligonucleotide may comprise two or more acidic groups (e.g., in natural phosphate linkages and / or modified internucleotidic linkages). In some embodiments, a pharmaceutically acceptable salt, or generally a salt, of such a compound comprises two or more cations, which can be the same or different. In some embodiments, in a pharmaceutically acceptable salt (or generally, a salt), all ionizable hydrogen (e.g., in an aqueous solution with a pKa no more than about 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2; in some embodiments, no more than about 7; in some embodiments, no more than about 6; in some embodiments, no more than about 5; in some embodiments, no more than about 4; in some embodiments, no more than about 3) in the acidic groups are replaced with cations. In some embodiments, each phosphorothioate and phosphate group independently exists in its salt form (e.g., if sodium salt, −O−P(O)(SNa)−O− and −O−P(O)(ONa)−O−, respectively). In some embodiments, each phosphorothioate and phosphate internucleotidic linkage independently exists in its salt form (e.g., if sodium salt, −O−P(O)(SNa)−O− and −O−P(O)(ONa)−O−, respectively). In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide. In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide, wherein each acidic phosphate and modified phosphate group (e.g., phosphorothioate, phosphate, etc.), if any, exists as a salt form (all sodium salt).

[0082] Predetermined: By predetermined (or pre-determined) is meant deliberately selected or non-random or controlled, for example as opposed to randomly occurring, random, or achieved without control. Those of ordinary skill in the art, reading the present specification, will appreciate that the presentdisclosure provides technologies that permit selection of particular chemistry and / or stereochemistry features to be incorporated into oligonucleotide compositions, and further permits controlled preparation of oligonucleotide compositions having such chemistry and / or stereochemistry features. Such provided compositions are “predetermined” as described herein. Compositions that may contain certain oligonucleotides because they happen to have been generated through a process that are not controlled to intentionally generate the particular chemistry and / or stereochemistry features are not “predetermined” compositions. In some embodiments, a predetermined composition is one that can be intentionally reproduced (e.g., through repetition of a controlled process). In some embodiments, a predetermined level of a plurality of oligonucleotides in a composition means that the absolute amount, and / or the relative amount (ratio, percentage, etc.) of the plurality of oligonucleotides in the composition is controlled. In some embodiments, a predetermined level of a plurality of oligonucleotides in a composition is achieved through chirally controlled oligonucleotide preparation.

[0083] Protecting group: The term “protecting group,” as used herein, is well known in the art and includes those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Also included are those protecting groups specially adapted for nucleoside and nucleotide chemistry described in Current Protocols in Nucleic Acid Chemistry, edited by Serge L. Beaucage et al.06 / 2012, the entirety of Chapter 2 is incorporated herein by reference. Suitable amino–protecting groups include methyl carbamate, ethyl carbamante, 9–fluorenylmethyl carbamate (Fmoc), 9–(2–sulfo)fluorenylmethyl carbamate, 9–(2,7–dibromo)fluoroenylmethyl carbamate, 2,7–di–t–butyl–[9–(10,10–dioxo–10,10,10,10– tetrahydrothioxanthyl)]methyl carbamate (DBD–Tmoc), 4–methoxyphenacyl carbamate (Phenoc), 2,2,2– trichloroethyl carbamate (Troc), 2–trimethylsilylethyl carbamate (Teoc), 2–phenylethyl carbamate (hZ), 1– (1–adamantyl)–1–methylethyl carbamate (Adpoc), 1,1–dimethyl–2–haloethyl carbamate, 1,1–dimethyl– 2,2–dibromoethyl carbamate (DB–t–BOC), 1,1–dimethyl–2,2,2–trichloroethyl carbamate (TCBOC), 1– methyl–1–(4–biphenylyl)ethyl carbamate (Bpoc), 1–(3,5–di–t–butylphenyl)–1–methylethyl carbamate (t– Bumeoc), 2–(2’– and 4’–pyridyl)ethyl carbamate (Pyoc), 2–(N,N–dicyclohexylcarboxamido)ethyl carbamate, t–butyl carbamate (BOC), 1–adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1–isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4–nitrocinnamyl carbamate (Noc), 8–quinolyl carbamate, N–hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p–methoxybenzyl carbamate (Moz), p–nitobenzyl carbamate, p–bromobenzyl carbamate, p–chlorobenzyl carbamate, 2,4–dichlorobenzyl carbamate, 4–methylsulfinylbenzyl carbamate (Msz), 9– anthrylmethyl carbamate, diphenylmethyl carbamate, 2–methylthioethyl carbamate, 2–methylsulfonylethyl carbamate, 2–(p–toluenesulfonyl)ethyl carbamate, [2–(1,3–dithianyl)]methyl carbamate (Dmoc), 4– methylthiophenyl carbamate (Mtpc), 2,4–dimethylthiophenyl carbamate (Bmpc), 2–phosphonioethylcarbamate (Peoc), 2–triphenylphosphonioisopropyl carbamate (Ppoc), 1,1–dimethyl–2–cyanoethyl carbamate, m–chloro–p–acyloxybenzyl carbamate, p–(dihydroxyboryl)benzyl carbamate, 5– benzisoxazolylmethyl carbamate, 2–(trifluoromethyl)–6–chromonylmethyl carbamate (Tcroc), m– nitrophenyl carbamate, 3,5–dimethoxybenzyl carbamate, o–nitrobenzyl carbamate, 3,4–dimethoxy–6– nitrobenzyl carbamate, phenyl(o–nitrophenyl)methyl carbamate, phenothiazinyl–(10)–carbonyl derivative, N’–p–toluenesulfonylaminocarbonyl derivative, N’–phenylaminothiocarbonyl derivative, t–amyl carbamate, S–benzyl thiocarbamate, p–cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p–decyloxybenzyl carbamate, 2,2– dimethoxycarbonylvinyl carbamate, o–(N,N–dimethylcarboxamido)benzyl carbamate, 1,1–dimethyl–3– (N,N–dimethylcarboxamido)propyl carbamate, 1,1–dimethylpropynyl carbamate, di(2–pyridyl)methyl carbamate, 2–furanylmethyl carbamate, 2–iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p–(p’–methoxyphenylazo)benzyl carbamate, 1–methylcyclobutyl carbamate, 1– methylcyclohexyl carbamate, 1–methyl–1–cyclopropylmethyl carbamate, 1–methyl–1–(3,5– dimethoxyphenyl)ethyl carbamate, 1–methyl–1–(p–phenylazophenyl)ethyl carbamate, 1–methyl–1– phenylethyl carbamate, 1–methyl–1–(4–pyridyl)ethyl carbamate, phenyl carbamate, p–(phenylazo)benzyl carbamate, 2,4,6–tri–t–butylphenyl carbamate, 4–(trimethylammonium)benzyl carbamate, 2,4,6– trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3–phenylpropanamide, picolinamide, 3–pyridylcarboxamide, N– benzoylphenylalanyl derivative, benzamide, p–phenylbenzamide, o–nitophenylacetamide, o– nitrophenoxyacetamide, acetoacetamide, (N’–dithiobenzyloxycarbonylamino)acetamide, 3–(p– hydroxyphenyl)propanamide, 3–(o–nitrophenyl)propanamide, 2–methyl–2–(o– nitrophenoxy)propanamide, 2–methyl–2–(o–phenylazophenoxy)propanamide, 4–chlorobutanamide, 3– methyl–3–nitrobutanamide, o–nitrocinnamide, N–acetylmethionine derivative, o–nitrobenzamide, o– (benzoyloxymethyl)benzamide, 4,5–diphenyl–3–oxazolin–2–one, N–phthalimide, N–dithiasuccinimide (Dts), N–2,3–diphenylmaleimide, N–2,5–dimethylpyrrole, N–1,1,4,4–tetramethyldisilylazacyclopentane adduct (STABASE), 5–substituted 1,3–dimethyl–1,3,5–triazacyclohexan–2–one, 5–substituted 1,3– dibenzyl–1,3,5–triazacyclohexan–2–one, 1–substituted 3,5–dinitro–4–pyridone, N–methylamine, N– allylamine, N–[2–(trimethylsilyl)ethoxy]methylamine (SEM), N–3–acetoxypropylamine, N–(1– isopropyl–4–nitro–2–oxo–3–pyroolin–3–yl)amine, quaternary ammonium salts, N–benzylamine, N–di(4– methoxyphenyl)methylamine, N–5–dibenzosuberylamine, N–triphenylmethylamine (Tr), N–[(4– methoxyphenyl)diphenylmethyl]amine (MMTr), N–9–phenylfluorenylamine (PhF), N–2,7–dichloro–9– fluorenylmethyleneamine, N–ferrocenylmethylamino (Fcm), N–2–picolylamino N’–oxide, N–1,1– dimethylthiomethyleneamine, N–benzylideneamine, N–p–methoxybenzylideneamine, N– diphenylmethyleneamine, N–[(2–pyridyl)mesityl]methyleneamine, N–(N’,N’–dimethylaminomethylene)amine, N,N’–isopropylidenediamine, N–p–nitrobenzylideneamine, N– salicylideneamine, N–5–chlorosalicylideneamine, N–(5–chloro–2– hydroxyphenyl)phenylmethyleneamine, N–cyclohexylideneamine, N–(5,5–dimethyl–3–oxo–1– cyclohexenyl)amine, N–borane derivative, N–diphenylborinic acid derivative, N– [phenyl(pentacarbonylchromium– or tungsten)carbonyl]amine, N–copper chelate, N–zinc chelate, N– nitroamine, N–nitrosoamine, amine N–oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o–nitrobenzenesulfenamide (Nps), 2,4– dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2–nitro–4–methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3–nitropyridinesulfenamide (Npys), p–toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,–trimethyl–4–methoxybenzenesulfonamide (Mtr), 2,4,6– trimethoxybenzenesulfonamide (Mtb), 2,6–dimethyl–4–methoxybenzenesulfonamide (Pme), 2,3,5,6– tetramethyl–4–methoxybenzenesulfonamide (Mte), 4–methoxybenzenesulfonamide (Mbs), 2,4,6– trimethylbenzenesulfonamide (Mts), 2,6–dimethoxy–4–methylbenzenesulfonamide (iMds), 2,2,5,7,8– pentamethylchroman–6–sulfonamide (Pmc), methanesulfonamide (Ms), β– trimethylsilylethanesulfonamide (SES), 9–anthracenesulfonamide, 4–(4’,8’– dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0084] Suitably protected carboxylic acids further include, but are not limited to, silyl–, alkyl–, alkenyl–, aryl–, and arylalkyl–protected carboxylic acids. Examples of suitable silyl groups include trimethylsilyl, triethylsilyl, t–butyldimethylsilyl, t–butyldiphenylsilyl, triisopropylsilyl, and the like. Examples of suitable alkyl groups include methyl, benzyl, p–methoxybenzyl, 3,4–dimethoxybenzyl, trityl, t–butyl, tetrahydropyran–2–yl. Examples of suitable alkenyl groups include allyl. Examples of suitable aryl groups include optionally substituted phenyl, biphenyl, or naphthyl. Examples of suitable arylalkyl groups include optionally substituted benzyl (e.g., p–methoxybenzyl (MPM), 3,4–dimethoxybenzyl, O– nitrobenzyl, p–nitrobenzyl, p–halobenzyl, 2,6–dichlorobenzyl, p–cyanobenzyl), and 2– and 4–picolyl.

[0085] Suitable hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t–butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p–methoxybenzyloxymethyl (PMBM), (4–methoxyphenoxy)methyl (p–AOM), guaiacolmethyl (GUM), t–butoxymethyl, 4–pentenyloxymethyl (POM), siloxymethyl, 2– methoxyethoxymethyl (MEM), 2,2,2–trichloroethoxymethyl, bis(2–chloroethoxy)methyl, 2– (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3–bromotetrahydropyranyl, tetrahydrothiopyranyl, 1–methoxycyclohexyl, 4–methoxytetrahydropyranyl (MTHP), 4– methoxytetrahydrothiopyranyl, 4–methoxytetrahydrothiopyranyl S,S–dioxide, 1–[(2–chloro–4–methyl)phenyl]–4–methoxypiperidin–4–yl (CTMP), 1,4–dioxan–2–yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a–octahydro–7,8,8–trimethyl–4,7–methanobenzofuran–2–yl, 1– ethoxyethyl, 1–(2–chloroethoxy)ethyl, 1–methyl–1–methoxyethyl, 1–methyl–1–benzyloxyethyl, 1– methyl–1–benzyloxy–2–fluoroethyl, 2,2,2–trichloroethyl, 2–trimethylsilylethyl, 2–(phenylselenyl)ethyl, t– butyl, allyl, p–chlorophenyl, p–methoxyphenyl, 2,4–dinitrophenyl, benzyl, p–methoxybenzyl, 3,4– dimethoxybenzyl, o–nitrobenzyl, p–nitrobenzyl, p–halobenzyl, 2,6–dichlorobenzyl, p–cyanobenzyl, p– phenylbenzyl, 2–picolyl, 4–picolyl, 3–methyl–2–picolyl N–oxido, diphenylmethyl, p,p’– dinitrobenzhydryl, 5–dibenzosuberyl, triphenylmethyl, α–naphthyldiphenylmethyl, p– methoxyphenyldiphenylmethyl, di(p–methoxyphenyl)phenylmethyl, tri(p–methoxyphenyl)methyl, 4–(4’– bromophenacyloxyphenyl)diphenylmethyl, 4,4’,4’’–tris(4,5–dichlorophthalimidophenyl)methyl, 4,4’,4’’– tris(levulinoyloxyphenyl)methyl, 4,4’,4’’–tris(benzoyloxyphenyl)methyl, 3–(imidazol–1–yl)bis(4’,4’’– dimethoxyphenyl)methyl, 1,1–bis(4–methoxyphenyl)–1’–pyrenylmethyl, 9–anthryl, 9–(9– phenyl)xanthenyl, 9–(9–phenyl–10–oxo)anthryl, 1,3–benzodithiolan–2–yl, benzisothiazolyl S,S–dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t–butyldimethylsilyl (TBDMS), t–butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri–p–xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t– butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p– chlorophenoxyacetate, 3–phenylpropionate, 4–oxopentanoate (levulinate), 4,4–(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4–methoxycrotonate, benzoate, p– phenylbenzoate, 2,4,6–trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9–fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2–trichloroethyl carbonate (Troc), 2– (trimethylsilyl)ethyl carbonate (TMSEC), 2–(phenylsulfonyl) ethyl carbonate (Psec), 2– (triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p–nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p–methoxybenzyl carbonate, alkyl 3,4–dimethoxybenzyl carbonate, alkyl o–nitrobenzyl carbonate, alkyl p–nitrobenzyl carbonate, alkyl S– benzyl thiocarbonate, 4–ethoxy–1–napththyl carbonate, methyl dithiocarbonate, 2–iodobenzoate, 4– azidobutyrate, 4–nitro–4–methylpentanoate, o–(dibromomethyl)benzoate, 2–formylbenzenesulfonate, 2– (methylthiomethoxy)ethyl, 4–(methylthiomethoxy)butyrate, 2–(methylthiomethoxymethyl)benzoate, 2,6– dichloro–4–methylphenoxyacetate, 2,6–dichloro–4–(1,1,3,3–tetramethylbutyl)phenoxyacetate, 2,4– bis(1,1–dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)–2– methyl–2–butenoate, o–(methoxycarbonyl)benzoate, α–naphthoate, nitrate, alkyl N,N,N’,N’– tetramethylphosphorodiamidate, alkyl N–phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4– dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). Forprotecting 1,2– or 1,3–diols, the protecting groups include methylene acetal, ethylidene acetal, 1–t– butylethylidene ketal, 1–phenylethylidene ketal, (4–methoxyphenyl)ethylidene acetal, 2,2,2– trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p–methoxybenzylidene acetal, 2,4–dimethoxybenzylidene ketal, 3,4– dimethoxybenzylidene acetal, 2–nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1–methoxyethylidene ortho ester, 1–ethoxyethylidine ortho ester, 1,2–dimethoxyethylidene ortho ester, α–methoxybenzylidene ortho ester, 1–(N,N– dimethylamino)ethylidene derivative, α–(N,N’–dimethylamino)benzylidene derivative, 2– oxacyclopentylidene ortho ester, di–t–butylsilylene group (DTBS), 1,3–(1,1,3,3– tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra–t–butoxydisiloxane–1,3–diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate.

[0086] In some embodiments, a hydroxyl protecting group is acetyl, t-butyl, tbutoxymethyl, methoxymethyl, tetrahydropyranyl, 1 -ethoxyethyl, 1 -(2-chloroethoxy)ethyl, 2- trimethylsilylethyl, p- chlorophenyl, 2,4-dinitrophenyl, benzyl, benzoyl, p-phenylbenzoyl, 2,6- dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl (trityl), 4,4'-dimethoxytrityl, trimethylsilyl, triethylsilyl, t- butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, triisopropylsilyl, benzoylformate, chloroacetyl, trichloroacetyl, trifiuoroacetyl, pivaloyl, 9- fluorenylmethyl carbonate, mesylate, tosylate, triflate, trityl, monomethoxytrityl (MMTr), 4,4'-dimethoxytrityl, (DMTr) and 4,4',4''-trimethoxytrityl (TMTr), 2- cyanoethyl (CE or Cne), 2-(trimethylsilyl)ethyl (TSE), 2-(2-nitrophenyl)ethyl, 2-(4-cyanophenyl)ethyl 2- (4-nitrophenyl)ethyl (NPE), 2-(4-nitrophenylsulfonyl)ethyl, 3,5-dichlorophenyl, 2,4-dimethylphenyl, 2- nitrophenyl, 4-nitrophenyl, 2,4,6-trimethylphenyl, 2-(2-nitrophenyl)ethyl, butylthiocarbonyl, 4,4',4''- tris(benzoyloxy)trityl, diphenylcarbamoyl, levulinyl, 2-(dibromomethyl)benzoyl (Dbmb), 2- (isopropylthiomethoxymethyl)benzoyl (Ptmt), 9-phenylxanthen-9-yl (pixyl) or 9-(p- methoxyphenyl)xanthine-9-y1 (MOX). In some embodiments, each of the hydroxyl protecting groups is, independently selected from acetyl, benzyl, t- butyldimethylsilyl, t-butyldiphenylsilyl and 4,4'- dimethoxytrityl. In some embodiments, the hydroxyl protecting group is selected from the group consisting of trityl, monomethoxytrityl and 4,4'-dimethoxytrityl group. In some embodiments, a phosphorous linkage protecting group is a group attached to the phosphorous linkage (e.g., an internucleotidic linkage) throughout oligonucleotide synthesis. In some embodiments, a protecting group is attached to a sulfur atom of an phosphorothioate group. In some embodiments, a protecting group is attached to an oxygen atom of an internucleotide phosphorothioate linkage. In some embodiments, a protecting group is attached to an oxygen atom of the internucleotide phosphate linkage. In some embodiments a protecting group is 2- cyanoethyl (CE or Cne), 2-trimethylsilylethyl, 2-nitroethyl, 2-sulfonylethyl, methyl, benzyl, o-nitrobenzyl, 2-(p-nitrophenyl)ethyl (NPE or Npe), 2-phenylethyl, 3-(N-tert-butylcarboxamido)-1-propyl, 4-oxopentyl,4-methylthio-l-butyl, 2-cyano-1,1-dimethylethyl, 4-N-methylaminobutyl, 3-(2-pyridyl)-1-propyl, 2-[N- methyl-N-(2-pyridyl)]aminoethyl, 2-(N-formyl,N-methyl)aminoethyl, or 4-[N-methyl-N-(2,2,2- trifluoroacetyl)amino]butyl.

[0087] Subject: As used herein, the term “subject” or “test subject” refers to any organism to which a provided compound (e.g., a provided oligonucleotide) or composition is administered in accordance with the present disclosure e.g., for experimental, diagnostic, prophylactic and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.) and plants. In some embodiments, a subject is a human. In some embodiments, a subject may be suffering from and / or susceptible to a disease, disorder and / or condition.

[0088] Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. A base sequence which is substantially identical to a second sequence is not identical to the second sequence, but is mostly or nearly identical to the second sequence. In addition, one of ordinary skill in the biological and / or chemical arts will understand that biological and chemical phenomena rarely, if ever, go to completion and / or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and / or chemical phenomena.

[0089] Sugar: The term “sugar” refers to a monosaccharide or polysaccharide in closed and / or open form. In some embodiments, sugars are monosaccharides. In some embodiments, sugars are polysaccharides. Sugars include, but are not limited to, ribose, deoxyribose, pentofuranose, pentopyranose, and hexopyranose moieties. As used herein, the term “sugar” also encompasses structural analogs used in lieu of conventional sugar molecules, such as glycol, polymer of which forms the backbone of the nucleic acid analog, glycol nucleic acid (“GNA”), etc. As used herein, the term “sugar” also encompasses structural analogs used in lieu of natural or naturally-occurring nucleotides, such as modified sugars. In some embodiments, a sugar is a RNA or DNA sugar (ribose or deoxyribose). In some embodiments, a sugar is a modified ribose or deoxyribose sugar, e.g., 2’-modified, 5’-modified, etc. As described herein, in some embodiments, when used in oligonucleotides and / or nucleic acids, modified sugars may provide one or more desired properties, activities, etc. In some embodiments, a sugar is optionally substituted ribose or deoxyribose. In some embodiments, a “sugar” refers to a sugar unit in an oligonucleotide or a nucleic acid.

[0090] Susceptible to: An individual who is “susceptible to” a disease, disorder and / or condition is one who has a higher risk of developing the disease, disorder and / or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition is predisposed to have that disease, disorder and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition may not have been diagnosed with thedisease, disorder and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition may exhibit symptoms of the disease, disorder and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition may not exhibit symptoms of the disease, disorder and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will develop the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will not develop the disease, disorder, and / or condition.

[0091] Therapeutic agent: As used herein, the term “therapeutic agent” in general refers to any agent that elicits a desired effect (e.g., a desired biological, clinical, or pharmacological effect) when administered to a subject. In some embodiments, an agent is considered to be a therapeutic agent if it demonstrates a statistically significant effect across an appropriate population. In some embodiments, an appropriate population is a population of subjects suffering from and / or susceptible to a disease, disorder or condition. In some embodiments, an appropriate population is a population of model organisms. In some embodiments, an appropriate population may be defined by one or more criterion such as age group, gender, genetic background, preexisting clinical conditions, prior exposure to therapy. In some embodiments, a therapeutic agent is a substance that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of, and / or reduces incidence of one or more symptoms or features of a disease, disorder, and / or condition in a subject when administered to the subject in an effective amount. In some embodiments, a “therapeutic agent” is an agent that has been or is required to be approved by a government agency before it can be marketed for administration to humans. In some embodiments, a “therapeutic agent” is an agent for which a medical prescription is required for administration to humans. In some embodiments, a therapeutic agent is a provided compound, e.g., a provided oligonucleotide.

[0092] Therapeutically effective amount: As used herein, the term “therapeutically effective amount” means an amount of a substance (e.g., a therapeutic agent, composition, and / or formulation) that elicits a desired biological response when administered as part of a therapeutic regimen. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition, to treat, diagnose, prevent, and / or delay the onset of the disease, disorder, and / or condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, etc. For example, the effective amount of compound in a formulation to treat a disease, disorder, and / or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and / or reduces incidence of one or more symptoms or features of the disease, disorder, and / or condition. In some embodiments, a therapeutically effective amount is administered in a single dose; in some embodiments,multiple unit doses are required to deliver a therapeutically effective amount.

[0093] Treat: As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and / or condition, for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and / or condition.

[0094] Unit dose: The term “unit dose” as used herein refers to an amount administered as a single dose and / or in a physically discrete unit of a pharmaceutical composition. In many embodiments, a unit dose contains a predetermined quantity of an active agent. In some embodiments, a unit dose contains an entire single dose of the agent. In some embodiments, more than one unit dose is administered to achieve a total single dose. In some embodiments, administration of multiple unit doses is required, or expected to be required, in order to achieve an intended effect. A unit dose may be, for example, a volume of liquid (e.g., an acceptable carrier) containing a predetermined quantity of one or more therapeutic agents, a predetermined amount of one or more therapeutic agents in solid form, a sustained release formulation or drug delivery device containing a predetermined amount of one or more therapeutic agents, etc. It will be appreciated that a unit dose may be present in a formulation that includes any of a variety of components in addition to the therapeutic agent(s). For example, acceptable carriers (e.g., pharmaceutically acceptable carriers), diluents, stabilizers, buffers, preservatives, etc., may be included as described infra. It will be appreciated by those skilled in the art, in many embodiments, a total appropriate daily dosage of a particular therapeutic agent may comprise a portion, or a plurality, of unit doses, and may be decided, for example, by the attending physician within the scope of sound medical judgment. In some embodiments, the specific effective dose level for any particular subject or organism may depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active compound employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active compound employed; duration of the treatment; drugs and / or additional therapies used in combination or coincidental with specific compound(s) employed, and like factors well known in the medical arts.

[0095] Unsaturated: The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0096] Wild-type: As used herein, the term “wild-type” has its art-understood meaning that refers to an entity having a structure and / or activity as found in nature in a “normal” (as contrasted with mutant, diseased, altered, etc.) state or context. Those of ordinary skill in the art will appreciate that wildtype genes and polypeptides often exist in multiple different forms (e.g., alleles).

[0097] As those skilled in the art will appreciate, methods and compositions described herein relating to provided compounds (e.g., oligonucleotides) generally also apply to pharmaceutically acceptable salts of such compounds. Description of Certain Embodiments

[0098] Oligonucleotides are useful tools for a wide variety of applications. For example, oligonucleotides are useful in various therapeutic, diagnostic, and research applications. Use of naturally occurring nucleic acids (e.g., unmodified DNA or RNA) is limited, for example, by their susceptibility to endo- and exo-nucleases. As such, various synthetic counterparts have been developed to circumvent these shortcomings and / or to further improve various properties and activities. These include synthetic oligonucleotides that contain chemical modifications, e.g., base modifications, sugar modifications, backbone modifications, etc., which, among other things, can render these molecules less susceptible to degradation and improve other properties and / or activities. From a structural point of view, modifications to internucleotidic linkages can introduce chirality, and certain properties may be affected by configurations of linkage phosphorus atoms of oligonucleotides. For example, binding affinity, sequence specific binding to complementary RNA, stability to nucleases, cleavage of target nucleic acids, delivery, pharmacokinetics, etc. can be affected by chirality of backbone linkage phosphorus atoms.

[0099] Among other things, the present disclosure provides technologies (e.g., oligonucleotides, compositions, methods, etc.) that comprise various structural elements and / or patterns thereof (e.g., modified sugars, modified internucleotidic linkages, patterns of sugars, patterns of internucleotidic linkages, patters of backbone linkage phosphorus, additional chemical moieties, etc.). With its incorporation and control of various structural elements in oligonucleotides, the present disclosure provides oligonucleotides with improved and / or new properties and / or activities for various applications, e.g., as therapeutic agents, probes, etc. In some embodiments, oligonucleotides of the present disclosure comprise one or more modified sugars and / or modified internucleotidic linkages as described herein. In some embodiments, various internucleotidic linkages oligonucleotides are independently chirally controlled. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions in which oligonucleotides comprises various modified sugars (e.g., sugars contain nitrogen atoms and / or acyclic sugars) and / or modified internucleotidic linkages (e.g., those with linkage phosphorus atoms bonded to nitrogen atoms, those of or comprising −C(O)−O− or −C(O)−N(R’)− in which −C(O)− is bonded to a nitrogen atom). Sugars

[0100] Various sugars, including modified sugars, can be utilized in accordance with the presentdisclosure. In some embodiments, the present disclosure provides sugar modifications and patterns thereof optionally in combination with other structural elements (e.g., internucleotidic linkage modifications and patterns thereof, pattern of backbone chiral centers thereof, etc.) that when incorporated into oligonucleotides can provide improved properties and / or activities.

[0101] The most common naturally occurring nucleosides comprise ribose sugars (e.g., in RNA) or deoxyribose sugars (e.g., in DNA) linked to the nucleobases adenosine (A), cytosine (C), guanine (G), thymine (T) or uracil (U). In some embodiments, a sugar is a natural DNA sugar (in DNA nucleic acids or oligonucleotides, having the structure ofwherein a nucleobase is attached to the 1’ position, and the 3’ and 5’ positions are connected to internucleotidic linkages (as appreciated by those skilled in the art, if at the 5’-end of an oligonucleotide, the 5’ position may be connected to a 5’-end group (e.g., typically −OH unless indicated otherwise), and if at the 3’-end of an oligonucleotide, the 3’ position may be connected to a 3’-end group (e.g., typically −OH unless indicated otherwise)). In some embodiments, a sugar is a natural RNA sugar (in RNA nucleic acids or oligonucleotides, having the structure ofwherein a nucleobase is attached to the 1’ position, and the 3’ and 5’ positions are connected to internucleotidic linkages (as appreciated by those skilled in the art, if at the 5’-end of an oligonucleotide, the 5’ position may be connected to a 5’-end group (e.g., typically −OH unless indicated otherwise), and if at the 3’-end of an oligonucleotide, the 3’ position may be connected to a 3’-end group (e.g., typically −OH unless indicated otherwise). In some embodiments, a sugar is a modified sugar in that it is not a natural DNA sugar or a natural RNA sugar. Among other things, modified sugars may provide improved stability. In some embodiments, modified sugars can be utilized to alter and / or optimize one or more hybridization characteristics. In some embodiments, modified sugars can be utilized to alter and / or optimize target recognition. In some embodiments, modified sugars can be utilized to optimize Tm. In some embodiments, modified sugars can be utilized to improve oligonucleotide activities. Sugars can be bonded to internucleotidic linkages at various positions. As non-limiting examples, internucleotidic linkages can be bonded to the 2’, 3’, 4’ or 5’ positions of ribose sugars. In some embodiments, as most commonly in natural nucleic acids, an internucleotidic linkage connects with one sugar at the 5’ position and another sugar at the 3’ position unless otherwise indicated.

[0102] In some embodiments, the present disclosure provides oligonucleotides comprising modified sugars comprising nitrogen. In some embodiments, oligonucleotides of the present disclosure comprise combinations of sugars comprising nitrogen, and deoxyribose sugars which are independently andoptionally modified as described herein (e.g., 2’-modifications such as R2s, bicyclic sugars comprising bridges between 2’-carbons and carbons at other positions (e.g., 4’-carbons)). In some embodiments, a sugar comprising nitrogen is bonded to an internucleotidic linkage via the nitrogen atom. In some embodiments, an internucleotidic linkage bonded to nitrogen has the structure of −PL(−X−RL)−Z−. In some embodiments, an internucleotidic linkage bonded to nitrogen has the structure of −C(O)−O−. In some embodiments, an internucleotidic linkage bonded to nitrogen has the structure of −C(O)−N(R’)−.

[0103] In some embodiments, a modified sugar has the structure owherein each variable is as described herein. In some embodiments, a sugar is bonded to an internucleotidic linkage, e.g., an internucleotidic linkage having the structure of −PL(−X−RL)−Z−, −C(O)−O−, or −C(O)−N(R’)−, at the nitrogen. In some embodiments, Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms. In some embodiments, Ring Asis an optionally substituted 3-10 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms. In some embodiments, Ring Asis an optionally substituted 3- 30 membered monocyclic ring having, in addition to the nitrogen, 0-5 heteroatoms. In some embodiments, Ring Asis an optionally substituted 3-30 membered monocyclic ring having, in addition to the nitrogen, one heteroatom. In some embodiments, the one heteroatom is oxygen. In some embodiments, Ring Asis saturated. In some embodiments, Ring Asis optionally substitutedsIn some embodiments, L is optionally substituted −CH2−. In some embodiments, Lsis −CH2−. In some embodiments, a modified sugar is optionally substituted. In some embodiments, a modified sugar iIn some embodiments, a modified sugar is optionally substitutedIn some embodiments, a modified sugar is . In some embodiments, a modified sugar has the structure of, wherein Rsis as described herein. In some embodiments, a modified sugar is. In some embodiments, a modified sugar is

[0104] In some embodiments, a nucleoside is Asm01, Tsm01, Csm01, Gsm01, in which the sugar is(e.g., Gsm01). In some embodiments, an oligonucleotide comprises one or more (e.g., 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) sm01. In some embodiments, an oligonucleotide contains no more than 10 sm01. In some embodiments, an oligonucleotide contains no more than 9 sm01. In some embodiments, an oligonucleotide contains no more than 8 sm01. In some embodiments, an oligonucleotide contains no more than 7 sm01. In some embodiments, an oligonucleotide contains no more than 6 sm01. In some embodiments, an oligonucleotide contains no more than 5 sm01. In some embodiments, an oligonucleotide contains no more than 4 sm01. In some embodiments, an oligonucleotide contains no more than 3 sm01. In some embodiments, an oligonucleotide contains no more than 10 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 9 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 8 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 7 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 6 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 5 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 4 consecutive sm01. In some embodiments, an oligonucleotide contains no more than 3 consecutive sm01. In some embodiments, one or more sm01 are each independently bonded at its nitrogen atom to a linkage whose linkage phosphorus is bonded to another nitrogen (e.g., as in sm01n001). In some embodiments, each sm01 is independently bonded at its nitrogen atom to a linkage whose linkage phosphorus is bonded to another nitrogen (e.g., as in sm01n001).

[0105] In some embodiments, a modified sugar is an acyclic sugar. In some embodiments, an acyclic sugar has the structure of a’−LSA1−LSA2(−LSA3−)−LSA4−b’, wherein each of LSA1, LSA3, and LSA4is independently optionally substituted bivalent C1-4aliphatic or C1-4aliphatic having 1-3 heteroatoms, and LSA2is optionally substituted CH or N. In some embodiments, wherein each of LSA1, LSA3, and LSA4isindependently optionally substituted bivalent C1-2aliphatic or C1-2aliphatic having 1-2 heteroatoms. In some embodiments, LSA3is bonded to a nucleobase. In some embodiments, LSA1is optionally substituted −CH2−. In some embodiments, LSA1is −CH2−. In some embodiments, LSA1is −CH(CH3)−. In some embodiments, LSA1is optionally substituted −CH2CH2−. In some embodiments, LSA1is −CH2CH2−. In some embodiments, LSA1is optionally substituted −CH2NH2−. In some embodiments, LSA1is −CH2NH2−. In some embodiments, LSA2is optionally substituted CH. In some embodiments, LSA2is optionally substituted N. In some embodiments, LSA3is optionally substituted −O−CH2−. In some embodiments, LSA3is −O−CH(CH3)−. In some embodiments, LSA3is −O−CH(CH2OH)−. In some embodiments, LSA3is optionally substituted −C(O)−CH2−. In some embodiments, LSA3is −C(O)−CH2−. In some embodiments, LSA4is optionally substituted −CH2−. In some embodiments, LSA4is −CH2−. In some embodiments, LSA4is −CH(CH3)−. In some embodiments, LSA4is optionally substituted −CH2CH2−. In some embodiments, LSA4is −CH2CH2−. In some embodiments, LSA4is optionally substituted −CH2NH2−. In some embodiments, LSA4is −CH2NH2−. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−LSA3−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, LSA3is −O−CH2−, wherein the CH2is optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH2−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH(CH3)−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH(CH3)−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH3)−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH3)−)−CH2−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH2OH)−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH2OH)−)−CH2−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−NHR’−b’, wherein each of the CH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−NHR’−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−NH2−b’, wherein each of the CH2, NH2and CH is independently optionally substituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−NH2−b’. In some embodiments, an acyclic sugar has the structure of a’−CH2−N[−C(O)−CH2−]−CH2CH2−b’, wherein each of the CH2and CH is independently optionallysubstituted. In some embodiments, an acyclic sugar has the structure of a’−CH2−N[−C(O)−CH2−]−CH2CH2−b’. In some embodiments, a’ is the 5’-end. In some embodiments, b’ is the 5’-end.

[0106] In some embodiments, an acyclic sugar isIn some embodiments, In some embodiments, a nucleoside is Asm04, Tsm04, Csm04, Gsm04, in which the sugar is( g Usm04 ). In some embodiments, an acyclic sugar is(e.g., as inIn some embodiments, an acyclic sugar is (e.g., as in).

[0107] In some embodiments, a modified sugar has the structure of wherein X4sis −O− or −N(R4s)−, and each of R1s, R2s, R3s, R4s, R5sand R6sis independently Rsas described herein. In some embodiments, X4sis −N(R4s)−. In some embodiments, X4sis −NH−. In some embodiments,a modified sugar has the structure of , wherein each variable is independentlyas described herein. In some embodiments, a modified sugar has the structure o, wherein each variable is independently as described herein. In some embodiments, a modified sugar has the structurewherein each variable is independently as described herein. In some embodiments, a modified sugar has the structure o, wherein each variable is independently as described herein. In some embodiments, a modified sugar has the structure of, wherein R2sis as described herein. In some embodiments, a modified sugar has the structure, wherein R2sis as described herein.

[0108] Various types of sugars may be utilized in accordance with the present disclosure. Sugarscomprising nitrogen and / or acyclic sugars are typically utilized together with other types of sugars, e.g., one or more natural sugars (in some embodiments, natural DNA sugars) and one or more other types of modified sugars (e.g., substitutedthat are not the typical natural DNA or RNA sugars. In some embodiments, oligonucleotides comprise one or more natural DNA sugars. In some embodiments, oligonucleotides comprise one or more natural RNA sugars. In some embodiments, oligonucleotides comprise one or more modified sugars. In some embodiments, a sugar is an optionally substituted natural DNA or RNA sugar. In some embodiments, a sugar is optionally substituted. In some embodiments, the 2’ position is optionally substituted. In some embodiments, a sugar issome embodiments, a sugar has the structure o, wherein each of R1s, R2s, R3s, R4s, and R5sis independently as described herein. In some embodiments, each of R1s, R2s, R3s, R4s, and R5sis independently −, a suitable substituent or suitable sugar modification (e.g., those described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858, the substituents, sugar modifications, descriptions of R1s, R2s, R3s, R4s, and R5s, and modified sugars of each of which are independently incorporated herein by reference). In some embodiments, each of R1s, R2s, R3s, R4s, and R5sis independently Rs, wherein each Rsis independently −H, −F, −Cl, −Br, −I, −CN, −N3, −NO, −NO2, −L−R’, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2, wherein each R’ is independently as described herein, and each L is independently a covalent bond or optionally substituted bivalent C1-6aliphatic or heteroaliphatic having 1-4 heteroatoms; or two Rsare taken together to form a bridge −L−. In some embodiments, R’ is optionally substituted C1-10aliphatic. In some embodiments, asugar has the structure of In some embodiments, a sugar has the structure of. In some embodiments, a sugar has the structure ofIn some embodiments, a sugar has the structure of In some embodiments, a sugar has the structure ofIn someembodiments, a sugar has the structure of. In some embodiments, a sugar has the structure of In some embodiments, a sugar has the structure of In someembodiments, a sugar has the structure of5sIn some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R5sis optionally substituted C1-6alkyl. In some embodiments, R5sis optionally substituted methyl. In some embodiments, R5sis methyl. In some embodiments, a sugar has the structure of In some embodiments, a sugar has the structureof In some embodiments, a sugar has the structure of In some embodiments,R4sis −H. In some embodiments, a sugar has the structure of2swherein R is −H, halogen, or −OR, wherein R is optionally substituted C1-6aliphatic. In some embodiments, R2sis −H. In some embodiments, R2sis −F. In some embodiments, a modified nucleoside is fA, fT, fC, fG, fU, etc., in which R2sis −F. In some embodiments, R2sis −OMe. In some embodiments, a modified nucleoside is mA, mT, mC, m5mC, mG, mU, etc., in which R2sis −OMe. In some embodiments, R2sis −OCH2CH2OMe. In some embodiments, a modified nucleoside is Aeo, Teo, Ceo, m5Ceo, Geo, Ueo, etc., in which R2sis −OCH2CH2OMe. In some embodiments, R2sis −OCH2CH2OH. In some embodiments, an oligonucleotide comprises a 2’-F modified sugar having the structure of(e.g., as in fA, fT, fC, f5mC, fG, fU, etc.). In some embodiments, an oligonucleotide comprises a 2’-OMe modified sugar having the structure of(e.g., as in mA, mT, mC, m5mC, mG, mU, etc.). In some embodiments, an oligonucleotide comprises a 2’-MOE modified sugar having the structure of (e.g.,as in Aeo, Teo, Ceo, m5Ceo, Geo, Ueo, etc.).

[0109] In some embodiments, a sugar has the structure of2s 4swherein R and R are taken together to form −L−, wherein L is a covalent bond or optionally substituted bivalent C1-6aliphatic or heteroaliphatic having 1-4 heteroatoms. In some embodiments, each heteroatom is independently selected from nitrogen, oxygen or sulfur). In some embodiments, L is optionally substituted C2−O−CH2−C4. In some embodiments, L is C2−O−CH2−C4. In some embodiments, L is C2−O−(R)- CH(CH2CH3)−C4. In some embodiments, L is C2−O−(S)-CH(CH2CH3)−C4.

[0110] In some embodiments, a sugar comprises a 5’-modification. In some embodiments, one R5sis R, wherein R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, it is 5’-(R)-methyl. In some embodiments, it is 5’-(S)-methyl.

[0111] In some embodiments, a sugar is a bicyclic sugar, e.g., sugars wherein R2sand R4sare taken together to form a link as described in the present disclosure. In some embodiments, a sugar is selected from LNA sugars, BNA sugars, cEt sugars, etc. In some embodiments, a bridge is between the 2’ and 4’- carbon atoms (corresponding to R2sand R4staken together with their intervening atoms to form an optionally substituted ring as described herein). In some embodiments, examples of bicyclic sugars include alpha-L-methyleneoxy (4'-CH2-O-2’) LNA, beta-D-methyleneoxy (4'-CH2-O-2’) LNA, ethyleneoxy (4' - (CH2)2-O-2’) LNA, aminooxy (4' -CH2-O-N(R)-2’) LNA, and oxyamino (4'-CH2-N(R)-O-2’) LNA. In some embodiments, a bicyclic sugar, e.g., a LNA or BNA sugar, is sugar having at least one bridge between two sugar carbons. In some embodiments, a bicyclic sugar in a nucleoside may have the stereochemical configurations of alpha-L-ribofuranose or beta-D-ribofuranose. In some embodiments, a sugar is a sugar described in WO 1999014226. In some embodiments, a 4’-2’ bicyclic sugar or 4’ to 2’ bicyclic sugar is a bicyclic sugar comprising a furanose ring which comprises a bridge connecting the 2’ carbon atom and the 4' carbon atom of the sugar ring. In some embodiments, a bicyclic sugar, e.g., a LNA or BNA sugar, comprises at least one bridge between two pentofuranosyl sugar carbons. In some embodiments, a LNA or BNA sugar, comprises at least one bridge between the 4' and the 2’ pentofuranosyl sugar carbons.

[0112] In some embodiments, a bicyclic sugar is a sugar of alpha-L-methyleneoxy (4'-CH2-O-2’) BNA, beta-D-methyleneoxy (4'-CH2-O-2’) BNA, ethyleneoxy (4'-(CH2)2-O-2’) BNA, aminooxy (4'-CH2- O-N(R)-2’) BNA, oxyamino (4'-CH2-N(R)-O-2’) BNA, methyl(methyleneoxy) (4'-CH(CH3)-O-2’) BNA (also referred to as constrained ethyl or cEt), methylene-thio (4'-CH2-S-2’) BNA, methylene-amino (4'- CH2-N(R)-2’) BNA, methyl carbocyclic (4'-CH2-CH(CH3)-2’) BNA, propylene carbocyclic (4'-(CH2)3-2’) BNA, or vinyl BNA.

[0113] In some embodiments, a sugar modification is 2’-OMe, 2’-MOE, 2’-LNA, 2’-F, 5’-vinyl, or S- cEt. In some embodiments, a modified sugar is a sugar of FRNA, FANA, or morpholino. In some embodiments, an oligonucleotide comprises a nucleic acid analog, e.g., GNA, LNA, PNA, TNA, F-HNA (F-THP or 3’-fluoro tetrahydropyran), MNA (mannitol nucleic acid, e.g., Leumann 2002 Bioorg. Med. Chem.10: 841-854), ANA (anitol nucleic acid), or morpholino, or a portion thereof. In some embodiments, a sugar modification replaces a natural sugar with another cyclic or acyclic moiety. Examples of such moieties are widely known in the art, e.g., those used in morpholino, glycol nucleic acids, etc. and may be utilized in accordance with the present disclosure. As appreciated by those skilled in the art, when utilized with modified sugars, in some embodiments internucleotidic linkages may be modified, e.g., as in morpholino, PNA, etc.

[0114] In some embodiments, a sugar is a 6’-modified bicyclic sugar that have either (R) or (S)- chirality at the 6-position, e.g., those described in US 7399845. In some embodiments, a sugar is a 5’- modified bicyclic sugar that has either (R) or (S)-chirality at the 5-position, e.g., those described in US20070287831.

[0115] In some embodiments, a modified sugar contains one or more substituents at the 2’ position (typically one substituent, and often at the axial position) independently selected from –F; –CF3, –CN, –N3, –NO, –NO2, –OR’, –SR’, or –N(R’)2, wherein each R’ is independently optionally substituted C1-10aliphatic; –O–(C1–C10alkyl), –S–(C1–C10alkyl), –NH–(C1–C10alkyl), or –N(C1–C10alkyl)2; –O–(C2–C10alkenyl), –S–(C2–C10alkenyl), –NH–(C2–C10alkenyl), or –N(C2–C10alkenyl)2; –O–(C2–C10alkynyl), –S– (C2–C10alkynyl), –NH–(C2–C10alkynyl), or –N(C2–C10alkynyl)2; or –O––(C1–C10alkylene)–O––(C1–C10alkyl), –O–(C1–C10alkylene)–NH–(C1–C10alkyl) or –O–(C1–C10alkylene)–NH(C1–C10alkyl)2, –NH–(C1– C10alkylene)–O–(C1–C10alkyl), or –N(C1–C10alkyl)–(C1–C10alkylene)–O–(C1–C10alkyl), wherein each of the alkyl, alkylene, alkenyl and alkynyl is independently and optionally substituted. In some embodiments, a substituent is –O(CH2)nOCH3, –O(CH2)nNH2, MOE, DMAOE, or DMAEOE, wherein wherein n is from 1 to about 10. In some embodiments, a modified sugar is one described in WO 2001 / 088198; and Martin et al., Helv. Chim. Acta, 1995, 78, 486-504. In some embodiments, a modified sugar comprises one or more groups selected from a substituted silyl group, an RNA cleaving group, a reporter group, a fluorescent label, an intercalator, a group for improving the pharmacokinetic properties of a nucleic acid, a group for improving the pharmacodynamic properties of a nucleic acid, or other substituents having similar properties. In some embodiments, modifications are made at one or more of the 2’, 3’, 4’, or 5’ positions, including the 3’ position of the sugar on the 3’-terminal nucleoside or in the 5’ position of the 5’-terminal nucleoside.

[0116] In some embodiments, the 2’-OH of a ribose is replaced with a group selected from –H, –F; – CF3, –CN, –N3, –NO, –NO2, –OR’, –SR’, or –N(R’)2, wherein each R’ is independently described in the present disclosure; –O–(C1–C10alkyl), –S–(C1–C10alkyl), –NH–(C1–C10alkyl), or –N(C1–C10alkyl)2; –O– (C2–C10alkenyl), –S–(C2–C10alkenyl), –NH–(C2–C10alkenyl), or –N(C2–C10alkenyl)2; –O–(C2–C10alkynyl), –S–(C2–C10alkynyl), –NH–(C2–C10alkynyl), or –N(C2–C10alkynyl)2; or –O––(C1–C10alkylene)– O––(C1–C10alkyl), –O–(C1–C10alkylene)–NH–(C1–C10alkyl) or –O–(C1–C10alkylene)–NH(C1–C10alkyl)2, –NH–(C1–C10alkylene)–O–(C1–C10alkyl), or –N(C1–C10alkyl)–(C1–C10alkylene)–O–(C1–C10alkyl), wherein each of the alkyl, alkylene, alkenyl and alkynyl is independently and optionally substituted. In some embodiments, the 2’–OH is replaced with –H (deoxyribose). In some embodiments, the 2’–OH is replaced with –F. In some embodiments, the 2’–OH is replaced with –OR’. In some embodiments, the 2’– OH is replaced with –OMe. In some embodiments, the 2’–OH is replaced with –OCH2CH2OMe.

[0117] In some embodiments, a sugar modification is a 2’-modification. Commonly used 2’- modifications include but are not limited to 2’−OR, wherein R is optionally substituted C1-6aliphatic. In some embodiments, a modification is 2’−OR, wherein R is optionally substituted C1-6alkyl. In some embodiments, a modification is 2’−OMe. In some embodiments, a modification is 2’-MOE. In someembodiments, a 2’-modification is S-cEt. In some embodiments, a modified sugar is an LNA sugar. In some embodiments, a 2’-modification is −F. In some embodiments, a 2’-modification is FANA. In some embodiments, a 2’-modification is FRNA. In some embodiments, a sugar modification is a 5’-modification, e.g., 5’-Me. In some embodiments, a sugar modification changes the size of the sugar ring. In some embodiments, a sugar modification is the sugar moiety in FHNA. In some embodiments, a 2’-modification is 2’-F.

[0118] In some embodiments, a sugar modification replaces a sugar moiety with another cyclic or acyclic moiety. Examples of such moieties are widely known in the art, including but not limited to those used in morpholino (optionally with its phosphorodiamidate linkage), glycol nucleic acids, etc.

[0119] In some embodiments, 5% or more of the sugars of an oligonucleotide are modified. In some embodiments, 10% or more of the sugars of an oligonucleotide are modified. In some embodiments, 15% or more of the sugars of an oligonucleotide are modified. In some embodiments, 20% or more of the sugars of an oligonucleotide are modified. In some embodiments, 25% or more of the sugars of an oligonucleotide are modified. In some embodiments, 30% or more of the sugars of an oligonucleotide are modified. In some embodiments, 35% or more of the sugars of an oligonucleotide are modified. In some embodiments, 40% or more of the sugars of an oligonucleotide are modified. In some embodiments, 45% or more of the sugars of an oligonucleotide are modified. In some embodiments, 50% or more of the sugars of an oligonucleotide are modified. In some embodiments, 55% or more of the sugars of an oligonucleotide are modified. In some embodiments, 60% or more of the sugars of an oligonucleotide are modified. In some embodiments, 65% or more of the sugars of an oligonucleotide are modified. In some embodiments, 70% or more of the sugars of an oligonucleotide are modified. In some embodiments, 75% or more of the sugars of an oligonucleotide are modified. In some embodiments, 80% or more of the sugars of an oligonucleotide are modified. In some embodiments, 85% or more of the sugars of an oligonucleotide are modified. In some embodiments, 90% or more of the sugars of an oligonucleotide are modified. In some embodiments, 95% or more of the sugars of an oligonucleotide are modified. In some embodiments, each sugar of an oligonucleotide is independently modified. In some embodiments, a modified sugar comprises a 2’- modification. In some embodiments, each modified sugar independently comprises a 2’-modification. In some embodiments, a 2’-modification is 2’-OR1. In some embodiments, a 2’-modification is a 2’-OMe. In some embodiments, a 2’-modification is a 2’-MOE. In some embodiments, a 2’-modification is an LNA sugar modification. In some embodiments, a 2’-modification is 2’-F. In some embodiments, each sugar modification is independently a 2’-modification. In some embodiments, each sugar modification is independently 2’-OR1or 2’-F. In some embodiments, each sugar modification is independently 2’-OR1or 2’-F, wherein R1is optionally substituted C1-6alkyl. In some embodiments, each sugar modification is independently 2’-OR1or 2’-F, wherein at least one is 2’-F. In some embodiments, each sugar modificationis independently 2’-OR1or 2’-F, wherein R1is optionally substituted C1-6alkyl, and wherein at least one is 2’-OR1. In some embodiments, each sugar modification is independently 2’-OR1or 2’-F, wherein at least one is 2’-F, and at least one is 2’-OR1. In some embodiments, each sugar modification is independently 2’- OR1or 2’-F, wherein R1is optionally substituted C1-6alkyl, and wherein at least one is 2’-F, and at least one is 2’-OR1. In some embodiments, each sugar modification is independently 2’-OR1. In some embodiments, each sugar modification is independently 2’-OR1, wherein R1is optionally substituted C1-6alkyl. In some embodiments, each sugar modification is 2’-OMe. In some embodiments, each sugar modification is 2’-MOE. In some embodiments, each sugar modification is independently 2’-OMe or 2’- MOE. In some embodiments, each sugar modification is independently 2’-OMe, 2’-MOE, or a LNA sugar.

[0120] In some embodiments, each sugar independently comprises a 2’-F or 2’-OR modification, wherein R is independently C1-6aliphatic. In some embodiments, R is −CH3.

[0121] In some embodiments, an oligonucleotide is or comprises a structure of 5’-a first region-a second region-a third region, each of which independently comprises one or more (e.g., 1-30, e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) nucleobases. In some embodiments, a first region comprises two or more (e.g., 2-10, e.g. about or at least about 2, 3, 4, 5, 6, 7, 8, 9, or 10) nucleobases. In some embodiments, a second region comprises two or more (e.g., 2-20, 5-20, 6- 20, 7-20, 8-20, e.g. about or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) nucleobases. In some embodiments, a third region comprises two or more (e.g., 2-10, e.g. about or at least about 2, 3, 4, 5, 6, 7, 8, 9, or 10) nucleobases.

[0122] In some embodiments, one or more (1-50, 1-40, 1-30, 1-25, 1-20, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, or more) sugars in an oligonucleotide comprise 2’-F modification. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in an oligonucleotide comprise a 2’-F modification. In some embodiments, each of the regions independently comprises one or more (1-50, 1-40, 1-30, 1-25, 1- 20, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, or more) sugars comprises 2’-F modification. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in each of the regions independently comprise a 2’-F modification. In some embodiments, the number of 2’-F modified sugars in an oligonucleotide or a region is 2 or more. In some embodiments, it is 3 or more. In some embodiments, it is 4 or more. In some embodiments, it is 5 or more. In some embodiments, it is 6 or more. In some embodiments, it is 7 or more. In some embodiments, it is 8 or more. In some embodiments, it is 9 or more. In some embodiments, it is 10 or more. In some embodiments, the percentage of 2’-F modified sugars in an oligonucleotide or a region is 50% or more. In some embodiments, it is 60% or more. In some embodiments, it is 70% or more. In some embodiments, it is 80% or more. In some embodiments, it is 90% or more. In some embodiments,it is 95% or more. In some embodiments, it is 100%. In some embodiments, two or more or all 2’-F modified sugars are consecutive.

[0123] In some embodiments, a first region comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more 2’-F modified sugars. In some embodiments, a first region comprises 5, 6, 7, or 8 2’-F modified sugars. In some embodiments, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in a first region comprise 2’-F. In some embodiments, each sugar is a first region comprises 2’-F. In some embodiments, a first region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more; in some embodiments, 5 or more) phosphorothioate internucleotidic linkages. In some embodiments, each phosphorothioate internucleotidic linkage in a first region is independently chirally controlled and is Sp. In some embodiments, a first region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) non-negatively charged internucleotidic linkages. In some embodiments, each non-negatively charged internucleotidic linkage in a first region is chirally controlled. In some embodiments, one or more non-negatively charged internucleotidic linkage in a first region is not chirally controlled. In some embodiments, each non- negatively charged internucleotidic linkage in a first region is chirally controlled and is Rp. In some embodiments, two or more or all 2’-F modified sugars in a first region are consecutive.

[0124] In some embodiments, a second region comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more 2’-F modified sugars. In some embodiments, a second region comprises 5, 6, 7, or 8 2’-F modified sugars. In some embodiments, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in a second region comprise 2’-F. In some embodiments, each sugar is a second region comprises 2’-F. In some embodiments, a second region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more; in some embodiments, 5 or more) phosphorothioate internucleotidic linkages. In some embodiments, each phosphorothioate internucleotidic linkage in a second region is independently chirally controlled and is Sp. In some embodiments, a second region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) non- negatively charged internucleotidic linkages. In some embodiments, each non-negatively charged internucleotidic linkage in a second region is chirally controlled. In some embodiments, one or more non- negatively charged internucleotidic linkage in a second region is not chirally controlled. In some embodiments, each non-negatively charged internucleotidic linkage in a second region is chirally controlled and is Rp. In some embodiments, each internucleotidic linkage in a second region is independently a phosphorothioate internucleotidic linkage. In some embodiments, two or more or all 2’-F modified sugars in a second region are consecutive. In some embodiments, a second region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) sugars that are not 2’-F modified. In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) or all sugars that are not 2’-F modified are 2’-OR modified, wherein R is optionally substituted C1-6aliphatic. In some embodiments, a second region comprises alternating 2’-F modified sugars and 2’-OR modified sugars, wherein R is optionally substituted C1-6aliphatic. In someembodiments, the first sugar in a second region (from 5’ to 3’) is a 2’-OR modified sugar, wherein R is optionally substituted C1-6aliphatic. In some embodiments, the last sugar in a second region (from 5’ to 3’) is a 2’-OR modified sugar, wherein R is optionally substituted C1-6aliphatic. In some embodiments, both the first and last sugars in a second region are independently a 2’-OR modified sugar, wherein R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl.

[0125] In some embodiments, a third region comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more 2’-F modified sugars. In some embodiments, a third region comprises 5, 6, 7, or 8 2’-F modified sugars. In some embodiments, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in a third region comprise 2’-F. In some embodiments, each sugar is a third region comprises 2’-F. In some embodiments, a third region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more; in some embodiments, 5 or more) phosphorothioate internucleotidic linkages. In some embodiments, each phosphorothioate internucleotidic linkage in a third region is independently chirally controlled and is Sp. In some embodiments, a third region comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) non-negatively charged internucleotidic linkages. In some embodiments, each non-negatively charged internucleotidic linkage in a third region is chirally controlled. In some embodiments, one or more non-negatively charged internucleotidic linkage in a third region is not chirally controlled. In some embodiments, each non- negatively charged internucleotidic linkage in a third region is chirally controlled and is Rp. In some embodiments, two or more or all 2’-F modified sugars in a third region are consecutive.

[0126] In some embodiments, one or more (1-50, 1-40, 1-30, 1-25, 1-20, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, or more) sugars comprises 2’-F modification.

[0127] Among other things, oligonucleotides comprising 2’-F modified sugars are useful for modulating splicing. In some embodiments, the present disclosure provides technologies to incorporating nitrogen-containing sugars, either cyclic or acyclic, into such oligonucleotides, e.g., in first, second and / or third regions. As demonstrated herein, provided oligonucleotides can provide various activities while bearing certain sugars (e.g., sugars comprising nitrogen) and / or internucleotidic linkages (those comprising nitrogen) and / or additional chemical moieties) for modulating and / or optimizing one or more properties (e.g., charges, delivery, distribution, binding strength, etc.).

[0128] In some embodiments, provided oligonucleotides comprise portions that can form DNA-RNA duplexes with RNA molecules. Such oligonucleotides may be useful, for example, RNase H-associated activities.

[0129] In some embodiments, a first region is referred to as a 5’-wing, a second region is referred to as a core, and a third region is referred to as a 3’-wing. In some embodiments, a wing comprises a sugar modification or a pattern thereof that is absent from a core. In some embodiments, a wing comprises a sugar modification that is absent from a core. In some embodiments, each sugar in a wing is the same. Insome embodiments, at least one sugar in a wing is different from another sugar in the wing. In some embodiments, one or more sugar modifications and / or patterns of sugar modifications in a first wing of an oligonucleotide (e.g., a 5’-wing) is / are different from one or more sugar modifications and / or patterns of sugar modifications in a second wing of the oligonucleotide (e.g., a 3’-wing). In some embodiments, a modification is a 2’-OR modification, wherein R is as described herein. In some embodiments, R is optionally substituted C1-4alkyl. In some embodiments, a modification is 2’-OMe. In some embodiments, a modification is a 2’-MOE. In some embodiments, a modified sugar is a high-affinity sugar, e.g., a bicyclic sugar (e.g., a LNA sugar), 2’-MOE, etc. In some embodiments, a 5’-wing comprises 2-MOE modifications. In some embodiments, each 5’-wing sugar is 2’-MOE modified. In some embodiments, a 3’-wing comprises 2-OMe modifications. In some embodiments, each 3’-wing sugar is 2’-OMe modified.

[0130] In some embodiments, an internucleotidic linkage linking a wing nucleoside and a core nucleoside is considered a core internucleotidic linkage.

[0131] In some embodiments, a wing comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) non- negatively charged internucleotidic linkages. In some embodiments, a non-negatively charged internucleotidic linkage is a neutral internucleotidic linkage. In some embodiments, as demonstrated herein, oligonucleotides that comprise wings comprising non-negatively charged internucleotidic linkages can deliver high activities and / or selectivities.

[0132] In some embodiments, a core sugar is a natural DNA sugar which comprises no substitution at the 2’ position (two −H at 2’-carbon). In some embodiments, each core sugar is a natural DNA sugar which comprises no substitution at the 2’ position (two −H at 2’-carbon).

[0133] In some embodiments, each wing and core is independently and optionally comprises a sugar comprising a nitrogen as described herein. In some embodiments, a 5’-wing comprises one or more sugar comprising nitrogen. In some embodiments, a 3’-wing comprises one or more sugar comprising nitrogen. In some embodiments, a core comprises one or more sugar comprising nitrogen.

[0134] As demonstrated herein, various oligonucleotides and compositions can provide various activities when incorporating sugars comprising nitrogen together with ribose / modified ribose sugars. Such sugars may also provide improved properties (e.g., charges, delivery, binding, selectivity, stability, etc.) over oligonucleotides comprising no sugars comprising nitrogen, and / or oligonucleotides comprising no ribose sugars (which can be independently modified or unmodified).

[0135] In some embodiments, a first wing (e.g., a 5’-wing) comprises one or more 2’-OR modifications, wherein R is optionally substituted C1-4aliphatic. In some embodiments, each sugar of a first wing comprises a 2’-OR modification. In some embodiments, 2’-OR is 2’-MOE. In some embodiments, each sugar of a first wing comprises 2’-MOE.

[0136] In some embodiments, a second wing (e.g., a 3’-wing) comprises one or more 2’-ORmodifications, wherein R is optionally substituted C1-4aliphatic. In some embodiments, each sugar of a second wing comprises a 2’-OR modification. In some embodiments, 2’-OR is 2’-OMe. In some embodiments, each sugar of a second wing comprises 2’-OMe. In some embodiments, a second wing, e.g., a 3’-wing, does not share the same pattern of sugar modifications of a first wing, e.g., a 5’-wing. In some embodiments, a second wing, e.g., a 3’-wing, does not contain a sugar modification of a first wing, e.g., a 5’-wing. As appreciated by those skilled in the art, in some embodiments, a first wing can be a 3’-wing, and a second wing can be a 5’-wing.

[0137] In some embodiments, a core comprises 1-25, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or sugars that comprises no 2’-OR groups or are not bicyclic or polycyclic sugars. In some embodiments, a core comprises 1-25, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or sugars that comprises no 2’-OR groups. In some embodiments, a core comprises 1-25, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or sugars that comprises two 2’-H. In many embodiments, a core comprises no 2’-OR groups. In many embodiments, sugars in core regions have two 2’-H.

[0138] In some embodiments, certain sugar modifications, e.g., 2’-MOE, provide more stability under certain conditions than other sugar modifications, e.g., 2’-OMe. In some embodiments, a wing comprises 2’-MOE modifications. In some embodiments, each nucleoside unit of a wing comprising a pyrimidine base (e.g., C, U, T, etc.) comprises a 2’-MOE modification. In some embodiments, each sugar unit of a wing comprises a 2’-MOE modification. In some embodiments, each nucleoside unit of a wing comprising a purine base (e.g., A, G, etc.) comprises no 2’-MOE modification (e.g., each such nucleoside unit comprises 2’-OMe, or no 2’-modification, etc.). In some embodiments, each nucleoside unit of a wing comprising a purine base comprises a 2’-OMe modification. In some embodiments, each internucleotidic linkage at the 3’-position of a sugar unit comprising a 2’-MOE modification is a natural phosphate linkage.

[0139] In some embodiments, a wing comprises no 2’-MOE modifications. In some embodiments, a wing comprises 2’-OMe modifications. In some embodiments, each nucleoside unit of a wing independently comprises a 2’-OMe modification.

[0140] In some embodiments, a wing comprises a bicyclic sugar. In some embodiments, each wing independently comprises one or more bicyclic sugars.

[0141] In some embodiments, sugars are connected by internucleotidic linkages, in some embodiments, modified internucleotidic linkage. In some embodiments, an internucleotidic linkage does not contain a linkage phosphorus. In some embodiments, an internucleotidic linkage is −L−. In some embodiments, an internucleotidic linkage is −OP(O)(−C≡CH)O−, −OP(O)(R)O− (e.g., R is −CH3), 3’ −NHP(O)(OH)O− 5’, 3’ −OP(O)(CH3)OCH2− 5’, 3’−CH2C(O)NHCH2−5’, 3’−SCH2OCH2−5’, 3’−OCH2OCH2−5’, 3’−CH2NR’CH2−5’, 3’−CH2N(Me)OCH2−5’, 3’−NHC(O)CH2CH2−5’,3’−NR’C(O)CH2CH2−5’, 3’-CH2CH2NR’−5’, 3’-CH2CH2NH−5’, or 3’−OCH2CH2N(R’)−5’. In some embodiments, a 5’ carbon may be optionally substituted with =O.

[0142] In some embodiments, a modified sugar is an optionally substituted pentose or hexose. In some embodiments, a modified sugar is an optionally substituted pentose. In some embodiments, a modified sugar is an optionally substituted hexose. In some embodiments, a modified sugar is an optionally substituted ribose or hexitol. In some embodiments, a modified sugar is an optionally substituted ribose. In some embodiments, a modified sugar is an optionally substituted hexitol.

[0143] In some embodiments, a sugar modification is 5’-vinyl (R or S), 5’-methyl (R or S), 2'-SH, 2’- F, 2’-OCH3, 2’-OCH2CH3, 2’-OCH2CH2F or 2’-O(CH2)20CH3. In some embodiments, a substituent at the 2’ position, e.g., a 2’-modification, is allyl, amino, azido, thio, O-allyl, O-C1-C10alkyl, OCF3, OCH2F, O(CH2)2SCH3, O(CH2)2-O-N(Rm)(Rn), O-CH2-C(=O)-N(Rm)(Rn), and O-CH2-C(=O)-N(R1)-(CH2)2- N(Rm)(Rn), wherein each allyl, amino and alkyl is optionally substituted, and each of Rl, Rmand Rnis independently R’ as described in the present disclosure. In some embodiments, each of Rl, Rmand Rnis independently −H or optionally substituted C1-C10alkyl.

[0144] In some embodiments, a sugar is a tetrahydropyran or THP sugar. In some embodiments, a modified nucleoside is tetrahydropyran nucleoside or THP nucleoside which is a nucleoside having a six- membered tetrahydropyran sugar substituted for a pentofuranosyl residue in typical natural nucleosides. THP sugars and / or nucleosides include those used in hexitol nucleic acid (HNA), anitol nucleic acid (ANA), mannitol nucleic acid (MNA) (e.g., Leumann, Bioorg. Med. Chem., 2002, 10, 841-854) or fluoro HNA (F- HNA).

[0145] In some embodiments, sugars comprise rings having more than 5 atoms and / or more than one heteroatom, e.g., morpholino sugars.

[0146] As those skilled in the art will appreciate, modifications of sugars, nucleobases, internucleotidic linkages, etc. can and are often utilized in combination in oligonucleotides, e.g., see various oligonucleotides in Table A1, A2, A3, and A4. For example, a combination of sugar modification and nucleobase modification is 2’-F (sugar) 5-methyl (nucleobase) modified nucleosides. In some embodiments, a combination is replacement of a ribosyl ring oxygen atom with S and substitution at the 2’-position.

[0147] In some embodiments, a 2’-modified sugar is a furanosyl sugar modified at the 2’ position. In some embodiments, a 2’-modification is halogen, −R’ (wherein R’ is not −H), −OR’ (wherein R’ is not −H), −SR’, −N(R’)2, optionally substituted −CH2−CH=CH2, optionally substituted alkenyl, or optionally substituted alkynyl. In some embodiments, a 2’-modifications is selected from −O[(CH2)nO]mCH3, −O(CH2)nNH2, −O(CH2)nCH3, −O(CH2)nF, −O(CH2)nONH2, −OCH2C(=O)N(H)CH3, and −O(CH2)nON[(CH2)nCH3]2, wherein each n and m is independently from 1 to about 10. In someembodiments, a 2’-modification is optionally substituted C1-C12alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkaryl, optionally substituted aralkyl, optionally substituted −O−alkaryl, optionally substituted −O−aralkyl, −SH, −SCH3, −OCN, −Cl, −Br, −CN, −F, −CF3, −OCF3, −SOCH3, −SO2CH3, −ONO2, −NO2, −N3, −NH2, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkaryl, optionally substituted aminoalkylamino, optionally substituted polyalkylamino, substituted silyl, a reporter group, an intercalator, a group for improving pharmacokinetic properties, a group for improving the pharmacodynamic properties, and other substituents. In some embodiments, a 2’-modification is a 2’-MOE modification.

[0148] In some embodiments, a 2’-modified or 2’-substituted sugar or nucleoside is a sugar or nucleoside comprising a substituent at the 2’ position of the sugar which is other than −H (typically not considered a substituent) or −OH. In some embodiments, a 2’-modified sugar is a bicyclic sugar comprising a bridge connecting two carbon atoms of the sugar ring one of which is the 2’ carbon. In some embodiments, a 2’-modification is non-bridging, e.g., allyl, amino, azido, thio, optionally substituted −O−allyl, optionally substituted −O−C1-C10alkyl, −OCF3, −O(CH2)2OCH3, 2’-O(CH2)2SCH3, −O(CH2)2ON(Rm)(Rn), or −OCH2C(=O)N(Rm)(Rn), where each Rmand Rnis independently −H or optionally substituted C1-C10alkyl.

[0149] In some embodiments, a sugar is the sugar of N-methanocarba, LNA, cMOE BNA, cEt BNA, ^-L-LNA or related analogs, HNA, Me-ANA, MOE-ANA, Ara-FHNA, FHNA, R-6'-Me-FHNA, S-6'-Me- FHNA, ENA, or c-ANA. In some embodiments, a modified internucleotidic linkage is C3-amide (e.g., sugar that has the amide modification attached to the C3’, Mutisya et al. 2014 Nucleic Acids Res. 2014 Jun 1; 42(10): 6542–6551), formacetal, thioformacetal, MMI [e.g., methylene(methylimino), Peoc'h et al. 2006 Nucleosides and Nucleotides 16 (7-9)], a PMO (phosphorodiamidate linked morpholino) linkage (which connects two sugars), or a PNA (peptide nucleic acid) linkage.

[0150] In some embodiments, a sugar is one described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858, the sugars of each of which are incorporated herein by reference.

[0151] In some embodiments a modified sugar is one described in US 5658873, US 5118800, US 5393878, US 5514785, US 5627053, US 7034133;7084125, US 7399845, US 5319080, US 5591722, US 5597909, US 5466786, US 6268490, US 6525191, US 5519134, US 5576427, US 6794499, US 6998484, US 7053207, US 4981957, US 5359044, US 6770748, US 7427672, US 5446137, US 6670461, US 7569686, US 7741457, US 8022193, US 8030467, US 8278425, US 5610300, US 5646265, US 8278426,US 5567811, US 5700920, US 8278283, US 5639873, US 5670633, US 8314227, US 2008 / 0039618, US 2009 / 0012281, WO 2021 / 030778, WO 2020 / 154344, WO 2020 / 154343, WO 2020 / 154342, WO 2020 / 165077, WO 2020 / 201406, WO 2020 / 216637, or WO 2020 / 252376.

[0152] Various additional sugars useful for preparing oligonucleotides or analogs thereof are known in the art and may be utilized in accordance with the present disclosure. Internucleotidic Linkages

[0153] Among other things, the present disclosure provides various internucleotidic linkages, including various modified internucleotidic linkages, either comprising phosphorus or not, that may be utilized together with other structural elements, e.g., various sugars as described herein, to provide oligonucleotides and compositions thereof.

[0154] As widely known by those skilled in the art, natural phosphate linkages are widely found in natural DNA and RNA molecules; they have the structure of −OP(O)(OH)O−, connect sugars in the nucleosides in DNA and RNA, and may be in various salt forms, for example, at physiological pH (about 7.4), natural phosphate linkages are predominantly exist in salt forms with the anion being −OP(O)(O−)O−. A modified internucleotidic linkage, or a non-natural phosphate linkage, is an internucleotidic linkage that is not natural phosphate linkage or a salt form thereof. Modified internucleotidic linkages, depending on their structures, may also be in their salt forms. For example, as appreciated by those skilled in the art, phosphorothioate internucleotidic linkages which have the structure of −OP(O)(SH)O− may be in various salt forms, e.g., at physiological pH (about 7.4) with the anion being −OP(O)(S−)O−.

[0155] In some embodiments, an oligonucleotide comprises different types of internucleotidic phosphorus linkages. In some embodiments, a chirally controlled oligonucleotide comprises at least one natural phosphate linkage and at least one modified (non-natural) internucleotidic linkage. In some embodiments, an oligonucleotide comprises no natural phosphate linkages. In some embodiments, an oligonucleotide comprises at least one natural phosphate linkage and at least one phosphorothioate. In some embodiments, an oligonucleotide comprises at least one non-negatively charged internucleotidic linkage. In some embodiments, an oligonucleotide comprises at least one natural phosphate linkage and at least one non-negatively charged internucleotidic linkage. In some embodiments, an oligonucleotide comprises at least one phosphorothioate internucleotidic linkage and at least one non-negatively charged internucleotidic linkage. In some embodiments, an oligonucleotide comprises at least one phosphorothioate internucleotidic linkage, at least one natural phosphate linkage, and at least one non-negatively charged internucleotidic linkage. In some embodiments, oligonucleotides comprise one or more, e.g., 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more non- negatively charged internucleotidic linkages. In some embodiments, a non-negatively chargedinternucleotidic linkage is not negatively charged in that at a given pH in an aqueous solution less than 50%, 40%, 40%, 30%, 20%, 10%, 5%, or 1% of the internucleotidic linkage exists in a negatively charged salt form. In some embodiments, a pH is about pH 7.4. In some embodiments, a pH is about 4-9. In some embodiments, the percentage is less than 10%. In some embodiments, the percentage is less than 5%. In some embodiments, the percentage is less than 1%. In some embodiments, an internucleotidic linkage is a non-negatively charged internucleotidic linkage in that the neutral form of the internucleotidic linkage has no pKa that is no more than about 1, 2, 3, 4, 5, 6, or 7 in water. In some embodiments, no pKa is 7 or less. In some embodiments, no pKa is 6 or less. In some embodiments, no pKa is 5 or less. In some embodiments, no pKa is 4 or less. In some embodiments, no pKa is 3 or less. In some embodiments, no pKa is 2 or less. In some embodiments, no pKa is 1 or less. In some embodiments, pKa of the neutral form of an internucleotidic linkage can be represented by pKa of the neutral form of a compound having the structure of CH3−the internucleotidic linkage−CH3. For example, pKa of can berepresented by pKa In some embodiments, a non-negatively charged internucleotidiclinkage is a neutral internucleotidic linkage. In some embodiments, a non-negatively charged internucleotidic linkage is a positively-charged internucleotidic linkage. In some embodiments, a non- negatively charged internucleotidic linkage comprises a guanidine moiety. In some embodiments, a non- negatively charged internucleotidic linkage comprises a heteroaryl base moiety. In some embodiments, a non-negatively charged internucleotidic linkage comprises a triazole moiety. In some embodiments, a non- negatively charged internucleotidic linkage comprises an alkynyl moiety.

[0156] Without wishing to be bound by any particular theory, the present disclosure notes that a neutral internucleotidic linkage can be more hydrophobic than a phosphorothioate internucleotidic linkage (PS), which can be more hydrophobic than a natural phosphate linkage (PO). Typically, unlike a PS or PO, a neutral internucleotidic linkage bears less charge. Without wishing to be bound by any particular theory, the present disclosure notes that incorporation of one or more neutral internucleotidic linkages into an oligonucleotide may increase oligonucleotides’ ability to be taken up by a cell and / or to escape from endosomes. Without wishing to be bound by any particular theory, the present disclosure notes that incorporation of one or more neutral internucleotidic linkages can be utilized to modulate melting temperature of duplexes formed between an oligonucleotide and its target nucleic acid. Without wishing to be bound by any particular theory, the present disclosure notes that incorporation of non-negativelycharged internucleotidic linkages, e.g., neutral internucleotidic linkages, into oligonucleotides may be able to increase the oligonucleotides’ ability to modulate levels, expressions and / or activities of target nucleic acids and / or products encoded thereby, e.g., through knock-down (e.g., by RNase H), exon skipping, etc. In some embodiments, a non-negatively charged internucleotidic linkage can improve the delivery and / or activity of an oligonucleotide.

[0157] In some embodiments, a linkage has the structure of or comprises −Y−PL(−X−RL)−Z−, or a salt form thereof, wherein: PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; Q−is an anion; each of X, Y and Z is independently –O–, –S–, −LL−N(–LL–RL)−LL−, −LL−N=C(–LL–RL)−LL−, or LL; each RLis independently −LL–N(R’)2, –LL–R’, −N=C(–LL–R’)2, −LL–N(R’)C(NR’)N(R’)2, −LL– N(R’)C(O)N(R’)2, a carbohydrate, or one or more additional chemical moieties optionally connected through a linker; each of LL1and LLis independently L; −CyIL− is −Cy−; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(NR’)N(R’)−, −N(R’)C(NR’)N(R’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, −OP(OR’)[B(R’)3]O−, and −[C(R’)2C(R’)2O]n−, wherein n is 1-50, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered,monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)N(R)2, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0158] In some embodiments, an internucleotidic linkage has the structure of −Y−PL(−X−RL)−Z−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−PL(−X−RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)(−X−RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)[−N(–LL–RL)−RL]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)(−NH– LL–RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)[−N(R’)2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)(−NHR’)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)(−NHSO2R)−O−, wherein each variable is independently as described herein. In some embodiments, R is methyl. In some embodiments, an internucleotidic linkage is −O−P(=O)(−NHSO2CH3)−O−. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)[−N=C(–LL–R’)2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −O−P(=W)[−N=C[N(R’)2]2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=W)(−N=C(R”)2)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=W)(−N(R”)2)−O−, wherein each variable is independently as described herein. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, such an internucleotidiclinkage is a non-negatively charged internucleotidic linkage. In some embodiments, such an internucleotidic linkage is a neutral internucleotidic linkage.

[0159] In some embodiments, an internucleotidic linkage has the structure of −PL(−X−RL)−Z−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −PL(−X−RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−X−RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)[−N(–LL–RL)−RL]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−NH–LL–RL)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)[−N(R’)2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−NHR’)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−NHSO2R)−O−, wherein each variable is independently as described herein. In some embodiments, R is methyl. In some embodiments, an internucleotidic linkage is −P(=O)(−NHSO2CH3)−O−. In some embodiments, an internucleotidic linkage has the structure of −P(=W)[−N=C(–LL–R’)2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)[−N=C[N(R’)2]2]−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−N=C(R”)2)−O−, wherein each variable is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=W)(−N(R”)2)−O−, wherein each variable is independently as described herein. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, such an internucleotidic linkage is a non-negatively charged internucleotidic linkage. In some embodiments, such an internucleotidic linkage is a neutral internucleotidic linkage. In some embodiments, P of such an internucleotidic linkage is bonded to N of a sugar.

[0160] In some embodiments, a linkage is a phosphoryl guanidine internucleotidic linkage. In some embodiments, a linkage is a thio-phosphoryl guanidine internucleotidic linkage.

[0161] In some embodiments, one or more methylene units are optionally and independently replaced with a moiety as described herein. In some embodiments, L or LLis or comprises −SO2−. In some embodiments, L or LLis or comprises −SO2N(R’)−. In some embodiments, L or LLis or comprises −C(O)−. In some embodiments, L or LLis or comprises −C(O)O−. In some embodiments, L or LLis or comprises −C(O)N(R’)−. In some embodiments, L or LLis or comprises −P(=W)(R’)−. In some embodiments, L or LLis or comprises −P(=O)(R’)−. In some embodiments, L or LLis or comprises −P(=S)(R’)−. In some embodiments, L or LLis or comprises −P(R’)−. In some embodiments, L or LLis or comprises−P(=W)(OR’)−. In some embodiments, L or LLis or comprises −P(=O)(OR’)−. In some embodiments, L or LLis or comprises −P(=S)(OR’)−. In some embodiments, L or LLis or comprises −P(OR’)−.

[0162] In some embodiments, −X−RLis −N(R’)SO2RL. In some embodiments, −X−RLis −N(R’)C(O)RL. In some embodiments, −X−RLis −N(R’)P(=O)(R’)RL.

[0163] In some embodiments, a linkage, e.g., a non-negatively charged internucleotidic linkage or neutral internucleotidic linkage, has the structure of or comprises −P(=W)(−N=C(R”)2)−, −P(=W)(−N(R’)SO2R”)−, −P(=W)(−N(R’)C(O)R”)−, −P(=W)(−N(R”)2)−, −P(=W)(−N(R’)P(O)(R”)2)−, −OP(=W)(−N=C(R”)2)O−, −OP(=W)(−N(R’)SO2R”)O−, −OP(=W)(−N(R’)C(O)R”)O−, −OP(=W)(−N(R”)2)O−, −OP(=W)(−N(R’)P(O)(R”)2)O−, −P(=W)(−N=C(R”)2)O−, −P(=W)(−N(R’)SO2R”)O−, −P(=W)(−N(R’)C(O)R”)O−, −P(=W)(−N(R”)2)O−, or −P(=W)(−N(R’)P(O)(R”)2)O−, or a salt form thereof, wherein: W is O or S; each R” is independently R’, −OR’, −P(=W)(R’)2, or −N(R’)2; each R’ is independently −R, −C(O)R, −C(O)N(R)2, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0164] In some embodiments, W is O. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N=C(R”)2)−, −P(=O)(−N(R’)SO2R”)−, −P(=O)(−N(R’)C(O)R”)−, −P(=O)(−N(R”)2)−, −P(=O)(−N(R’)P(O)(R”)2)−, −OP(=O)(−N=C(R”)2)O−, −OP(=O)(−N(R’)SO2R”)O−, −OP(=O)(−N(R’)C(O)R”)O−, −OP(=O)(−N(R”)2)O−, −OP(=O)(−N(R’)P(O)(R”)2)O−, −P(=O)(−N=C(R”)2)O−, −P(=O)(−N(R’)SO2R”)O−, −P(=O)(−N(R’)C(O)R”)O−, −P(=O)(−N(R”)2)O−, or −P(=O)(−N(R’)P(O)(R”)2)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N=C(R”)2)− −P(=O)(−N(R”)2)−, −OP(=O)(−N=C(R”)2)−O−, −OP(=O)(−N(R”)2)−O−, −P(=O)(−N=C(R”)2)−O− or −P(=O)(−N(R”)2)−O− or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N=C(R”)2)−O− or−OP(=O)(−N(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N=C(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)SO2R”)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)C(O)R”)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)P(O)(R”)2)O−, or a salt form thereof. In some embodiments, a internucleotidic linkage is n001.

[0165] In some embodiments, W is S. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N=C(R”)2)−, −P(=S)(−N(R’)SO2R”)−, −P(=S)(−N(R’)C(O)R”)−, −P(=S)(−N(R”)2)−, −P(=S)(−N(R’)P(O)(R”)2)−, −OP(=S)(−N=C(R”)2)O−, −OP(=S)(−N(R’)SO2R”)O−, −OP(=S)(−N(R’)C(O)R”)O−, −OP(=S)(−N(R”)2)O−, −OP(=S)(−N(R’)P(O)(R”)2)O−, −P(=S)(−N=C(R”)2)O−, −P(=S)(−N(R’)SO2R”)O−, −P(=S)(−N(R’)C(O)R”)O−, −P(=S)(−N(R”)2)O−, or −P(=S)(−N(R’)P(O)(R”)2)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N=C(R”)2)− −P(=S)(−N(R”)2)−, −OP(=S)(−N=C(R”)2)−O−, −OP(=S)(−N(R”)2)−O−, −P(=S)(−N=C(R”)2)−O− or −P(=S)(−N(R”)2)−O− or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N=C(R”)2)−O− or −OP(=S)(−N(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N=C(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R”)2)−O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)SO2R”)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)C(O)R”)O−, or a salt form thereof. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)P(O)(R”)2)O−, or a salt form thereof. In some embodiments, a internucleotidic linkage is *n001.

[0166] In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)SO2R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)SO2R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)SO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)SO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)SO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)SO2R”)O−, wherein R” is as described herein. In some embodiments, R’, e.g., of −N(R’)−, is hydrogen or optionally substituted C1-6aliphatic. In some embodiments, R’ is C1-6alkyl. In some embodiments, R’ is hydrogen. In some embodiments, R”, e.g., in −SO2R”, is R’ as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHSO2R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHSO2R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHSO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHSO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−NHSO2R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−NHSO2R”)O−, wherein R” is as described herein. In some embodiments, −X−RLis −N(R’)SO2RL, wherein each of R’ and RLis independently as described herein. In some embodiments, RLis R”. In some embodiments, RLis R’. In some embodiments, −X−RLis −N(R’)SO2R”, wherein R’ is as described herein. In some embodiments, −X−RLis −N(R’)SO2R’, wherein R’ is as described herein. In some embodiments, −X−RLis −NHSO2R’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, R’ is optionally substituted C1-6aliphatic. In some embodiments, R’ is optionally substituted C1-6alkyl. In some embodiments, R’ is optionally substituted phenyl. In some embodiments, R’ is optionally substituted heteroaryl. In some embodiments, R”, e.g., in −SO2R”, is R. In some embodiments, R is an optionally substituted group selected from C1-6aliphatic, aryl, heterocyclyl, and heteroaryl. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is optionally substituted C1-6alkenyl. In some embodiments, R is optionally substituted C1-6alkynyl. In some embodiments, R is optionally substituted methyl. In some embodiments, −X−RLis −NHSO2CH3. In some embodiments, R is −CF3. In some embodiments, R is methyl. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is ethyl. In some embodiments, R is −CH2CHF2. In some embodiments, R is −CH2CH2OCH3. In some embodiments, R is optionally substituted propyl. In some embodiments, R is optionally substituted butyl. In some embodiments, R is n-butyl. In some embodiments, R is −(CH2)6NH2. In some embodiments, R is an optionally substituted linear C2-20aliphatic. In some embodiments, R is optionally substituted linear C2-20alkyl. In some embodiments, R is linear C2-20alkyl. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20aliphatic. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is optionally substituted linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R isphenyl. In some embodiments, R is p-methylphenyl. In some embodiments, R is 4-dimethylaminophenyl. In some embodiments, R is 3-pyridinyl. In some embodiments,. In somesome embodiments, R is benzyl. In some embodiments, R is optionally substituted heteroaryl. In some embodiments, R is optionally substituted 1,3-diazolyl. In some embodiments, R is optionally substituted 2-(1,3)-diazolyl. In some embodiments, R is optionally substituted 1-methyl-2-(1,3)-diazolyl. In some embodiments, R is isopropyl. In some embodiments, R” is −N(R’)2. In some embodiments, R” is −N(CH3)2. In some embodiments, R”, e.g., in −SO2R”, is −OR’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, R” is −OCH3. In some embodiments, a linkage is −OP(=O)(−NHSO2R)O−, wherein R is as described herein. In some embodiments, R is optionally substituted linear alkyl as described herein. In some embodiments, R is linear alkyl as described herein. In some embodiments, a linkage is −OP(=O)(−NHSO2CH3)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2CH2CH3)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2CH2CH2OCH3)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2CH2Ph)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2CH2CHF2)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2(4-methylphenyl))O−. In some embodiments, −X−RL. In some embodiments, a linkage is −OP(=O)(−X−RL)O−, wherein −X−RLis. In some embodiments, a linkage is −OP(=O)(−NHSO2CH(CH3)2)O−. In some embodiments, a linkage is −OP(=O)(−NHSO2N(CH3)2)O−.

[0167] In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)C(O)R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)C(O)R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)C(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)C(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)C(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)C(O)R”)O−, wherein R” is as described herein. In some embodiments, R’, e.g., of −N(R’)−, is hydrogen or optionally substituted C1-6aliphatic. In some embodiments, R’ is C1-6alkyl. In some embodiments, R’ is hydrogen. In some embodiments, R”, e.g., in −C(O)R”, is R’ as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHC(O)R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHC(O)R”)−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHC(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHC(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−NHC(O)R”)O−, wherein R” is as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−NHC(O)R”)O−, wherein R” is as described herein. In some embodiments, −X−RLis −N(R’)CORL, wherein RLis as described herein. In some embodiments, −X−RLis −N(R’)COR”, wherein R” is as described herein. In some embodiments, −X−RLis −N(R’)COR’, wherein R’ is as described herein. In some embodiments, −X−RLis −NHCOR’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, R’ is optionally substituted C1-6aliphatic. In some embodiments, R’ is optionally substituted C1-6alkyl. In some embodiments, R’ is optionally substituted phenyl. In some embodiments, R’ is optionally substituted heteroaryl. In some embodiments, R”, e.g., in −C(O)R”, is R. In some embodiments, R is an optionally substituted group selected from C1-6aliphatic, aryl, heterocyclyl, and heteroaryl. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is optionally substituted C1-6alkenyl. In some embodiments, R is optionally substituted C1-6alkynyl. In some embodiments, R is methyl. In some embodiments, −X−RLis −NHC(O)CH3. In some embodiments, R is optionally substituted methyl. In some embodiments, R is −CF3. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is ethyl. In some embodiments, R is −CH2CHF2. In some embodiments, R is −CH2CH2OCH3. In some embodiments, R is optionally substituted C1-20(e.g., C1-6, C2-6, C3-6, C1-10, C2-10, C3-10, C2-20, C3-20, C10-20, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, etc.) aliphatic. In some embodiments, R is optionally substituted C1-20(e.g., C1-6, C2-6, C3-6, C1-10, C2-10, C3-10, C2-20, C3-20, C10-20, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, etc.) alkyl. In some embodiments, R is an optionally substituted linear C2-20aliphatic. In some embodiments, R is optionally substituted linear C2-20alkyl. In some embodiments, R is linear C2-20alkyl. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20aliphatic. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is optionally substituted linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In someembodiments, R is optionally substituted aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is p-methylphenyl. In some embodiments, R is benzyl. In some embodiments, R is optionally substituted heteroaryl. In some embodiments, R is optionally substituted 1,3-diazolyl. In some embodiments, R is optionally substituted 2-(1,3)-diazolyl. In some embodiments, R is optionally substituted 1-methyl-2-(1,3)-diazolyl. In some embodiments, RLis −(CH2)5NH2. In some embodiments,some embodiments, R” is −N(R’)2. In some embodiments, R” is −N(CH3)2. In some embodiments, −X−RLis −N(R’)CON(RL)2, wherein each of R’ and RLis independently as described herein. In some embodiments, −X−RLis −NHCON(RL)2, wherein RLis as described herein. In some embodiments, two R’ or two RLare taken together with the nitrogen atom to which they are attached to form a ring as described herein, e.g., optionallyembodiments, R”, e.g., in −C(O)R”, is −OR’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, is optionally substituted C1-6aliphatic. In some embodiments, is optionally substituted C1-6alkyl. In some embodiments, R” is −OCH3. In some embodiments, −X−RLis −N(R’)C(O)ORL, wherein each of R’ and RLis independently as described herein. In some embodiments, R is. In some embodiments, −X−RLis −NHC(O)OCH3. In some embodiments, −X−RLis −NHC(O)N(CH3)2. In some embodiments, a linkage is −OP(O)(NHC(O)CH3)O−. In some embodiments, a linkage is −OP(O)(NHC(O)OCH3)O−. In some embodiments, a linkage is −OP(O)(NHC(O)(p-methylphenyl))O−. In some embodiments, a linkage is −OP(O)(NHC(O)N(CH3)2)O−. In some embodiments, −X−RLis −N(R’)RL, wherein each of R’ and RLis independently as described herein. In some embodiments, −X−RLis −N(R’)RL, wherein each of R’ and RLis independently not hydrogen. In some embodiments, −X−RLis −NHRL, wherein RLis as described herein. In some embodiments, RLis not hydrogen. In some embodiments, RLis optionally substituted aryl or heteroaryl. In some embodiments, RLis optionally substituted aryl. In some embodiments, RLis optionally substituted phenyl. In some embodiments, −X−RLis −N(R’)2, wherein each R’ is independently asdescribed herein. In some embodiments, −X−RLis −NHR’, wherein R’ is as described herein. In some embodiments, −X−RLis −NHR, wherein R is as described herein. In some embodiments, −X−RLis RL, wherein RLis as described herein. In some embodiments, RLis −N(R’)2, wherein each R’ is independently as described herein. In some embodiments, RLis −NHR’, wherein R’ is as described herein. In some embodiments, RLis −NHR, wherein R is as described herein. In some embodiments, RLis −N(R’)2, wherein each R’ is independently as described herein. In some embodiments, none of R’ in −N(R’)2is hydrogen. In some embodiments, RLis −N(R’)2, wherein each R’ is independently C1-6aliphatic. In some embodiments, RLis −L−R’, wherein each of L and R’ is independently as described herein. In some embodiments, RLis −L−R, wherein each of L and R is independently as described herein. In some embodiments, RLis −N(R’)−Cy−N(R’)−R’. In some embodiments, RLis −N(R’)−Cy−C(O)−R’. In some embodiments, RLis −N(R’)−Cy−O−R’. In some embodiments, RLis −N(R’)−Cy−SO2−R’. In some embodiments, RLis −N(R’)−Cy−SO2−N(R’)2. In some embodiments, RLis −N(R’)−Cy−C(O)−N(R’)2. In some embodiments, RLis −N(R’)−Cy−OP(O)(R”)2. In some embodiments, −Cy− is an optionally substituted bivalent aryl group. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,4-phenylene. In some embodiments, −Cy− is 1,4- phenylene. In some embodiments, RLis −N(CH3)2. In some embodiments, RLis −N(i-Pr)2. In someembodiments, RLis . In some embodiments, RLis . In some embodiments, RLis . In some embodiments, RLis . In some embodiments, RLisIn some embodiments,, orents, −X−RLis −N(R’)−C(O)−Cy−RL. In some embodiments, −X−RLis RL. In some embodiments, RLis −N(R’)−C(O)−Cy−O−R’. In some embodiments, RLis −N(R’)−C(O)−Cy−R’. In some embodiments, RLis −N(R’)−C(O)−Cy−C(O)−R’. In some embodiments, RLis −N(R’)−C(O)−Cy−N(R’)2. In some embodiments, RLis −N(R’)−C(O)−Cy−SO2−N(R’)2. In some embodiments, RLis −N(R’)−C(O)−Cy−C(O)−N(R’)2. In some embodiments, RLis −N(R’)−C(O)−Cy−C(O)−N(R’)−SO2−R’. In some embodiments, R’ is R as described herein. In some embodiments, RLis

[0168] As described herein, in some embodiments, one or more methylene units of L, or a variable which comprises or is L, are independently replaced with −O−, −N(R’)−, −C(O)−, −C(O)N(R’)−, −SO2−, −SO2N(R’)−, or −Cy−. In some embodiments, a methylene unit is replaced with −Cy−. In some embodiments, −Cy− is an optionally substituted bivalent aryl group. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,4-phenylene. In some embodiments, −Cy− is an optionally substituted bivalent 5-20 (e.g. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) membered heteroaryl group having 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) heteroatoms. In some embodiments, −Cy− is monocyclic. In some embodiments, −Cy− is bicyclic. In some embodiments, −Cy− is polycyclic. In some embodiments, each monocyclic unit in −Cy− is independently 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered, and is independently saturated, partially saturated, or aromatic. In some embodiments, −Cy− is an optionally substituted 3-20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) membered monocyclic, bicyclic or polycyclic aliphatic group. In some embodiments, −Cy− is an optionally substituted 3-20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) membered monocyclic, bicyclic or polycyclic heteroaliphatic group having 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) heteroatoms.

[0169] In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)P(O)(R”)2)−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)P(O)(R”)2)−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−N(R’)P(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−N(R’)P(O)(R”)2)O−, wherein eachR” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−N(R’)P(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−N(R’)P(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, R’, e.g., of −N(R’)−, is hydrogen or optionally substituted C1-6aliphatic. In some embodiments, R’ is C1-6alkyl. In some embodiments, R’ is hydrogen. In some embodiments, R”, e.g., in −P(O)(R”)2, is R’ as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHP(O)(R”)2)−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHP(O)(R”)2)−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=O)(−NHP(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −P(=S)(−NHP(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=O)(−NHP(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an internucleotidic linkage has the structure of −OP(=S)(−NHP(O)(R”)2)O−, wherein each R” is independently as described herein. In some embodiments, an occurrence of R”, e.g., in −P(O)(R”)2, is R. In some embodiments, R is an optionally substituted group selected from C1-6aliphatic, aryl, heterocyclyl, and heteroaryl. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is optionally substituted C1-6alkenyl. In some embodiments, R is optionally substituted C1-6alkynyl. In some embodiments, R is methyl. In some embodiments, R is optionally substituted methyl. In some embodiments, R is −CF3. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is ethyl. In some embodiments, R is −CH2CHF2. In some embodiments, R is −CH2CH2OCH3. In some embodiments, R is optionally substituted C1-20(e.g., C1-6, C2-6, C3-6, C1-10, C2-10, C3-10, C2-20, C3-20, C10-20, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, etc.) aliphatic. In some embodiments, R is optionally substituted C1-20(e.g., C1-6, C2-6, C3-6, C1-10, C2-10, C3-10, C2-20, C3-20, C10-20, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, etc.) alkyl. In some embodiments, R is an optionally substituted linear C2-20aliphatic. In some embodiments, R is optionally substituted linear C2-20alkyl. In some embodiments, R is linear C2-20alkyl. In some embodiments, R is isopropyl. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20aliphatic. In some embodiments, R is optionally substituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is optionally substituted linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, R is linear C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20alkyl. In some embodiments, each R” is independently R as described herein, for example, insome embodiments, each R” is methyl. In some embodiments, R” is optionally substituted aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is p-methylphenyl. In some embodiments, R is benzyl. In some embodiments, R is optionally substituted heteroaryl. In some embodiments, R is optionally substituted 1,3-diazolyl. In some embodiments, R is optionally substituted 2-(1,3)-diazolyl. In some embodiments, R is optionally substituted 1-methyl-2-(1,3)-diazolyl. In some embodiments, an occurrence of R” is −N(R’)2. In some embodiments, R” is −N(CH3)2. In some embodiments, an occurrence of R”, e.g., in −P(O)(R”)2, is −OR’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, is optionally substituted C1-6aliphatic. In some embodiments, is optionally substituted C1-6alkyl. In some embodiments, R” is −OCH3. In some embodiments, each R” is −OR’ as described herein. In some embodiments, each R” is −OCH3. In some embodiments, each R” is −OH. In some embodiments, a linkage is −OP(O)(NHP(O)(OH)2)O−. In some embodiments, a linkage is −OP(O)(NHP(O)(OCH3)2)O−. In some embodiments, a linkage is −OP(O)(NHP(O)(CH3)2)O−.

[0170] In some embodiments, −N(R”)2is −N(R’)2. In some embodiments, −N(R”)2is −NHR. In some embodiments, −N(R”)2is −NHC(O)R. In some embodiments, −N(R”)2is −NHC(O)OR. In some embodiments, −N(R”)2is −NHS(O)2R.

[0171] In some embodiments, an internucleotidic linkage is a phosphoryl guanidine internucleotidic linkage. In some embodiments, an internucleotidic linkage comprises −X−RLas described herein. In some embodiments, −X−RLis −N=C(–LL–RL)2.In some embodiments, −X−RLis −N=C[N(RL)2]2.In some embodiments, −X−RLis −N=C[NR’RL]2.In some embodiments, −X−RLis −N=C[N(R’)2]2.In some embodiments, −X−RLis −N=C[N(RL)2](CHRL1RL2), wherein each of RL1and RL2is independently as described herein. In some embodiments, −X−RLis −N=C(NR’RL)(CHRL1RL2), wherein each of RL1and RL2is independently as described herein. In some embodiments, −X−RLis −N=C(NR’RL)(CR’RL1RL2), wherein each of RL1and RL2is independently as described herein. In some embodiments, −X−RLis −N=C[N(R’)2](CHR’RL2). In some embodiments, −X−RLis −N=C[N(RL)2](RL). In some embodiments, −X−RLis −N=C(NR’RL)(RL). In some embodiments, −X−RLis −N=C(NR’RL)(R’). In some embodiments, −X−RLis −N=C[N(R’)2](R’). In some embodiments, −X−RLis −N=C(NR’RL1)(NR’RL2), wherein each RL1and RL2is independently RL, and each R’ and RLis independently as described herein. In some embodiments, −X−RLis −N=C(NR’RL1)(NR’RL2), wherein variable is independently as described herein. In some embodiments, −X−RLis −N=C(NR’RL1)(CHR’RL2), wherein variable is independently as described herein. In some embodiments, −X−RLis −N=C(NR’RL1)(R’), wherein variable is independently as described herein. In some embodiments, each R’ is independently R. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, −X−RLis. In some embodiments, two groups selected from R’, RL, RL1, RL2, etc. (in some embodiments, on the same atom (e.g., −N(R’)2, or −NR’RL, or −N(RL)2, wherein R’ and RLcan independently be R as described herein), etc.), or on different atoms (e.g., the two R’ in −N=C(NR’RL)(CR’RL1RL2) or −N=C(NR’RL1)(NR’RL2); can also be two other variables that can be R, e.g., RL, RL1, RL2, etc.)) are independently R and are taken together with their intervening atoms to form a ring as described herein. In some embodiments, two of R, R’, RL, RL1, or RL2on the same atom, e.g., of −N(R’)2, −N(RL)2, −NR’RL, −NR’RL1, −NR’RL2, −CR’RL1RL2, etc., are taken together to form a ring as described herein. In some embodiments, two R’, RL, RL1, or RL2on two different atoms, e.g., the two R’ in −N=C(NR’RL)(CR’RL1RL2), −N=C(NR’RL1)(NR’RL2), etc. are taken together to form a ring as described herein. In some embodiments, a formed ring is an optionally substituted 3-20 (e.g., 3-15, 3-12, 3-10, 3-9, 3-8, 3-7, 3-6, 4-15, 4-12, 4-10, 4-9, 4-8, 4-7, 4-6, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.) monocyclic, bicyclic or tricyclic ring having 0-5 additional heteroatoms. In some embodiments, a formed ring is monocyclic as described herein. In some embodiments, a formed ring is an optionally substituted 5-10 membered monocyclic ring. In some embodiments, a formed ring is bicyclic. In some embodiments, a formed ring is polycyclic. In some embodiments, two groups that are or can be R (e.g., the two R’ in −N=C(NR’RL)(CR’RL1RL2) or −N=C(NR’RL1)(NR’RL2), the two R’ in −N=C(NR’RL)(CR’RL1RL2), −N=C(NR’RL1)(NR’RL2), etc.) are taken together to form an optionally substituted bivalent hydrocarbon chain, e.g., an optionally substituted C1-20aliphatic chain, optionally substituted −(CH2)n− wherein n is 1-20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, a hydrocarbon chain is saturated. In some embodiments, a hydrocarbon chain is partially unsaturated. In some embodiments, a hydrocarbon chain is unsaturated. In some embodiments, two groups that are or can be R (e.g., the two R’ in −N=C(NR’RL)(CR’RL1RL2) or −N=C(NR’RL1)(NR’RL2), the two R’ in −N=C(NR’RL)(CR’RL1RL2), −N=C(NR’RL1)(NR’RL2), etc.) are taken together to form an optionally substituted bivalent heteroaliphatic chain, e.g., an optionally substituted C1-20heteroaliphatic chain having 1-10 heteroatoms. In some embodiments, a heteroaliphatic chain is saturated. In some embodiments, a heteroaliphatic chain is partially unsaturated. In some embodiments, a heteroaliphatic chain is unsaturated. In some embodiments, a chain is optionally substituted −(CH2)−. In some embodiments, a chain is optionally substituted −(CH2)2−. In some embodiments, a chain is optionally substituted −(CH2)−. In some embodiments, a chain is optionally substituted −(CH2)2−. In some embodiments, a chain is optionally substituted −(CH2)3−. In some embodiments, a chain is optionally substituted −(CH2)4−. In some embodiments, a chain is optionallysubstituted −(CH2)5−. In some embodiments, a chain is optionally substituted −(CH2)6−. In some embodiments, a chain is optionally substituted −CH=CH−. In some embodiments, a chain is optionally substitutedIn some embodiments, a chain is optionally substituted In someembodiments, a chain is optionally substitutedIn some embodiments, a chain is optionally substituted In some embodiments, a chain is optionally substituted In someembodiments, a chain is optionally substituted In some embodiments, a chain is optionallysubstituted In some embodiments, a chain is optionally substitutedIn someembodiments, a chain is optionally substituted In some embodiments, two of R, R’, RL, RL1, LR2, etc. on different atoms are taken together to form a ring as described herein. For examples, in some embodiments, −X−RLisIn some embodiments, −X−RLisIn some embodiments, −X−RLisIn some embodiments, −X−RLisIn some embodiments, −X−RLis In some embodiments, −X−RLis In someembodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −N(R’)2, −N(R)2, −N(RL)2, −NR’RL, −NR’RL1, −NR’RL2, −NRL1RL2, etc. is a formed ring. In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted . In some embodiments, a ring is optionally substituted .

[0172] In some embodiments, RL1and RL2are the same. In some embodiments, RL1and RL2aredifferent. In some embodiments, each of RL1and RL2is independently RLas described herein, e.g., below.

[0173] In some embodiments, RLis optionally substituted C1-30aliphatic. In some embodiments, RLis optionally substituted C1-30alkyl. In some embodiments, RLis linear. In some embodiments, RLis optionally substituted linear C1-30alkyl. In some embodiments, RLis optionally substituted C1-6alkyl. In some embodiments, RLis methyl. In some embodiments, RLis ethyl. In some embodiments, RLis n- propyl. In some embodiments, RLis isopropyl. In some embodiments, RLis n-butyl. In some embodiments, RLis tert-butyl. In some embodiments, RLis (E)−CH2−CH=CH−CH2−CH3. In some embodiments, RLis (Z)−CH2−CH=CH−CH2−CH3. In some embodiments, RLis In some embodiments, RLisIn someembodiments, RLis CH3(CH2)2C≡CC≡C(CH2)3−. In some embodiments, RLis CH3(CH2)5C≡C−. In some embodiments, RLoptionally substituted aryl. In some embodiments, RLis optionally substituted phenyl. In some embodiments, RLis phenyl substituted with one or more halogen. In some embodiments, RLis phenyl optionally substituted with halogen, −N(R’), or −N(R’)C(O)R’. In some embodiments, RLis phenyl optionally substituted with −Cl, −Br, −F, −N(Me)2, or −NHCOCH3. In some embodiments, RLis −LL−R’, wherein LLis an optionally substituted C1-20saturated, partially unsaturated or unsaturated hydrocarbon chain. In some embodiments, such a hydrocarbon chain is linear. In some embodiments, such a hydrocarbon chain is unsubstituted. In some embodiments, LLis (E)−CH2−CH=CH−. In some embodiments, LLis −CH2−C≡C−CH2−. In some embodiments, LLis −(CH2)3−. In some embodiments, LLis −(CH2)4−. In some embodiments, LLis −(CH2)n−, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In some embodiments, R’ is optionally substituted aryl as described herein. In some embodiments, R’ is optionally substituted phenyl. In some embodiments, R’ is phenyl. In some embodiments, R’ is optionally substituted heteroaryl as described herein. In some embodiments, R’ is 2’-pyridinyl. In some embodiments, R’ is 3’- pyridinyl. In some embodiments, RLis In some embodiments, RLis Insome embodiments, RLis In some embodL Liments, R is −L –N(R’)2, wherein each variable is independently as described herein. In some embodiments, each R’ is independently C1-6aliphatic as described herein. In some embodiments, −N(R’)2is −N(CH3)2. In some embodiments, −N(R’)2is −NH2. In some embodiments, RLis −(CH2)n−N(R’)2, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In some embodiments, RLis −(CH2CH2O)n−CH2CH2−N(R’)2, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In someembodiments, RLisIn some embodiments, RLisIn some embodiments, RLis In some embodimentLs, R is −(CH2)n−NH2. In some embodiments, RLis −(CH2CH2O)n−CH2CH2−NH2. In some embodiments, RLis −(CH2CH2O)n−CH2CH2−R’, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In some embodiments, RLis −(CH2CH2O)n−CH2CH2CH3, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In some embodiments, RLis −(CH2CH2O)n−CH2CH2OH, wherein n is 1-30 (e.g., 1-20, 5-30, 6-30, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, etc.). In some embodiments, RLis or comprises a carbohydrate moiety, e.g., GalNAc. In some embodiments, RLis −LL−GalNAc. In some embodiments, RLisIn some embodiments, one or more methylene units of LLare independently replaced with −Cy− (e.g., optionally substituted 1,4-phenylene, a 3-30 membered bivalent optionally substituted monocyclic, bicyclic, or polycyclic cycloaliphatic ring, etc.), −O−, −N(R’)− (e.g., −NH), −C(O)−, −C(O)N(R’)− (e.g., −C(O)NH−), −C(NR’)− (e.g., −C(NH)−), −N(R’)C(O)(N(R’)− (e.g., −NHC(O)NH−), −N(R’)C(NR’)(N(R’)− (e.g., −NHC(NH)NH−), −(CH2CH2O)n−, etc. For example, in some embodiments, RLis . In some embodiments, RLis . In some embodiments, RLis . In some embodiments, RLis . In some embodiments, RLiswherein n is 0-20. In some embodiments, RLis or comprises one or more additional chemical moieties (e.g., carbohydrate moieties, GalNAc moieties, etc.) optionally substituted connected through a linker (which can be bivalent or polyvalent). For example, in some embodiments, RLis, wherein n is 0-20. In some embodiments, RLis wherein n is 0-20. In some Lembodiments, R is R’ as described herein. As described herein, many variable can independently be R’. In some embodiments, R’ is R as described herein. As described herein, various variables can independently be R. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is methyl. In some embodiments, R is optionally substituted cycloaliphatic. In some embodiments, R is optionally substituted cycloalkyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted heteroaryl. In some embodiments, R is optionally substituted heterocyclyl. In some embodiments, R is optionally substituted C1-20heterocyclyl having 1-5 heteroatoms, e.g., one of which is nitrogen. In some embodiments, R is optionally substituted In some embodiments, R is optionally substituted In some embodiments, Ris optionally substituted. In some embodiments, R is optionally substituted. In some embodiments, R is optionally substituted. In some embodiments, R is optionally substituted. In some embodiments, R is optionally substituted In some embodiments, Ris optionally substituted . In some embodiments, R is optionally substituted. In some embodiments, R is optionally substitutedIn some embodiments, R is optionally substituted In some embodiments, R is optionally substituted n some embodiments, Ris optionally substituted In some embodiments, R is optionally substituted In someembodiments, R is optionally substituted

[0174] In some embodiments, −X−RLis. In some embodiments, −X−RLis In sLLome embodiments, −X−R is . In some embodiments, −X−R is. In some embodiments, −X−RLisIn some embodiments, −X−RLis In some embodiments, −X−RLis In some embodiments, −X−RLis. In some embodiments, −X−RLis In soLme embodiments, −X−R is . In some embodiments, −X−RLisLIn some embodiments, −X−R is. In some embodiments, −X−RLwherein n is 1-20. In some embodiments, −X−RLis wherein n is 1-20. In some embodiments, −X−RLisselected from:In some embodiments, −X−RLis. In some embodiments, −X−RLis . In some embodiments, −X−RLis .

[0175] In some embodiments, RLis R” as described herein. In some embodiments, RLis R as described herein.

[0176] In some embodiments, R” or RLis or comprises an additional chemical moiety. In some embodiments, R” or RLis or comprises an additional chemical moiety, wherein the additional chemical moiety is or comprises a carbohydrate moiety. In some embodiments, R” or RLis or comprises a GalNAc. In some embodiments, RLor R” is replaced with, or is utilized to connect to, an additional chemical moiety.

[0177] In some embodiments, X is –O–. In some embodiments, X is –S–. In some embodiments, X is −LL−N(–LL–RL)−LL−. In some embodiments, X is −N(–LL–RL)−LL−. In some embodiments, X is −LL−N(–LL–RL)−. In some embodiments, X is −N(–LL–RL)−. In some embodiments, X is −LL−N=C(– LL–RL)−LL−. In some embodiments, X is −N=C(–LL–RL)−LL−. In some embodiments, X is −LL−N=C(– LL–RL)−. In some embodiments, X is −N=C(–LL–RL)−. In some embodiments, X is LL. In some embodiments, X is a covalent bond.

[0178] In some embodiments, Y is a covalent bond. In some embodiments, Y is −O−. In some embodiments, Y is −N(R’)−. In some embodiments, Z is a covalent bond. In some embodiments, Z is −O−. In some embodiments, Z is −N(R’)−. In some embodiments, R’ is R. In some embodiments, R is −H. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is propyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl.

[0179] As described herein, various variables in structures in the present disclosure can be or comprise R. Suitable embodiments for R are described extensively in the present disclosure. As appreciated by those skilled in the art, R embodiments described for a variable that can be R may also be applicable to another variable that can be R. Similarly, embodiments described for a component / moiety (e.g., L) for a variable may also be applicable to other variables that can be or comprise the component / moiety.

[0180] In some embodiments, R” is R’. In some embodiments, R” is −N(R’)2.

[0181] In some embodiments, −X−RLis −SH. In some embodiments, −X−RLis −OH.

[0182] In some embodiments, −X−RLis −N(R’)2. In some embodiments, each R’ is independently optionally substituted C1-6aliphatic. In some embodiments, each R’ is independently methyl.

[0183] In some embodiments, a non-negatively charged internucleotidic linkage has the structure of−OP(=O)(−N=C((N(R’)2)2−O−. In some embodiments, a R’ group of one N(R’)2is R, a R’ group of the other N(R’)2is R, and the two R groups are taken together with their intervening atoms to form an optionally substituted ring, e.g., a 5-membered ring as in n001. In some embodiments, each R’ is independently R, wherein each R is independently optionally substituted C1-6aliphatic.

[0184] In some embodiments, −X−RLis −N=C(–LL–R’)2. In some embodiments, −X−RLis −N=C(– LL1−LL2−LL3–R’)2, wherein each LL1, LL2and LL3is independently L”, wherein each L” is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, LL2is −Cy−. In some embodiments, LL1is a covalent bond. In some embodiments, LL3is a covalent bond. In some embodiments, −X−RLis −N=C(–LL1−Cy−LL3–R’)2. In some embodiments, −X−RLIn some embodiments, −X−RLis In some embodiments, −X−RLisIn some embodiments, −X−RLis In some embodiments, −X−RLisIn some embodiLments, −X−R i

[0185] In some embodiments, as utilized in the present disclosure, L is covalent bond. In someembodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, or −C(O)O−.

[0186] In some embodiments, an internucleotidic linkage is a phosphoryl guanidine internucleotidic linkage. In some embodiments, −X−RLis −N=C[N(R’)2]2.In some embodiments, each R’ is independentlyR. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, −X−RLis . In some embodiments, one R’ on a nitrogen atom is taken with a R’ on the other nitrogen to form a ring as described herein.

[0187] In some embodiments, −X−RLis , wherein R1and R2are independently R’. In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, two R’ on the same nitrogen are taken together to form a ring as described herein. In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In someembodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis , wherein nis 1-20. In some embodiments, −X−RLis , wherein n is 1-20.

[0188] In some embodiments, −X−RLis R as described herein. In some embodiments, R is not hydrogen. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is methyl.

[0189] In some embodiments, an internucleotidic linkage, e.g., a non-negatively charged internucleotidic linkage or neutral internucleotidic linkage, has the structure of −OP(=W)(−N=C(R”)2)−O−, −OP(=W)(−N(R”)2)−O−, −P(=W)(−N=C(R”)2)−O− or −P(=W)(−N(R”)2)−O−, wherein: W is O or S; each R” is independently R’ or −N(R’)2; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or: two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms, or: two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0190] In some embodiments, W is O. In some embodiments, W is S.

[0191] In some embodiments, Y is a covalent bond. In some embodiments, Y is −O−. In some embodiments, Y is −N(R’)−. In some embodiments, Z is a covalent bond. In some embodiments, Z is −O−. In some embodiments, Z is −N(R’)−. In some embodiments, R’ is R. In some embodiments, R is −H. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is propyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl.

[0192] As described herein, various variables in structures in the present disclosure can be or comprise R. Suitable embodiments for R are described extensively in the present disclosure. As appreciated by thoseskilled in the art, R embodiments described for a variable that can be R may also be applicable to another variable that can be R. Similarly, embodiments described for a component / moiety (e.g., L) for a variable may also be applicable to other variables that can be or comprise the component / moiety.

[0193] In some embodiments, R” is R’. In some embodiments, R” is −N(R’)2.

[0194] In some embodiments, −X−RLis −SH. In some embodiments, −X−RLis −OH.

[0195] In some embodiments, −X−RLis −N(R’)2. In some embodiments, each R’ is independently optionally substituted C1-6aliphatic. In some embodiments, each R’ is independently methyl.

[0196] In some embodiments, a non-negatively charged internucleotidic linkage has the structure of −OP(=O)(−N=C((N(R’)2)2−O−. In some embodiments, a R’ group of one N(R’)2is R, a R’ group of the other N(R’)2is R, and the two R groups are taken together with their intervening atoms to form an optionally substituted ring, e.g., a 5-membered ring as in n001. In some embodiments, each R’ is independently R, wherein each R is independently optionally substituted C1-6aliphatic.

[0197] In some embodiments, −X−RLis −N=C(–LL–R’)2. In some embodiments, −X−RLis −N=C(– LL1−LL2−LL3–R’)2, wherein each LL1, LL2and LL3is independently L”, wherein each L” is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, LL2is −Cy−. In some embodiments, LL1is a covalent bond. In some embodiments, LL3is a covalent bond. In some embodiments, −X−RLis −N=C(–LL1−Cy−LL3–R’)2. In some embodiments, −X−RLis In some embodiments, −X−RLis In some embodiments, −X−RLisIn some embodiments, −X−RLis In somLe embodiments, −X−R isIn some embLodiments, −X−R is

[0198] In some embodiments, as utilized in the present disclosure, L is covalent bond. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by a group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-20aliphatic group and a C1-20heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by a group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-10(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, 1- 9, 1-8, 1-7, 1-6, etc.) aliphatic group and a C1-10(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, 1-9, 1-8, 1-7, 1-6, etc.) heteroaliphatic group having 1-5 (e.g., 1, 2, 3, 4, or 5) heteroatoms, wherein one or more methylene units are optionally and independently replaced by a group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally andindependently replaced with CyL. In some embodiments, one or more methylene units are optionally and independently replaced by an optionally substituted group selected from , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, or −C(O)O−. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units are optionally and independently replaced by , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−. In some embodiments, L is a bivalent, optionally substituted, linear or branched group selected from a C1-10aliphatic group and a C1-10heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units are optionally and independently replaced by , −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, or −C(O)O−.

[0199] In some embodiments, −X−RLis −N=C[N(R’)2]2.In some embodiments, each R’ is independently R. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is methyl. In some embodiments, −X−RLis . In some embodiments, one R’ on a nitrogen atom is taken with a R’ on the other nitrogen to form a ring as described herein. In some embodiments, a formed ring is optionally substituted 5-10 membered ring having 0-3 additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is optionally substituted 5-10 membered ring having no additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is optionally substituted 5-membered ring having no additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is optionally substituted 6-membered ring having no additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is optionally substituted 7-membered ring having no additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is optionally substituted 8-membered ring having no additional heteroatoms in addition to the two nitrogen atoms. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring is bicyclic. In some embodiments, a formed ring comprises no double or triple bond. In some embodiments, a formed ring comprises a double bond. In some embodiments,−X−RLis optionally substituted . In some embodiments, −X−RLis , wherein R1and R2are independently R’. In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, two R’ on the same nitrogen are taken together to form a ring as described herein. In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis. In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis, wherein n is 1-20. In some embodiments, −X−RLis , wherein n is 1-20. In some embodiments, −X−RLis selected from , , , , , , , and . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis . In some embodiments, −X−RLis optionally substituted . In some embodiments, −X−RLis optionally substituted , wherein each of R1and R2is independently R’ as described herein. In some embodiments, −X−RLis optionally substituted . In some embodiments, −X−RLis optionally substitutedwherein each of R1and R2is independently R’ as described herein.In some embodiments, R1is R as described herein. In some embodiments, R1is optionally substituted C1-30, C1-20, C1-10, or C1-6aliphatic. In some embodiments, R1is methyl. In some embodiments, R2is R as described herein. In some embodiments, R2is optionally substituted C1-30, C1-20, C1-10, or C1-6aliphatic. In some embodiments, R2is methyl.

[0200] In some embodiments, −X−RLis selected from Tables below. In some embodiments, X is as described herein. In some embodiments, RLis as described herein. In some embodiments, a linkage has the structure of −Y−PL(−X−RL)−Z−, wherein −X−RLis selected from Tables below, and each other variable is independently as described herein. In some embodiments, a linkage has the structure of or comprises −P(O)(−X−RL)−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −P(S)(−X−RL)−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −P(−X−RL)−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −P(O)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −P(S)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −P(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −P(O)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −P(S)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −P(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, P is bonded to a nitrogen atom (e.g., a nitrogen atom in sm01). In some embodiments, a linkage has the structure of or comprises −O−P(O)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −O−P(S)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of or comprises −O−P(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −O−P(O)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −O−P(S)(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, a linkage has the structure of −O−P(−X−RL)−O−, wherein −X−RLis selected from Tables below. In some embodiments, the Tables below, n is 0-20 or as described herein. As those skilled in the art appreciate, a linkage may exist in a salt form. Table L-1. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).wherein each RLSis independently Rs. In some embodiments, each RLSis independently −Cl, −Br, −F, −N(Me)2, or −NHCOCH3. Table L-2. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).Table L-3. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).Table L-4. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).Table L-5. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).Table L-6. Certain useful moieties bonded to linkage phosphorus (e.g., −X−RL).Page 104 of 583

[0201] In some embodiments, −X−RLis −NHSO2R’, wherein R’ is as described herein. In some embodiments, −X−RLis −NHCOR’, wherein R’ is as described herein. In some embodiments, R’ is R as described herein. In some embodiments, R’ is optionally substituted C1-6aliphatic. In some embodiments, R’ is optionally substituted C1-6alkyl. In some embodiments, R’ is optionally substituted phenyl. In some embodiments, R’ is optionally substituted heteroaryl.

[0202] In some embodiments, an internucleotidic linkage, e.g., a non-negatively charged internucleotidic linkage or a neutral internucleotidic linkage, has the structure of −LL1−CyIL−LL2−. In some embodiments, LL1is bonded to a 3’-carbon of a sugar. In some embodiments, LL2is bonded to a 5’-carbon of a sugar. In some embodiments, LL1is −O−CH2−. In some embodiments, LL2is a covalent bond. In some embodiments, LL2is a −N(R’)−. In some embodiments, LL2is a −NH−. In some embodiments, LL2is bonded to a 5’-carbon of a sugar, which 5’-carbon is substituted with =O. In some embodiments, CyILis optionally substituted 3-10 membered saturated, partially unsaturated, or aromatic ring having 0-5 heteroatoms. In some embodiments, CyILis an optionally substituted triazole ring. In some embodiments,In some embodiments, a linkage is

[0203] In some embodiments, a non-negatively charged internucleotidic linkage has the structure of −OP(=W)(−N(R’)2)−O−.

[0204] In some embodiments, R’ is R. In some embodiments, R’ is H. In some embodiments, R’ is −C(O)R. In some embodiments, R’ is −C(O)OR. In some embodiments, R’ is −S(O)2R.

[0205] In some embodiments, R” is −NHR’. In some embodiments, −N(R’)2is −NHR’.

[0206] As described herein, some embodiments, R is H. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is methyl. In some embodiments, R is substituted methyl. In some embodiments, R is ethyl. In some embodiments, R is substituted ethyl.

[0207] In some embodiments, as described herein, a non-negatively charged internucleotidic linkage is a neutral internucleotidic linkage.

[0208] In some embodiments, a modified internucleotidic linkage (e.g., a non-negatively charged internucleotidic linkage) comprises optionally substituted triazolyl. In some embodiments, a modified internucleotidic linkage (e.g., a non-negatively charged internucleotidic linkage) comprises optionally substituted alkynyl. In some embodiments, a modified internucleotidic linkage comprises a triazole or alkyne moiety. In some embodiments, a triazole moiety, e.g., a triazolyl group, is optionally substituted. In some embodiments, a triazole moiety, e.g., a triazolyl group) is substituted. In some embodiments, a triazole moiety is unsubstituted. In some embodiments, a modified internucleotidic linkage comprises anoptionally substituted cyclic guanidine moiety. In some embodiments, a modified internucleotidic linkage comprises an optionally substituted cyclic guanidine moiety and has the structure of:, wherein W is O or S. In some embodiments, W is O. In someembodiments, W is S. In some embodiments, a non-negatively charged internucleotidic linkage is stereochemically controlled.

[0209] In some embodiments, a non-negatively charged internucleotidic linkage or a neutral internucleotidic linkage is an internucleotidic linkage comprising a triazole moiety. In some embodiments, a non-negatively charged internucleotidic linkage or a non-negatively charged internucleotidic linkage comprises an optionally substituted triazolyl group. In some embodiments, an internucleotidic linkage comprising a triazole moiety (e.g., an optionally substituted triazolyl group) has the structure ofIn some embodiments, an internucleotidic linkage comprising a triazole moiety has the structure of In some embodiments, an internucleotidic linkage, e.g., a non-negatively charged internucleotidic linkage, a neutral internucleotidic linkage, comprises a cyclic guanidine moiety. In some embodiments, an internucleotidic linkage comprising a cyclic guanidine moiety has the structure of In some embodiments, a non-negatively charged internucleotidic linkage,or a neutral internucleotidic linkage, is or comprising a structure selected fromwherein W is O or S.

[0210] In some embodiments, an internucleotidic linkage comprises a Tmg group (In some embodiments, an internucleotidic linkage comprises a Tmg group and has the structure of(the “Tmg internucleotidic linkage”). In some embodiments, neutral internucleotidic linkages include internucleotidic linkages of PNA and PMO, and an Tmg internucleotidic linkage.

[0211] In some embodiments, a non-negatively charged internucleotidic linkage has the structure of In some embodiments, a non-negatively charged internucleotidic linkage has thestructure ofIn some embodiments, a non-negatively charged internucleotidic linkage has the structure ofIn some embodiments, a non-negatively charged internucleotidic linkage has the structure ofIn some embodiments, a non-negatively chargedinternucleotidic linkage has the structure ofIn some embodiments, a non- negatively charged internucleotidic linkage has the structure of In someembodiments, a non-negatively charged internucleotidic linkage has the structure of. In some embodiments, a non-negatively charged internucleotidic linkage has the structure ofIn some embodiments, a non-negatively charged internucleotidic linkage has the structure of. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, a neutral internucleotidic linkage is a non-negatively charged internucleotidic linkage described above.

[0212] In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 3-20 membered heterocyclyl or heteroaryl group having 1-10 heteroatoms. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 3-20 membered heterocyclyl or heteroaryl group having 1-10 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, such a heterocyclyl or heteroaryl group is of a 5-membered ring. In some embodiments, such a heterocyclyl or heteroaryl group is of a 6-membered ring.

[0213] In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5-20 membered heteroaryl group having 1-10 heteroatoms. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5-20 membered heteroaryl group having 1-10 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5-6 membered heteroaryl group having 1-4 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5- membered heteroaryl group having 1-4 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, a heteroaryl group is directly bonded to a linkage phosphorus. In some embodiments, a non- negatively charged internucleotidic linkage comprises an optionally substituted 5-20 membered heterocyclyl group having 1-10 heteroatoms. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5-20 membered heterocyclyl group having 1- 10 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted 5-6 membered heterocyclyl group having 1-4 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, a non- negatively charged internucleotidic linkage comprises an optionally substituted 5-membered heterocyclylgroup having 1-4 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, at least two heteroatoms are nitrogen. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted triazolyl group. In some embodiments, a non-negatively charged internucleotidic linkage comprises an unsubstituted triazolyl group, e.g., In someembodiments, a non-negatively charged internucleotidic linkage comprises a substituted triazolyl group, e.g., In some embodiments, a heterocyclyl group is directly bonded to a linkage phosphorus.In some embodiments, a heterocyclyl group is bonded to a linkage phosphorus through a linker, e.g., =N− when the heterocyclyl group is part of a guanidine moiety who directed bonded to a linkage phosphorus through its =N−. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substitutedgroup. In some embodiments, a non-negatively charged internucleotidic linkage comprises an substitutedgroup. In some embodiments, a non-negatively charged internucleotidic linkage comprises a group. In some embodiments, a non-negatively chargedinternucleotidic linkage comprises an optionally substituted group. In some embodiments, a non-negatively charged internucleotidic linkage comprises an substitutedgroup. In some embodiments, a non-negatively charged internucleotidic linkage comprises agroup. In some embodiments, a non-negatively charged internucleotidic linkage comprises an optionally substituted group. In some embodiments, a non-negatively charged internucleotidic linkage comprises ansubstitutedgroup. In some embodiments, a non-negatively charged internucleotidic linkage comprises a group. In some embodiments, each R1is independently optionally substitutedC1-6alkyl. In some embodiments, each R1is independently methyl. In some embodiments, −X−RLis such a group.

[0214] In some embodiments, a non-negatively charged internucleotidic linkage, e.g., a neutral internucleotidic linkage is not chirally controlled. In some embodiments, a non-negatively charged internucleotidic linkage is chirally controlled. In some embodiments, a non-negatively charged internucleotidic linkage is chirally controlled and its linkage phosphorus is Rp. In some embodiments, a non-negatively charged internucleotidic linkage is chirally controlled and its linkage phosphorus is Sp.

[0215] In some embodiments, an internucleotidic linkage comprises no linkage phosphorus. In some embodiments, an internucleotidic linkage has the structure of −C(O)−(O)− or −C(O)−N(R’)−, wherein R’ is as described herein. In some embodiments, an internucleotidic linkage has the structure of −C(O)−(O)−. In some embodiments, an internucleotidic linkage has the structure of −C(O)−N(R’)−, wherein R’ is as described herein. In various embodiments, −C(O)− is bonded to nitrogen. In some embodiments, an internucleotidic linkage is or comprises −C(O)−O− which is part of a carbamate moiety. In some embodiments, an internucleotidic linkage is or comprises −C(O)−O− which is part of a urea moiety.

[0216] In some embodiments, an oligonucleotide comprises 1-20, 1-15, 1-10, 1-5, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide comprises 1-20, 1-15, 1-10, 1-5, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more neutral internucleotidic linkages. In some embodiments, each of non-negatively charged internucleotidic linkage and / or neutral internucleotidic linkages is optionally and independently chirally controlled. In some embodiments, each non-negatively charged internucleotidic linkage in an oligonucleotide is independently a chirally controlled internucleotidic linkage. In some embodiments, each neutral internucleotidic linkage in an oligonucleotide is independently a chirally controlled internucleotidic linkage. In some embodiments, at least one non-negatively charged internucleotidic linkage / neutral internucleotidic linkage has the structure ofIn some embodiments, an oligonucleotide comprises at least one non- negatively charged internucleotidic linkage wherein its linkage phosphorus is in Rp configuration, and atleast one non-negatively charged internucleotidic linkage wherein its linkage phosphorus is in Sp configuration.

[0217] In many embodiments, as demonstrated extensively, oligonucleotides of the present disclosure comprise two or more different internucleotidic linkages. In some embodiments, an oligonucleotide comprises a phosphorothioate internucleotidic linkage and a non-negatively charged internucleotidic linkage. In some embodiments, an oligonucleotide comprises a phosphorothioate internucleotidic linkage, a non-negatively charged internucleotidic linkage, and a natural phosphate linkage. In some embodiments, a non-negatively charged internucleotidic linkage is a neutral internucleotidic linkage. In some embodiments, a non-negatively charged internucleotidic linkage is n001, n002 (In some embodiments, a non-negatively charged internucleotidic linkage is n001.In some embodiments, each phosphorothioate internucleotidic linkage is independently chirally controlled. In some embodiments, each chiral modified internucleotidic linkage is independently chirally controlled. In some embodiments, one or more non-negatively charged internucleotidic linkage are not chirally controlled.

[0218] A typical connection, as in natural DNA and RNA, is that an internucleotidic linkage formsbonds with two sugars (which can be either unmodified or modified as described herein). In many embodiments, as exemplified herein an internucleotidic linkage forms bonds through its oxygen atoms or heteroatoms with one optionally modified ribose or deoxyribose at its 5’ carbon, and the other optionally modified ribose or deoxyribose at its 3’ carbon. In some embodiments, internucleotidic linkages connect sugars that are not ribose sugars, e.g., sugars comprising N ring atoms and acyclic sugars as described herein.

[0219] In some embodiments, each nucleoside units connected by an internucleotidic linkage independently comprises a nucleobase which is independently an optionally substituted A, T, C, G, or U, or an optionally substituted tautomer of A, T, C, G or U.

[0220] In some embodiments, an oligonucleotide comprises a modified internucleotidic linkage (e.g., a modified internucleotidic linkage having the structure of Formula I, I-a, I-b, or I-c, I-n-1, I-n-2, I-n-3, I- n-4, II, II-a-1, II-a-2, II-b-1, II-b-2, II-c-1, II-c-2, II-d-1, II-d-2, etc., or a salt form thereof) as described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858 the internucleotidic linkages (e.g., those of Formula I, I-a, I-b, or I-c, I-n-1, I-n-2, I-n-3, I-n-4, II, II-a-1, II-a-2, II-b-1, II-b-2, II-c-1, II-c-2, II-d-1, II-d-2, etc.,) of each of which are independently incorporated herein by reference. In some embodiments, a modified internucleotidic linkage is a non-negatively charged internucleotidic linkage. In some embodiments, provided oligonucleotides comprise one or more non-negatively charged internucleotidic linkages. In some embodiments, a non-negatively charged internucleotidic linkage is a positively charged internucleotidic linkage. In some embodiments, a non-negatively charged internucleotidic linkage is a neutral internucleotidic linkage. In some embodiments, the present disclosure provides oligonucleotides comprising one or more neutral internucleotidic linkages. In some embodiments, a non-negatively charged internucleotidic linkage or a neutral internucleotidic linkage (e.g., one of Formula I-n-1, I-n-2, I-n-3, I-n-4, II, II-a-1, II-a-2, II-b-1, II-b-2, II-c-1, II-c-2, II-d-1, II-d-2, etc.) is as described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858. In some embodiments, a non-negatively charged internucleotidic linkage or neutral internucleotidic linkage is one of Formula I-n- 1, I-n-2, I-n-3, I-n-4, II, II-a-1, II-a-2, II-b-1, II-b-2, II-c-1, II-c-2, II-d-1, II-d-2, etc. as described inWO 2018 / 223056, WO 2019 / 032607, WO 2019 / 075357, WO 2019 / 032607, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858, such internucleotidic linkages of each of which are independently incorporated herein by reference.

[0221] As appreciated by those skilled in the art, many other types of internucleotidic linkages may be utilized in accordance with the present disclosure, for example, those described in U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,177,195; 5,023,243; 5,034,506; 5,166,315; 5,185,444; 5,188,897; 5,214,134; 5,216,141; 5,235,033; 5,264,423; 5,264,564; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,938; 5,405,939; 5,434,257; 5,453,496; 5,455,233; 5,466,677; 5,466,677; 5,470,967; 5,476,925; 5,489,677; 5,519,126; 5,536,821; 5,541,307; 5,541,316; 5,550,111; 5,561,225; 5,563,253; 5,571,799; 5,587,361; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,625,050; 5,633,360; 5,64,562; 5,663,312; 5,677,437; 5,677,439; 6,160,109; 6,239,265; 6,028,188; 6,124,445; 6,169,170; 6,172,209; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; or RE39464. In some embodiments, a modified internucleotidic linkage is one described in US 9394333, US 9744183, US 9605019, US 9598458, US 9982257, US 10160969, US 10479995, US 2020 / 0056173, US 2018 / 0216107, US 2019 / 0127733, US 10450568, US 2019 / 0077817, US 2019 / 0249173, US 2019 / 0375774, WO 2018 / 223056, WO 2018 / 223073, WO 2018 / 223081, WO 2018 / 237194, WO 2019 / 032607, WO 2019 / 055951, WO 2019 / 075357, WO 2019 / 200185, WO 2019 / 217784, WO 2019 / 032612, WO 2020 / 191252, and / or WO 2021 / 071858, the nucleobases, sugars, internucleotidic linkages, chiral auxiliaries / reagents, and technologies for oligonucleotide synthesis (reagents, conditions, cycles, etc.) of each of which is independently incorporated herein by reference. In some embodiments, an internucleotidic linkage is described in WO 2012 / 030683, WO 2021 / 030778, WO 2019112485, US 20170362270, WO 2018156056, WO 2018056871, WO 2020 / 154344, WO 2020 / 154343, WO 2020 / 154342, WO 2020 / 165077, WO 2020 / 201406, WO 2020 / 216637, or WO 2020 / 252376, and can be utilized in accordance with the present disclosure.

[0222] In some embodiments, each internucleotidic linkage in an oligonucleotide is independently selected from a natural phosphate linkage, a phosphorothioate linkage, and a non-negatively charged internucleotidic linkage (e.g., n001, n003, n004, n006, n008, n009, or n013). In some embodiments, each internucleotidic linkage in an oligonucleotide is independently selected from a natural phosphate linkage, a phosphorothioate linkage, and a neutral internucleotidic linkage (e.g., n001, n003, n004, n006, n008, n009, or n013). In some embodiments, an oligonucleotide comprises an internucleotidic linkage selected from n001, n002, n003, n004, n006, n008, n009, n012, n013 n020, n021, n024, n025, n026, n029, n030, n031, n033, n034, n035, n036, n037, n041, n043, n044, n046, n047, n048, n051, n052, n054, n055, and n057.

[0223] In some embodiments, an oligonucleotide comprises one or more (e.g., 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) non-negatively charged internucleotidic linkage. In some embodiments, an oligonucleotide contains no more than 10 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 9 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 8 non- negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 7 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 6 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 5 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 4 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 3 non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 10 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 9 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 8 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 7 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 6 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 5 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 4 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide contains no more than 3 consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide comprises 2 or more consecutive non- negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide comprises 3 or more consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide comprises 4 or more consecutive non-negatively charged internucleotidic linkages. In some embodiments, an oligonucleotide comprises 5 or more consecutive non-negatively charged internucleotidic linkages. In some embodiments, one or more or all non-negatively charged internucleotidic linkages are in wings of an oligonucleotide comprising wing-core-wing. In some embodiments, one or more or all non-negatively charged internucleotidic linkages are in a wing of an oligonucleotide comprising wing-core-wing. In some embodiments, one or more or all non-negatively charged internucleotidic linkages are in a core of an oligonucleotide comprising wing-core-wing. In some embodiments, each non- negatively charged internucleotidic linkages is in a wing. In some embodiments, each non-negatively charged internucleotidic linkages is in the same wing. In some embodiments, each non-negatively charged internucleotidic linkages is in a core. In some embodiments, one or more non-negatively chargedinternucleotidic linkages are in wings, and one or more non-negatively charged internucleotidic linkages are in a core. In some embodiments, each non-negatively charged internucleotidic linkage is independently a neutral internucleotidic linkage. In some embodiments, each non-negatively charged internucleotidic linkage independently comprises a linkage phosphorus bonded to a nitrogen atom which connects a sugar to a linkage. In some embodiments, each non-negatively charged internucleotidic linkage independently comprises −NR’ −N=C[N(R’)2]2, or −N=C(–LL–R’)2. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n001. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n003. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n004. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n008. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n025. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n026. In some embodiments, one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) internucleotidic linkages are independently n029. In some embodiments, each non-negatively charged internucleotidic linkage is independently selected from n001, n003, n004, n008, n025, n026, n029, n030, n031, n033, n036, and n037. In some embodiments, each non-negatively charged internucleotidic linkage is independently selected from n001, n003, n004, n025, n026, and n029. In some embodiments, one or more non-negatively charged internucleotidic linkage is n001, and one or more internucleotidic linkage is selected from n003, n004, n008, n025, n026, n029, n030, n031, n033, n036, and n037. In some embodiments, each non-negatively charged internucleotidic linkage is the same. In some embodiments, each non-negatively charged internucleotidic linkage is independently n001. In some embodiments, each non-negatively charged internucleotidic linkage is independently n003. In some embodiments, each non-negatively charged internucleotidic linkage is independently n004. In some embodiments, each non-negatively charged internucleotidic linkage is independently n008. In some embodiments, each non-negatively charged internucleotidic linkage is independently n025. In some embodiments, each non-negatively charged internucleotidic linkage is independently n026. In some embodiments, each non-negatively charged internucleotidic linkage is independently n029.

[0224] In some embodiments, an oligonucleotide comprises one or more (e.g., 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) n001. In some embodiments, an oligonucleotide contains no more than 10 n001. In some embodiments, an oligonucleotide contains no more than 9 n001. In some embodiments, an oligonucleotide contains no more than 8 n001. In some embodiments, an oligonucleotide contains no more than 7 n001. In some embodiments, an oligonucleotide contains no more than 6 n001. In some embodiments, an oligonucleotide contains no more than 5 n001. In some embodiments, anoligonucleotide contains no more than 4 n001. In some embodiments, an oligonucleotide contains no more than 3 n001. In some embodiments, an oligonucleotide contains no more than 10 consecutive n001. In some embodiments, an oligonucleotide contains no more than 9 consecutive n001. In some embodiments, an oligonucleotide contains no more than 8 consecutive n001. In some embodiments, an oligonucleotide contains no more than 7 consecutive n001. In some embodiments, an oligonucleotide contains no more than 6 consecutive n001. In some embodiments, an oligonucleotide contains no more than 5 consecutive n001. In some embodiments, an oligonucleotide contains no more than 4 consecutive n001. In some embodiments, an oligonucleotide contains no more than 3 consecutive n001. In some embodiments, an oligonucleotide comprises 2 or more consecutive n001. In some embodiments, an oligonucleotide comprises 3 or more consecutive n001. In some embodiments, an oligonucleotide comprises 4 or more consecutive n001. In some embodiments, an oligonucleotide comprises 5 or more consecutive n001. In some embodiments, one or more or all n001 are in wings of an oligonucleotide comprising wing-core-wing. In some embodiments, one or more or all n001 are in a wing of an oligonucleotide comprising wing-core- wing. In some embodiments, one or more or all n001 are in a core of an oligonucleotide comprising wing- core-wing. In some embodiments, each n001 is in a wing. In some embodiments, each n001 is in the same wing. In some embodiments, each n001 is in a core. In some embodiments, one or more n001 are in wings, and one or more n001 are in a core.

[0225] In some embodiments, an oligonucleotide comprises one or more (e.g., 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) n013. In some embodiments, an oligonucleotide contains no more than 10 n013. In some embodiments, an oligonucleotide contains no more than 9 n013. In some embodiments, an oligonucleotide contains no more than 8 n013. In some embodiments, an oligonucleotide contains no more than 7 n013. In some embodiments, an oligonucleotide contains no more than 6 n013. In some embodiments, an oligonucleotide contains no more than 5 n013. In some embodiments, an oligonucleotide contains no more than 4 n013. In some embodiments, an oligonucleotide contains no more than 3 n013. In some embodiments, an oligonucleotide contains no more than 10 consecutive n013. In some embodiments, an oligonucleotide contains no more than 9 consecutive n013. In some embodiments, an oligonucleotide contains no more than 8 consecutive n013. In some embodiments, an oligonucleotide contains no more than 7 consecutive n013. In some embodiments, an oligonucleotide contains no more than 6 consecutive n013. In some embodiments, an oligonucleotide contains no more than 5 consecutive n013. In some embodiments, an oligonucleotide contains no more than 4 consecutive n013. In some embodiments, an oligonucleotide contains no more than 3 consecutive n013. In some embodiments, one or more n013 are each independently bonded to a nitrogen atom (e.g., of sm01 as in sm01n013). In some embodiments, each n013 is independently bonded to a nitrogen atom (e.g., of sm01 as in sm01n013). As confirmed in the Examples, various compositions of oligonucleotides comprising n013 can provide desiredactivities. In some embodiments, one or more or all n013 are in wings of an oligonucleotide comprising wing-core-wing. In some embodiments, one or more or all n013 are in a wing of an oligonucleotide comprising wing-core-wing. In some embodiments, one or more or all n013 are in a core of an oligonucleotide comprising wing-core-wing. In some embodiments, each n013 is in a wing. In some embodiments, each n013 is in the same wing. In some embodiments, each n013 is in a core. In some embodiments, one or more n013 are in wings, and one or more n013 are in a core.

[0226] In some embodiments, a linkage is or comprises −CH2C(O)NR’−, wherein the −CH2− is optionally substituted. In some embodiments, R’ is H. In some embodiments, −NR’− is connected to a 3’ side sugar.

[0227] In some embodiments, a linkage is or comprises In some embodiments,the −O− is connected to a 5’ side sugar. In some embodiments, a linkage is or comprises. In some embodiments, −CH2− is connected to a 5’ side sugar.

[0228] Oligonucleotides can comprise various numbers of natural phosphate linkages, e.g., 1-50, 1- 40, 1-30, 1-25, 1-20, 1-10, 1-5, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more. In some embodiments, one or more (e.g., 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, 1-5, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) of the natural phosphate linkages in an oligonucleotide are consecutive. In some embodiments, provided oligonucleotides comprise no natural phosphate linkages. In some embodiments, provided oligonucleotides comprise one natural phosphate linkage. In some embodiments, provided oligonucleotides comprise 1 to 30 or more natural phosphate linkages.

[0229] In some embodiments, a modified internucleotidic linkage is a chiral internucleotidic linkage which comprises a chiral linkage phosphorus. In some embodiments, a chiral internucleotidic linkage is a phosphorothioate linkage. In some embodiments, a chiral internucleotidic linkage is a non-negatively charged internucleotidic linkage. In some embodiments, a chiral internucleotidic linkage is a neutral internucleotidic linkage. In some embodiments, a chiral internucleotidic linkage is chirally controlled with respect to its chiral linkage phosphorus. In some embodiments, a chiral internucleotidic linkage is stereochemically pure with respect to its chiral linkage phosphorus. In some embodiments, a chiral internucleotidic linkage is not chirally controlled. In some embodiments, a pattern of backbone chiral centers comprises or consists of positions and linkage phosphorus configurations of chirally controlled internucleotidic linkages (Rp or Sp) and positions of achiral internucleotidic linkages (e.g., natural phosphate linkages).

[0230] In some embodiments, provided oligonucleotides comprise one or more non-negativelycharged internucleotidic linkages. In some embodiments, provided oligonucleotides comprise one or more neutral internucleotidic linkages. In some embodiments, provided oligonucleotides comprise one or more phosphoryl guanidine internucleotidic linkages. In some embodiments, a neutral internucleotidic linkage or non-negatively charged internucleotidic linkage is a phosphoryl guanidine internucleotidic linkage. In some embodiments, each neutral internucleotidic linkage or non-negatively charged internucleotidic linkage is independently a phosphoryl guanidine internucleotidic linkage. In some embodiments, each neutral internucleotidic linkage and non-negatively charged internucleotidic linkage is independently n001.

[0231] In some embodiments, each internucleotidic linkage in a provided oligonucleotide is independently selected from a phosphorothioate internucleotidic linkage, a phosphoryl guanidine internucleotidic linkage, and a natural phosphate linkage. In some embodiments, each internucleotidic linkage in a provided oligonucleotide is independently selected from a phosphorothioate internucleotidic linkage, n001, and a natural phosphate linkage.

[0232] Various types of internucleotidic linkages may be utilized in combination of other structural elements, e.g., sugars, to achieve desired oligonucleotide properties and / or activities. For example, the present disclosure routinely utilizes modified internucleotidic linkages and modified sugars, optionally with natural phosphate linkages and natural sugars, in designed oligonucleotides. In some embodiments, the present disclosure provides an oligonucleotide comprising one or more modified sugars. In some embodiments, the present disclosure provides an oligonucleotide comprising one or more modified sugars and one or more modified internucleotidic linkages, one or more of which are natural phosphate linkages.

[0233] In some embodiments, an internucleotidic linkage is a phosphoryl guanidine, phosphoryl amidine, phosphoryl isourea, phosphoryl isothiourea, phosphoryl imidate, or phosphoryl imidothioate internucleotidic linkage, e.g., those as described in US 20170362270.

[0234] In some embodiments, stability of various internucleotidic linkages is assessed. In some embodiments, internucleotidic linkages are exposed to various conditions utilized for oligonucleotide manufacturing, e.g., solid phase oligonucleotide synthesis, including reagents, solvents, temperatures (in some cases, temperatures higher than room temperature), cleavage conditions, deprotection conditions, purification conditions, etc., and stability is assessed. In some embodiments, stable internucleotidic linkages (e.g., those having no more than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% degradation when exposed to one or more conditions and / or processes, or after a complete oligonucleotide manufacturing process) are selected for utilization in various oligonucleotide compositions and applications.

[0235] As described herein, various variables can be R, e.g., R’, RL, etc. Various embodiments for R are described in the present disclosure (e.g., when describing variables that can be R). Such embodiments are generally useful for all variables that can be R. In some embodiments, R is hydrogen. In someembodiments, R is optionally substituted C1-30(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) aliphatic. In some embodiments, R is optionally substituted C1-20aliphatic. In some embodiments, R is optionally substituted C1-10aliphatic. In some embodiments, R is optionally substituted C1-6aliphatic. In some embodiments, R is optionally substituted alkyl. In some embodiments, R is optionally substituted C1-6alkyl. In some embodiments, R is optionally substituted methyl. In some embodiments, R is methyl. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is optionally substituted propyl. In some embodiments, R is isopropyl. In some embodiments, R is optionally substituted butyl. In some embodiments, R is optionally substituted pentyl. In some embodiments, R is optionally substituted hexyl.

[0236] In some embodiments, R is optionally substituted 3-30 membered (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) cycloaliphatic. In some embodiments, R is optionally substituted cycloalkyl. In some embodiments, cycloaliphatic is monocyclic, bicyclic, or polycyclic, wherein each monocyclic unit is independently saturated or partially saturated. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is optionally substituted cyclohexyl. In some embodiments, R is optionally substituted adamantyl.

[0237] In some embodiments, R is optionally substituted C1-30(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) heteroaliphatic having 1-10 heteroatoms. In some embodiments, R is optionally substituted C1-20aliphatic having 1-10 heteroatoms. In some embodiments, R is optionally substituted C1-10aliphatic having 1-10 heteroatoms. In some embodiments, R is optionally substituted C1-6aliphatic having 1-3 heteroatoms. In some embodiments, R is optionally substituted heteroalkyl. In some embodiments, R is optionally substituted C1-6heteroalkyl. In some embodiments, R is optionally substituted 3-30 membered (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) heterocycloaliphatic having 1-10 heteroatoms. In some embodiments, R is optionally substituted heteroclycloalkyl. In some embodiments, heterocycloaliphatic is monocyclic, bicyclic, or polycyclic, wherein each monocyclic unit is independently saturated or partially saturated.

[0238] In some embodiments, R is optionally substituted C6-30aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is C6-14aryl. In some embodiments, R is optionally substituted bicyclic aryl. In some embodiments, R is optionally substituted polycyclic aryl. In some embodiments, R is optionally substituted C6-30arylaliphatic. In some embodiments, R is C6-30arylheteroaliphatic having 1-10 heteroatoms.

[0239] In some embodiments, R is optionally substituted 5-30 (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) membered heteroaryl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-20 membered heteroaryl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-10 membered heteroaryl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having one heteroatom. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 6-membered heteroaryl having one heteroatom. In some embodiments, R is optionally substituted monocyclic heteroaryl. In some embodiments, R is optionally substituted bicyclic heteroaryl. In some embodiments, R is optionally substituted polycyclic heteroaryl. In some embodiments, a heteroatom is nitrogen.

[0240] In some embodiments, R is optionally substituted 2-pyridinyl. In some embodiments, R is optionally substituted 3-pyridinyl. In some embodiments, R is optionally substituted 4-pyridinyl. In some embodiments, R is optionally substituted

[0241] In some embodiments, R is optionally substituted 3-30 (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) membered heterocyclyl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 3-membered heterocyclyl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 4-membered heterocyclyl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 5-20 membered heterocyclyl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-10 membered heterocyclyl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-membered heterocyclyl having 1-5heteroatoms. In some embodiments, R is optionally substituted 5-membered heterocyclyl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heterocyclyl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 5-membered heterocyclyl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 5-membered heterocyclyl having one heteroatom. In some embodiments, R is optionally substituted 6-membered heterocyclyl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 6-membered heterocyclyl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 6-membered heterocyclyl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 6-membered heterocyclyl having 1-2 heteroatoms. In some embodiments, R is optionally substituted 6-membered heterocyclyl having one heteroatom. In some embodiments, R is optionally substituted monocyclic heterocyclyl. In some embodiments, R is optionally substituted bicyclic heterocyclyl. In some embodiments, R is optionally substituted polycyclic heterocyclyl. In some embodiments, R is optionally substituted saturated heterocyclyl. In some embodiments, R is optionally substituted partially unsaturated heterocyclyl. In some embodiments, a heteroatom is nitrogen. In some embodiments, R is optionally substituted. In some embodiments, R is optionally substituted . In some embodiments, R is optionally substituted.

[0242] In some embodiments, two R groups are optionally and independently taken together to form a covalent bond. In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0243] Various variables may comprises an optionally substituted ring, or can be taken together with their intervening atom(s) to form a ring. In some embodiments, a ring is 3-30 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) membered. In some embodiments, a ring is 3-20 membered. In some embodiments, a ring is 3-15 membered. In some embodiments, a ring is 3-10 membered. In some embodiments, a ring is 3-8 membered. In some embodiments, a ring is 3-7 membered. In some embodiments, a ring is 3-6 membered. In some embodiments, a ring is 4-20 membered. In some embodiments, a ring is 5-20 membered. In some embodiments, a ring is monocyclic. In some embodiments, a ring is bicyclic. In some embodiments, a ringis polycyclic. In some embodiments, each monocyclic ring or each monocyclic ring unit in bicyclic or polycyclic rings is independently saturated, partially saturated or aromatic. In some embodiments, each monocyclic ring or each monocyclic ring unit in bicyclic or polycyclic rings is independently 3-10 membered and has 0-5 heteroatoms.

[0244] In some embodiments, each heteroatom is independently selected oxygen, nitrogen, sulfur, silicon, and phosphorus. In some embodiments, each heteroatom is independently selected oxygen, nitrogen, sulfur, and phosphorus. In some embodiments, each heteroatom is independently selected oxygen, nitrogen, and sulfur. In some embodiments, a heteroatom is in an oxidized form. Nucleobases

[0245] Various nucleobases may be utilized in provided oligonucleotides in accordance with the present disclosure. In some embodiments, a nucleobase is a natural nucleobase, the most commonly occurring ones being A, T, C, G and U. In some embodiments, a nucleobase is a modified nucleobase in that it is not A, T, C, G or U. In some embodiments, a nucleobase is optionally substituted A, T, C, G or U, or a substituted tautomer of A T, C, G or U. In some embodiments, a nucleobase is optionally substituted A, T, C, G or U, e.g., 5mC, 5-hydroxymethyl C, etc. In some embodiments, a nucleobase is alkyl- substituted A, T, C, G or U. In some embodiments, a nucleobase is A. In some embodiments, a nucleobase is T. In some embodiments, a nucleobase is C. In some embodiments, a nucleobase is G. In some embodiments, a nucleobase is U. In some embodiments, a nucleobase is 5mC. In some embodiments, a nucleobase is substituted A, T, C, G or U. In some embodiments, a nucleobase is a substituted tautomer of A, T, C, G or U. In some embodiments, substitution protects certain functional groups in nucleobases to minimize undesired reactions during oligonucleotide synthesis. Suitable technologies for nucleobase protection in oligonucleotide synthesis are widely known in the art and may be utilized in accordance with the present disclosure. In some embodiments, modified nucleobases improves properties and / or activities of oligonucleotides. For example, in many cases, 5mC may be utilized in place of C to modulate certain undesired biological effects, e.g., immune responses. In some embodiments, when determining sequence identity, a substituted nucleobase having the same hydrogen-bonding pattern is treated as the same as the unsubstituted nucleobase, e.g., 5mC may be treated the same as C [e.g., an oligonucleotide having 5mC in place of C (e.g., AT5mCG) is considered to have the same base sequence as an oligonucleotide having C at the corresponding location(s) (e.g., ATCG)].

[0246] In some embodiments, an oligonucleotide comprises one or more A, T, C, G or U. In some embodiments, an oligonucleotide comprises one or more optionally substituted A, T, C, G or U. In some embodiments, an oligonucleotide comprises one or more 5-methylcytidine, 5-hydroxymethylcytidine, 5- formylcytosine, or 5-carboxylcytosine. In some embodiments, an oligonucleotide comprises one or more5-methylcytidine. In some embodiments, each nucleobase in an oligonucleotide is selected from the group consisting of optionally substituted A, T, C, G and U, and optionally substituted tautomers of A, T, C, G and U. In some embodiments, each nucleobase in an oligonucleotide is optionally protected A, T, C, G and U. In some embodiments, each nucleobase in an oligonucleotide is optionally substituted A, T, C, G or U. In some embodiments, each nucleobase in an oligonucleotide is selected from the group consisting of A, T, C, G, U, and 5mC.

[0247] In some embodiments, a nucleobase is a natural nucleobase or a modified nucleobase derived from a natural nucleobase. Examples include uracil, thymine, adenine, cytosine, and guanine optionally having their respective amino groups protected by acyl protecting groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs such as pseudoisocytosine and pseudouracil and other modified nucleobases such as 8-substituted purines, xanthine, or hypoxanthine (the latter two being the natural degradation products). Certain examples of modified nucleobases are disclosed in Chiu and Rana, RNA, 2003, 9, 1034-1048, Limbach et al. Nucleic Acids Research, 1994, 22, 2183-2196 and Revankar and Rao, Comprehensive Natural Produc...

Claims

CLAIMS 1. An oligonucleotide having the structure of:or a salt thereof, wherein: BA is an optionally substituted or protected nucleobase; RT5is optionally substituted or protected hydroxyl, an optionally substituted or protected nucleotide moiety, an oligonucleotide moiety, R’, or an additional chemical moiety optionally connected through a linker; RT3is hydrogen, an optionally substituted or protected or nucleoside nucleotide moiety, an oligonucleotide moiety, R’, or an additional chemical moiety optionally connected through a linker; W is O, S or Se; Z is –O–, –S–, –N(R’)−; each RLis independently –LL–R’ or −N=C(–LL–R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; each of Ls, LL1, LL2and LLis independently L; −CyIL− is −Cy−; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

2. The oligonucleotide of claim 1, wherein the oligonucleotide has the structure ofsalt thereof.

3. An oligonucleotide, wherein the oligonucleotide has the structure of:or a salt thereof, wherein: BA is an optionally substituted or protected nucleobase; RT5is optionally substituted or protected hydroxyl, an optionally substituted or protected nucleotide moiety, an oligonucleotide moiety, R’, or an additional chemical moiety optionally connected through a linker; RT3is hydrogen, an optionally substituted or protected or nucleoside nucleotide moiety, an oligonucleotide moiety, R’, or an additional chemical moiety optionally connected through a linker; LINLis −Y−PL(−X−RL)−Z−, −C(O)−O− wherein −C(O)− in bonded to a nitrogen atom, −C(O)−N(R’)−,or −LL1−CyIL−LL2−,PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; Q−is an anion; each of X, Y and Z is independently –O–, –S–, –N(–LL–RL)–, or LL; each RLis independently –LL–R’ or −N=C(–LL–R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; each of Ls, LL1, LL2and LLis independently L; −CyIL− is −Cy−; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, inaddition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

4. The oligonucleotide of any one of claims 1-3, wherein RT5is optionally protected hydroxyl, an optionally substituted or protected nucleotide moiety or an oligonucleotide moiety, and RT3is a nucleoside, nucleotide or oligonucleotide moiety connected to a solid support optionally through a linker.

5. An oligonucleotide, comprising: one or more sugar units independently selected from: a sugar having the structure of:and an acyclic sugar, or one or more modified internucleotidic linkages each independently having the structure of: −Y−PL(−X−RL)−Z−, −C(O)−O− wherein −C(O)− in bonded to a nitrogen atom, −C(O)−N(R’)−,or −LL1−CyIL−LL2−, wherein: PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; Q−is an anion; each of X, Y and Z is independently –O–, –S–, –N(–LL–RL)–, or LL; each RLis independently –LL–R’ or −N=C(–LL–R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; each of Ls, LL1, LL2and LLis independently L; −CyIL− is −Cy−; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms,wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

6. The oligonucleotide of any one of the preceding claims, comprising a nucleoside unit comprising a morpholine unit, wherein the nitrogen of the morpholine unit is bonded to an internucleotidic linkage having the structure of −P(=W)(−N=C[N(R’)2]2)−O−.

7. The oligonucleotide of any one of the preceding claims, wherein an occurrence of PLis P(=O) or P(=S).

8. The oligonucleotide of any one of the preceding claims, wherein an occurrence of PLis PN, P=N−C(–LL–R’)(=LN−R’), or P=N–LL–RL.

9. The oligonucleotide of any one of the preceding claims, wherein an occurrence of Y is a covalent bond, or wherein an occurrence of Y is −O−.

10. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises a nucleoside unit comprising a morpholine unit, wherein the nucleoside unit has the structure of or a salt form thereof, wherein BA is a nucleobase, the N is bond to −C(O)−O−, wherein the −C(O)− is bonded to N.

11. The oligonucleotide of any one of the preceding claims, wherein each Z is −O−, and wherein an occurrence of W is O or S, or wherein each W is O.

12. The oligonucleotide of any one of the preceding claims, wherein an occurrence of −LL−RLis −N(R’)2or wherein RLis −N=C(–LL–R’)2or −N=C[N(R’)2]2.

13. The oligonucleotide of claim 12, wherein two R’ on the same nitrogen are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, or wherein RLis or .

14. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises 15-50 nucleobases.

15. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) phosphorothioate internucleotidic linkages, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all chiral internucleotidic linkages independently chirally controlled, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 5% of all chirally controlled phosphorothioate internucleotidic linkages are Sp, and / or at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all chirally controlled non-negatively charged internucleotidic linkages are Rp, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all chirally controlled internucleotidic linkages are Sp, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all modified internucleotidic linkages are phosphorothioate internucleotidic linkages, and / or at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all modified internucleotidic linkages are phosphorothioate internucleotidic linkages having a Sp configuration, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all internucleotidic linkages are phosphorothioate internucleotidic linkages, and / or wherein at least 60%, 70%, 75%, 80%, 85%, 90% or 95% of all internucleotidic linkages are phosphorothioate internucleotidic linkages having a Sp configuration.

16. The oligonucleotide of any one of the preceding claims, wherein the pattern of backbone chiralcenters comprises [(Rp / Op)n(Sp)m]y, wherein each of n, m, and y is independently 1-50, and each Np is independently Rp or Sp, and / or wherein the pattern of backbone chiral centers comprises (Np)t[(Rp / Op)n(Sp)m]y, wherein each of t, n, m, and y is independently 1-50, and each Np is independently Rp or Sp, and / or wherein the pattern of backbone chiral centers comprises (Sp)t[(Rp / Op)n(Sp)m]y, wherein each of t, n, m, and y is independently 1-50, and / or wherein each Op indicates a linkage phosphorus being achiral in a natural phosphate linkage.

17. The oligonucleotide of any one of the preceding claims, comprising one or more (e.g., about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; or about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% of all, or all) sugars independently having the structure of , optionally: wherein an occurrence of R5sis −CH3, or wherein in one an occurrence of sugar one R5sis −CH3, and the other is −H, and / or wherein the 5’-carbon is R or wherein the 5’-carbon is S; and / or wherein an occurrence of R5sis −H; and / or each occurrence of R4sis independently −H, or is taken together with a R2sto form a bridge having the structure of −Lb−Lb−, wherein each Lbis independently L; and / or wherein each occurrence of R3sis −H; and / or an occurrence of R2sis −H, −F, −OR, wherein R is optionally substituted C1-6alkyl, −OMe, or −OCH2CH2OCH3; and / or each occurrence of R1sis −H.

18. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide consists of or comprises a structure of 5’-a first region-a second region-a third region-3’, wherein each of the regions independently comprises 1-20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) or more nucleosides.

19. The oligonucleotide of any one of the preceding claims, wherein the first region comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleosides, and / or wherein the second region comprises 8 or more nucleosides, and / or the third region comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleosides, and / or wherein the first region comprises one or more internucleotidic linkages each independently of the structure −O−P(O)[−N=C[N(R’)2]2]−O−, and / or wherein the first region comprises one or more n001 internucleotidic linkages, and / or wherein at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in a second region comprises 2’-OR modified sugars, wherein R is optionally substituted C1-6aliphatic, and / or each sugar in the second region is independently a natural DNA sugar, and / or wherein at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95%, or 100% of all sugars in a third region comprises 2’-OR modified sugars, wherein R is optionally substituted C1-6aliphatic.

20. The oligonucleotide of any one of the preceding claims, wherein the pattern of backbone chiral centers of the oligonucleotide or the second region is or comprises wherein the pattern is or comprises (Np)t[(Rp)n(Sp)m]y or (Sp)t[(Rp)n(Sp)m]y, wherein each of t, n and m is independently 1-50 and y is 1- 10.

21. The oligonucleotide of any one of the preceding claims, wherein at least one n is 1 or wherein each n is 1, and / or wherein y is 1 or 2, and / or wherein t is 2 or more, and / or wherein each m is independently 2-20, and / or wherein each Rp in a pattern of backbone chiral centers is independently of a phosphorothioate internucleotidic linkage, and / or wherein each Sp in a pattern of backbone chiral centers is independently of a phosphorothioate internucleotidic linkage.

22. The oligonucleotide of any one of the preceding claims, wherein each nucleobase is independently optionally substituted A, T, C, G or U, or an optionally substituted tautomer of A, T, C, G or U.

23. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide chain is conjugated with an additional moiety which is or comprises a lipid moiety, a carbohydrate moiety, and / or a targeting moiety, and / or wherein the additional moiety is or comprises , , , , , , , , , , or .

24. An oligonucleotide comprising or a compound comprising , optionally wherein R’ is -Ac.

25. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide is in a form of a pharmaceutically acceptable salt.

26. The oligonucleotide of any one of the preceding claims, wherein each chirally controlled phosphorothioate internucleotidic linkage of the oligonucleotide independently has a diastereomeric purity of at least 85%, 90%, 95%, 96%, 97%, 98%, or 99%, and / or wherein the oligonucleotide has a diastereomeric purity of at least (DS)nc, wherein DS is 55%-100% (e.g., about or at least about 55%, 60%,70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%), and nc is the number of chirally controlled internucleotidic linkages, and / or wherein the oligonucleotide has a diastereomeric purity of about 5%- 100%, 10%-100%, 20-100%, 30%-100%, 40%-100%, 50%-100%, 5%-90%, 10%-90%, 20-90%, 30%- 90%, 40%-90%, 50%-90%, 5%-85%, 10%-85%, 20-85%, 30%-85%, 40%-85%, 50%-85%, 5%-80%, 10%-80%, 20-80%, 30%-80%, 40%-80%, 50%-80%, 5%-75%, 10%-75%, 20-75%, 30%-75%, 40%- 75%, 50%-75%, 5%-70%, 10%-70%, 20-70%, 30%-70%, 40%-70%, 50%-70%, 5%-65%, 10%-65%, 20- 65%, 30%-65%, 40%-65%, 50%-65%, 5%-60%, 10%-60%, 20-60%, 30%-60%, 40%-60%, 50%-60%.

27. A chirally controlled oligonucleotide composition comprising a plurality of oligonucleotides, wherein the oligonucleotides share: 1) a common base sequence, 2) a common pattern of backbone linkages, and 3) the same linkage phosphorus stereochemistry at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) chiral internucleotidic linkages (chirally controlled internucleotidic linkages), wherein about 1-100% of all oligonucleotides within the composition that share the common base sequence and common pattern of backbone linkages are the oligonucleotides of the plurality, each oligonucleotide of the plurality is independently an oligonucleotide of any one of claims 1- 25; or a chirally controlled oligonucleotide composition comprising a plurality of oligonucleotides, wherein the oligonucleotides share: 1) a common constitution, and 2) the same linkage phosphorus stereochemistry at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) chiral internucleotidic linkages (chirally controlled internucleotidic linkages), wherein the composition is enriched, relative to a substantially racemic preparation of oligonucleotides sharing the common constitution, for oligonucleotides of the plurality, and each oligonucleotide of the plurality is independently an oligonucleotide of any one of claims 1- 25; or a chirally controlled oligonucleotide composition comprising a plurality of oligonucleotides, wherein the oligonucleotides share: 1) a common constitution, and 2) the same linkage phosphorus stereochemistry at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) chiral internucleotidic linkages (chirally controlled internucleotidic linkages),wherein about 1-100% of all oligonucleotides within the composition that share the common constitution are the oligonucleotides of the plurality, and each oligonucleotide of the plurality is independently an oligonucleotide of any one of claims 1- 25. an oligonucleotide composition comprising a plurality of oligonucleotides, wherein: each oligonucleotide of the plurality is independently a particular oligonucleotide or a salt thereof, about 1-100% of all oligonucleotides within the composition that share the same constitution as the particular oligonucleotide or a salt thereof are oligonucleotides of the plurality, and the particular oligonucleotide is an oligonucleotide of any one of claims 1-25; or an oligonucleotide composition comprising a plurality of oligonucleotides, wherein: each oligonucleotide of the plurality is independently a particular oligonucleotide or a salt thereof, about 1-100% of all oligonucleotides within the composition that share the same base sequence as the particular oligonucleotide or a salt thereof are oligonucleotides of the plurality, and the particular oligonucleotide is an oligonucleotide of any one of claims 1-25.

28. The composition of any one of the preceding claims, wherein the percentage is about or more than about (DS)nc, wherein DS is 55%-100% (e.g., about or at least about 55%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%), and nc is the number of chirally controlled internucleotidic linkages among oligonucleotides of the plurality; and / or wherein the percentage is 5%-100%, 10%-100%, 20- 100%, 30%-100%, 40%-100%, 50%-100%, 5%-90%, 10%-90%, 20-90%, 30%-90%, 40%-90%, 50%- 90%, 5%-85%, 10%-85%, 20-85%, 30%-85%, 40%-85%, 50%-85%, 5%-80%, 10%-80%, 20-80%, 30%- 80%, 40%-80%, 50%-80%, 5%-75%, 10%-75%, 20-75%, 30%-75%, 40%-75%, 50%-75%, 5%-70%, 10%-70%, 20-70%, 30%-70%, 40%-70%, 50%-70%, 5%-65%, 10%-65%, 20-65%, 30%-65%, 40%- 65%, 50%-65%, 5%-60%, 10%-60%, 20-60%, 30%-60%, 40%-60%, 50%-60%.

29. The composition of any one of the preceding claims, wherein oligonucleotides of the plurality are each independently in a pharmaceutically acceptable salt form.

30. A pharmaceutical composition comprising or delivering an oligonucleotide or a composition of any one of the preceding claims and a pharmaceutically acceptable carrier.

31. A method for modulating expression, level and / or activity of a target nucleic acid and / or a product thereof, comprising contacting the target nucleic acid with an oligonucleotide or composition of any one of the preceding claims, wherein the base sequence of the oligonucleotide, or the common base sequence of oligonucleotides of a plurality in a composition, is complementary to that of the target nucleic acid; ora method, comprising administering to a system expressing a target nucleic acid an oligonucleotide or composition of any one of the preceding claims, wherein the base sequence of the oligonucleotide, or the common base sequence of oligonucleotides of a plurality in a composition, is complementary to that of the target nucleic acid.

32. The method of claim 31, wherein expression, level and / or activity of a target nucleic acid and / or a product thereof is reduced, and / or wherein a product is mRNA, and / or wherein a product is a protein; and / or wherein expression, level and / or activity of a product is increased, wherein the product is mRNA or a protein encoded thereby; and / or wherein the mRNA is a product of splicing modulation; and / or wherein the mRNA is a product of exon skipping; and / or wherein the system is a human.

33. A compound of formula AC-I, AC-I-a, AC-I-b, AC-I-c, AC-I-d, AC-I-e or a salt thereof, or a compound selected from34. A compound having the structure of LG-I:LG-I or a salt thereof, wherein: LG is a leaving group; each of XMand XNis independently −L−O−, −L−S− or −L−NRMN−; PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL;LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; each LL1is independently L; Q−is an anion; each of RM1, RM2and RMNis independently −LM−RM; each RLis independently –LL–R’ or −N=C(–LL–R’)2; each RMis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; each of LLand LMis independently L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted, trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic orpolycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

35. The compound of claim 33, wherein XMis −S− or −NRMN−, and / or wherein RM1and RM2are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein RM1, RM2and RMNare taken together with their intervening atoms to form an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms, and / or wherein LG is −C1, −N(R’)2, or −N(iPr)2.

36. A compound having the structure of LG-II:LG-II or a salt thereof, wherein: LG is a leaving group; each of XMand XNis independently −L−O−, −L−S− or −L−NRMN−; PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; each RLis independently –LL–R’ or −N=C(–LL–R’)2; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; each LL1is independently L; Q−is an anion; each of RM1and RMNis independently −LM−RM; each RLis independently –LL–R’ or −N=C(–LL–R’)2; each RMis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; t is 0-10; each of LLand LMis independently L; Ring M is an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

37. The compound of claim 36, wherein XMis −S− or −NRMN−, and / or Ring M is 5-membered or 6- membered, and / or Ring M is saturated, and / or wherein Ring M has no heteroatoms in addition to the intervening atoms, and / or wherein t is 2; and / or wherein each RM1is independently R; and / or wherein each RM1is independently optionally substituted C1-30aliphatic; and / or wherein is ; and / or wherein is ; and / or wherein is, wherein RM1and RM2are trans; and / or wherein is , wherein the H and RM2are trans; and / or wherein is .wherein XMis −S−; and / or wherein RM1is −C(CH3)=CH2or −CH3; and / or wherein is ; and / or wherein LG is −C1, −N(R’)2, or −N(iPr)2.

38. A compound having the structure of formula M-I: M-I or a salt thereof, wherein: each of XMand XNis independently −L−O−, −L−S− or −L−NRMN−; PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; each LL1is independently L; Q−is an anion; each of RM1, RM2and RMNis independently −LM−RM; each RLis independently –LL–R’ or −N=C(–LL–R’)2; each RMis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; each of LLand LMis independently L;BA is a nucleobase; SU is a sugar; LPSis a L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted, trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

39. The compound of claim 38, wherein XMis −S− or −NRMN−, and / or wherein RM1and RM2are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein the formed ring is 5-membered or 6-membered, and / or the formed ring is substituted,and / or wherein RM1, RM2and RMNare taken together with their intervening atoms to form an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms.

40. A compound having the structure of formula M-II:M-II or a salt thereof, wherein: each of XMand XNis independently −L−O−, −L−S− or −L−NRMN−; PLis P, P(=W), P−>B(–LL–RL)3, or PN; W is O, N(–LL–RL), S or Se; PNis P=N−C(–LL–R’)(=LN−R’) or P=N–LL–RL; LNis =N−LL1−, =CH−LL1− wherein CH is optionally substituted, or =N+(R’)(Q−)−LL1−; each LL1is independently L; Q−is an anion; each of RM1and RMNis independently −LM− RM; each RLis independently –LL–R’ or −N=C(–LL–R’)2; each RMis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; t is 0-10; each of LLand LL1is independently L; Ring M is an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; BA is a nucleobase; SU is a sugar; LPSis a L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−,−P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

41. The compound of claim 40, wherein XMis −S− or −NRMN−, and / or Ring M is 5-membered, and / or M is 6-membered, and / or wherein t is 1-10 or t is 2, and / or each RM1is independently R or independently optionally substituted C1-30aliphatic.

42. The compound of claim 40, wherein is , and / or wherein is , and / or wherein is , wherein RM1and RM2are trans, and / or wherein is , wherein the H and RM2are trans, and / or wherein is , and / or wherein is , and / or wherein RM1is −C(CH3)=CH2, and / or RM2is −CH3, and / or wherein is 43. The compound of any one of claims 40-42, wherein SU is , wherein: R6sis Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−,−C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

44. The compound of claim 43, wherein the N is bonded to PL, and / or wherein Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or whereinoptionally substitutedwhereinoptionally substitutedwhereinand / or wherein is , , or .

45. The compound of any one of claims 33-42, wherein S, wherein: each of R1s, R2s, R3s, R4s, R5s, and R6sis independently Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with theatom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

46. The compound of claim 45, wherein C1 is bonded to BA, and / or wherein Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein R1sis −H, and / or wherein R3sis −H, and / or wherein Sand / or wherein R2sis −H, −OR, wherein R is C1-6aliphatic, −OMe, or −MOE, and / or R4sis −H, and / or wherein R2sand R4sare taken together to form−L−, and / or wherein R2sand R4sare taken together to form−L−, wherein L is 2’−O−CH2−4’, wherein the −CH2− is optionally substituted.

47. The compound of claim 45, wherein SU is an acyclic sugar or −LPS−SU’− R6s, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein R6sis DMTrO−.

48. The compound of any one of the preceding claims, wherein XNis −O−, −S−, or −NRMN−.

49. The compound of any one of the preceding claims, wherein PLis P, or PLis P(=W), wherein W is O, or PLis P(=W), wherein W is S, or wherein PLis P(=W), wherein W is Se, or wherein PLis P(=W), wherein W is N(–LL–RL), or wherein PLis PN, or wherein PLis P=N−C(–LL–R’)[=N+(R’)(Q−)−LL1−R’], or wherein PLis P=N−C(–LL–R’)[=N+(R’)(Q−)−R’)], or wherein PLis P=N−C[N(R’)2][=N+(R’)(Q−)−LL1−R’], or wherein PLis P=N−C[N(R’)2][=N+(R’)2(Q−)], and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 5-membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0 heteroatoms, and / or wherein the formed ring is saturated, and / or wherein PNis Q−, and / or wherein PNisQ−, and / orwherein PNis Q−, and / or wherein PNis Q−, and / or wherein Q−is PF6−.

50. A compound having the structure of formula M-III:BA−SU−C(O)−LGM, M-III or a salt thereof, wherein: BA is a nucleobase; SU is a sugar; and LGMis a leaving group.

51. The compound of claim 50, wherein LGMis optionally substituted heteroaryl, and / or wherein LGMis optionally substituted , and / or wherein LGMis , and / or wherein LGMis optionally substituted , and / or wherein LGMis , and / or wherein SU is , wherein: R6sis Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

52. The compound of claim 51, wherein the N is bonded to −C(O)−RM, and / or Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein is optionally substituted , and / or wherein is optionally substituted , and / or wherein is , and / or wherein is , , .

53. The compound of claim 51, wherein SU is , wherein: each of R1s, R2s, R3s, R4s, R5s, and R6sis independently Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2;Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

54. The compound of claim 53, wherein C1 is bonded to BA, and / or wherein Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein R1sis −H, and / or wherein R3sis −H, and / or wherein SU is ,and / or wherein R2sis −H, −OR, wherein R is C1-6aliphatic, −OMe, or −MOE, and / or R4sis −H, and / or wherein R2sand R4sare taken together to form−L−, and / or wherein R2sand R4sare taken together to form−L−, wherein L is 2’−O−CH2−4’, wherein the −CH2− is optionally substituted.

55. The compound of claim 51, wherein SU is an acyclic sugar or −LPS−SU’− R6s, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein LPSis −O−, −NR’−, or a covalent bond, and / or wherein R6sis −O−L−R’, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein R6sis DMTrO−.

56. A method for preparing a compound of any one of claims 34-37, comprising contacting a compound of claim 33 with a second compound.

57. The method of claim 56, wherein the second compound is PCl3.

58. A method, comprising a coupling step that comprises: contacting a first compound with a second compound comprising a hydroxyl group or an amino group, wherein the first compound is a compound any one of claims 49-55; or a method, comprising a coupling step that comprises: contacting a first compound with a second compound comprising a hydroxyl group or an amino group in the presence of a base, wherein the first compound is a compound of claim 49.

59. The method of claim 58, wherein the P of the PNin the first compound forms a bond with the O of the −OH of the second compound.

60. A method, comprising a coupling step that comprises: contacting a first composition with a second compound comprising a hydroxyl group or an amino group, wherein the first composition is prepared by a method comprising contacting a compound of claim 49 with a compound of formula AZ-1: N3−C(–LL–R’)[=N+(R’)(Q−)−LL1−R’]. AZ-I 61. The method of claim 58, wherein a first compound is prepared by contacting a compound of claim 49 with a compound having the structure of AZ-1: N3−C(–LL–R’)[=N+(R’)(Q−)−LL1−R’]. AZ-I 62. The method of claim 58, wherein a first compound is utilized without isolation and / or purification, or the method of any one of claims 60-62, wherein a compound of formula AZ-I is a compound of formula N3−C(–LL–R’)[=N+(R’)(Q−)−R’], or the method of any one of claims 60-62, wherein a compound of formula AZ-I is a compound of formula N3−C[N(R’)2][=N+(R’)(Q−)−LL1−R’], or the method of any one of claims 60-62, wherein a compound of formula AZ-I is a compound of formula N3−C[N(R’)2][=N+(R’)2(Q−)], or the method of any one of claims 60-62, wherein a compound of formulaAZ-I is a compound of formula N3−C(–LL–R’)[=N+(R’)2(Q−)].

63. The method of any one of claims 60-62, wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 5-membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0 heteroatoms, and / or wherein the formed ring is saturated, and / or wherein a compound of formula AZ-1 is Q−, and / or wherein a compound of formula AZ-1 is Q−., and / or wherein a compound of formula AZ-1 is Q−, and / or wherein a compound of formula AZ-1 is Q−, and / or wherein Q−is PF6−.

64. The method of any one of claims 58-63, wherein the contacting produces a third compound comprising −P(=W)(−X−LL−RL)−Z−, and / or wherein Z is −O−, and / or wherein W is O, and / or wherein an occurrence of X is a covalent bond, and RLis −N=C(–LL–R’)2, and / or wherein an occurrence of −LL− is −N(R’)−, and / or wherein RLis −N=C[N(R’)2]2, and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 5-membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0 heteroatoms, and / or wherein the formed ring is saturated, and / or wherein RLis , , , or , and / or wherein the P of −P(=W)(−X−LL−RL)−Z− is the P of the PNof the first compound.

65. The method of any one of claims 58-64, comprising converting PLin a first compound or composition which PLis P=N−C(–LL–R’)[=N+(R’)(Q−)−LL1−R’] into P−N=C(–LL–R’)[N(R’)−LL1−R’], or comprising converting PLin a first compound or composition which PLis P=N−C(–LL–R’)[=N+(R’)(Q−)−R’] into P−N=C(–LL–R’)[−N(R’)2], or comprising converting PLin a first compound or composition which PLis P=N−C[N(R’)2][=N+(R’)(Q−)−LL1−R’] into P=N−C[N(R’)2][−N(R’)−LL1−R’], or comprising converting PLin a first compound or composition which PLis P=N−C[N(R’)2][=N+(R’)2(Q−)] into P=N−C[N(R’)2][−N(R’)2], optionally wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms, and / or wherein one R’ on one N and one R’ or the other N are taken together with their intervening atoms to form an optionally substituted, 5-membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0 heteroatoms, and / or wherein the formed ring is saturated, and / or wherein RLis , , , or , and / or wherein the P of −P(=W)(−X−LL−RL)−Z− is the P of the PNof the first compound, and / or wherein Q−is PF6−.

66. A method, comprising a coupling step that comprises: contacting a first compound with a second compound comprising a hydroxyl group or amino group, wherein the first compound is a compound of claim 49; or a method, comprising a coupling step that comprises: contacting a first composition with a second compound comprising a hydroxyl group or an amino group, wherein the first composition is prepared by a method comprising contacting a compound of claim 49 with sulfurization agent.

67. The method of claim 66, wherein a first compound is prepared by contacting a compound of claim 49 with a sulfurization agent, and / or wherein a first compound is utilized without isolation and / or purification; and / or wherein a sulfurization agent is , and / or wherein the contacting produces a third compound comprising −P(=W)(−X−LL−RL)−Z−, and / or wherein Z is −O−, and / or wherein W is O, and / or wherein −X−LL−RLis −S−H.

68. A method, comprising a coupling step that comprises: contacting a first compound with a second compound comprising a hydroxyl or amino group, wherein the first compound is a compound of any one of claim 50-55.

69. The method of any one of claims 58-68, wherein the second compound is or comprises a nucleoside comprising a −OH group, and / or wherein the second compound is or comprises an oligonucleotide comprising a −OH group, and / or wherein the second compound is or comprises a nucleoside comprising an amino group, and / or wherein the second compound is or comprises anoligonucleotide comprising an amino group.

70. The method of any one of claims 60-69, wherein the nucleoside or oligonucleotide is or comprises , wherein: R6sis −OH; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with theatom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

71. The method of claim 70, where the N is bonded to −C(O)−RM, and / or Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein is optionally substituted , and / or wherein is optionally substituted , and / or wherein is , and / or wherein is , , .

72. The method of any one of claims 60-69, wherein the nucleoside or oligonucleotide is or comprises , wherein: R6sis −OH; each of R1s, R2s, R3s, R4s, and R5sis independently Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−,−S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

73. The method of claim 72, wherein C1 is bonded to BA, and / or wherein Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein R1sis −H, and / or wherein R3sis −H, and / or wherein SU is , and / or wherein R2sis −H, −OR, wherein R is C1-6aliphatic, −OMe, or −MOE, and / or R4sis −H, and / or wherein R2sand R4sare taken together to form−L−, and / or wherein R2sand R4sare taken together to form−L−, wherein L is 2’−O−CH2−4’, wherein the −CH2− is optionally substituted.

74. The method of any one of claims 60-69, wherein SU is an acyclic sugar or −LPS−SU’− R6s, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein LPSis −O−, −NR’−, or a covalent bond, and / or wherein R6sis −O−L−R’, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein R6sis DMTrO−.

75. The method of any one of claims 58-74 wherein the second compound is linked to a solid support optionally through a linker, and / or wherein the second compound is a nucleoside or an oligonucleotide linked to a solid support through a linker, and / or the linker comprises one or more −N(R’)−, wherein R’ is not −H, and / or wherein the linker comprises one or more −(CH2)m−N(R’)−C(O)−(CH2)n−C(O), wherein R’ is not −H, each of m and n is independently 1-20, and each −CH2− is independent optionally substituted, and / or wherein the linker comprises one or more −(CH2)m−N(R’)−C(O)−(CH2)2−C(O), wherein R’ is not −H, each of m and n is independently 1-20, and each −CH2− is independent optionally substituted, and / or the linker comprises one or more −N(R’)−, wherein R’ is optionally substituted C1-6aliphatic, and / or wherein the linker comprises one or more −N(R’)−, wherein R’ is methyl, and / or wherein the linker comprises no −NH−, and / or wherein the solid support is CPG.

76. The method of any one the preceding claims, wherein the contacting is performed in the presence of a base, optionally wherein the base is DBU, and / or comprising a capping step that comprises a condition under which a −OH group can be capped, and / or comprising a capping step that comprises: contacting a product of a coupling step with a capping composition comprising a compound having the structure of [R’C(O)]2, optionally wherein a capping step comprises contacting a product of a coupling step with a capping composition comprising Ac2O, and / or comprising a deprotection step that comprises a condition under which a protected −OH group can be deprotected, and / or comprising a deprotection step that comprises: contacting a product of a coupling or a capping step with a deprotection composition comprising an acid, and / or comprising a deprotection step that comprises: contacting a product of a coupling or a capping step with a deprotection composition comprising an acid, wherein a DMTrO− is converted into −OH.

77. A method, comprising one or more cycles each independently comprising: a) a coupling step, b) a capping step, and c) optionally a deprotection step, wherein each of the coupling step, capping step, and deprotection step is independently as described in any one of claims 58-76.

78. The method of claim 77, wherein at least one cycle comprise a deprotection step, and / or wherein each one of the one or more cycles independently comprise a deprotection step, and / or wherein the cycle comprise no steps that modify the linkage phosphorus, and / or wherein the coupling step comprises coupling with a compound of any one of claims 49-55.

79. The method of any one of claims 60-78, further comprising one or more cycles each of whichindependently comprising: a) a coupling step, b) optionally a first capping step, c) a modification step, d) optionally a second capping step, and e) optionally a deprotection step, 80. The method of claim 79, wherein the coupling step comprises coupling with a compound of claim 49, and / or comprising a first capping step which comprises an amidation condition, and / or comprising a modification step which modifies a linkage phosphorus form P to P=O, P=S or P=N−, and / or comprising a second capping step which comprises an esterification condition.

81. A method for preparing a compound of claim 49, comprising contacting a compound of any one of claims 33-37 with a nucleoside.

82. The method of claim 81, wherein the nucleoside is A, T, C or G, optionally protected for oligonucleotide synthesis, and / or wherein the nucleoside is of the structure H−SU−BA or a salt thereof; and / or wherein SU is , wherein: R6sis Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Ring Asis an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the nitrogen, 0-10 heteroatoms; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−,−OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms; and / or wherein the N is bonded to H, and / or Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein is optionally substituted , and / or wherein is optionally substituted , and / or wherein is , and / or wherein is , , ; and / orwherein SU is , wherein: each of R1s, R2s, R3s, R4s, R5s, and R6sis independently Rs; each Rsis independently −H, halogen, −CN, −N3, −NO, −NO2, −L−R’, −L−Si(R’)3, −L−OR’, −L−SR’, −L−N(R’)2, −O−L−R’, −O−L−Si(R’)3, −O−L−OR’, −O−L−SR’, or −O−L−N(R’)2; Lsis L; each L is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C1-30aliphatic group and a C1-30heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C1-6alkylene, C1-6alkenylene, , a bivalent C1–C6heteroaliphatic group having 1-5 heteroatoms, −C(R’)2−, −Cy−, −O−, −S−, −S−S−, −N(R’)−, −C(O)−, −C(S)−, −C(NR’)−, −C(O)N(R’)−, −N(R’)C(O)N(R’)−, −N(R’)C(O)O−, −S(O)−, −S(O)2−, −S(O)2N(R’)−, −C(O)S−, −C(O)O−, −P(O)(OR’)−, −P(O)(SR’)−, −P(O)(R’)−, −P(O)(NR’)−, −P(S)(OR’)−, −P(S)(SR’)−, −P(S)(R’)−, −P(S)(NR’)−, −P(R’)−, −P(OR’)−, −P(SR’)−, −P(NR’)−, −P(OR’)[B(R’)3]−, −OP(O)(OR’)O−, −OP(O)(SR’)O−, −OP(O)(R’)O−, −OP(O)(NR’)O−, −OP(OR’)O−, −OP(SR’)O−, −OP(NR’)O−, −OP(R’)O−, or −OP(OR’)[B(R’)3]O−, and one or more nitrogen or carbon atoms are optionally and independently replaced with CyL; each −Cy− is independently an optionally substituted bivalent 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each CyLis independently an optionally substituted trivalent or tetravalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms; each R’ is independently −R, −C(O)R, −C(O)OR, or −S(O)2R; each R is independently −H, or an optionally substituted group selected from C1-30aliphatic, C1-30heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30arylaliphatic, C6-30arylheteroaliphatic having 1- 10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic orpolycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms; and / or wherein C1 is bonded to BA, and / or wherein Lsis −C(R5s)2, wherein each R5sis independently Rs, and / or wherein Lsis optionally substituted −CH2−, and / or wherein Lsis −CH2−, and / or wherein R1sis −H, and / or wherein R3sis −H, and / or wherein SU is , and / or wherein R2sis −H, −OR, wherein R is C1-6aliphatic, −OMe, or −MOE, and / or R4sis −H, and / or wherein R2sand R4sare taken together to form−L−, and / or wherein R2sand R4sare taken together to form−L−, wherein L is 2’−O−CH2−4’, wherein the −CH2− is optionally substituted; and / or wherein SU is an acyclic sugar or −LPS−SU’− R6s, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein LPSis −O−, −NR’−, or a covalent bond, and / or wherein R6sis −O−L−R’, and / or wherein R6sis −OH protected for oligonucleotide synthesis, and / or wherein R6sis DMTrO−.

83. The oligonucleotide, compound, composition or method of any one of the preceding claims, wherein an acyclic sugar has the structure of a’−LSA1−LSA2(−LSA3−)−LSA4−b’, wherein each of LSA1, LSA3, and LSA4is independently optionally substituted bivalent C1-4aliphatic or C1-4aliphatic having 1-3 heteroatoms, and LSA2is optionally substituted CH or N, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−LSA3−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted, and −LSA3− is bonded to a nucleobase, and is −O−CH2−, wherein the −CH2− is optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−O−CH2−)−CH(CH3)−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH3)−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−O−CH(CH2OH)−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(−LSA3−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−NHR’−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(O−CH2−)−CH2−N(CH3)−b’, wherein each of the CH2and CH is independently optionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(O−CH(CH3)−)−CH2−N(CH3)−b’, wherein each of the CH2and CH is independentlyoptionally substituted, and / or wherein an acyclic sugar has the structure of a’−CH2−CH(O−CH(CH2OH)−)−CH2−b’, wherein each of the CH2and CH is independently optionally substituted.

84. The oligonucleotide, compound, composition or method of any one of the preceding claims, wherein each heteroatom is independently boron, oxygen, sulfur, nitrogen, phosphorus, or silicon, and / or wherein each heteroatom is independently oxygen, sulfur, nitrogen, phosphorus, or silicon, and / or wherein each ring heteroatom is independently oxygen, sulfur, or nitrogen.

85. A method for modulating expression, level and or activity of a nucleic acid or a product thereof, comprising contacting the nucleic acid with an oligonucleotide or composition of any one of the any one of the preceding claims, or a method for modulating expression, level and or activity of a nucleic acid or a product thereof in a system, comprising administering to the system an oligonucleotide or composition of any one of the any one of the preceding claims, optimally wherein the expression, level and or activity of a nucleic acid or a product thereof is reduced.

86. A method for modulating splicing of a nucleic acid, comprising contacting the nucleic acid with an oligonucleotide or composition of any one of the any one of the preceding claims, or a method for modulating splicing of a nucleic acid in a system, comprising administering to the system an oligonucleotide or composition of any one of the any one of the preceding claims, optionally wherein skipping of a target exon is increased, and / or wherein inclusion of a target exon is increased, and / or wherein the nucleic acid is a transcript.

87. The method of any one of claims 85-86, wherein base sequence of the oligonucleotide or oligonucleotides in the composition is complementary or identical to the base sequence of the nucleic acid, and / or wherein a system is an in vitro assay, a cell, a tissue, an organ, an organism, an animal, a subject or a human.

88. The oligonucleotide, composition, compound, or method described in the Specification or of Embodiments 1-743.

Citation Information

Patent Citations

  • Modified oligonucleotides and methods for their synthesis

    WO2016028187A1

  • Oligonucleotide compositions and methods of use thereof

    WO2019200185A1

  • Oligonucleotide compositions and methods of use thereof

    WO2019217784A1